

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 August 2010 (19.08.2010)

PCT

(10) International Publication Number
WO 2010/093904 A2

(51) International Patent Classification:

A61K 48/00 (2006.01) A61P 25/28 (2006.01)
A61K 38/16 (2006.01) A61P 25/00 (2006.01)
A61P 25/16 (2006.01)

(21) International Application Number:

PCT/US2010/024075

(22) International Filing Date:

12 February 2010 (12.02.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/152,132 12 February 2009 (12.02.2009) US

(71) Applicant (for all designated States except US): **CUR-NA, INC.** [US/US]; 555 Heritage Drive, Suite 110, Jupiter, FL 33458 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COLLARD, Joseph** [US/US]; 1004 Brooks Lane, Delray Beach, FL 33483 (US). **KHORKOVA SHERMAN, Olga** [US/US]; 18288 Se Heritage Drive, Tequesta, FL 33469 (US). **COITO, Carlos** [US/US]; 4518 Corniche Circle, #26, West Palm Beach, FL 33417 (US).

(74) Agents: **ELAMRANI, Samir** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF

FIGURE 1

A



(57) Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.

WO 2010/093904 A2

**TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF)
RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE
TRANSCRIPT TO BDNF**

CROSS REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application No. 61/152,132 filed February 12, 2009, which application is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

[0002] Embodiments of the invention comprise oligonucleotides modulating expression
5 and/or function of BDNF and associated molecules.

BACKGROUND

[0003] DNA-RNA and RNA-RNA hybridization are important to many aspects of nucleic acid function including DNA replication, transcription, and translation. Hybridization is also central to a variety of technologies that either detect a particular nucleic acid or alter its
10 expression. Antisense nucleotides, for example, disrupt gene expression by hybridizing to target RNA, thereby interfering with RNA splicing, transcription, translation, and replication. Antisense DNA has the added feature that DNA-RNA hybrids serve as a substrate for digestion by ribonuclease H, an activity that is present in most cell types. Antisense molecules can be delivered into cells, as is the case for oligodeoxynucleotides (ODNs), or they can be
15 expressed from endogenous genes as RNA molecules. The FDA recently approved an antisense drug, VITRAVENE™ (for treatment of cytomegalovirus retinitis), reflecting that antisense has therapeutic utility.

SUMMARY

[0004] This Summary is provided to present a summary of the invention to briefly indicate
20 the nature and substance of the invention. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.

[0005] In one embodiment, the invention provides methods for inhibiting the action of a natural antisense transcript by using antisense oligonucleotide(s) targeted to any region of the natural antisense transcript resulting in up-regulation of the corresponding sense gene. It is
25 also contemplated herein that inhibition of the natural antisense transcript can be achieved by siRNA, ribozymes and small molecules, which are considered to be within the scope of the present invention.

[0006] One embodiment provides a method of modulating function and/or expression of an BDNF polynucleotide in patient cells or tissues *in vivo* or *in vitro* comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides 1 to 3175 of SEQ ID NO: 2 (Figure 3) thereby modulating function and/or expression of the BDNF polynucleotide in patient cells or tissues *in vivo* or *in vitro*.

[0007] In another preferred embodiment, an oligonucleotide targets a natural antisense sequence of BDNF polynucleotides, for example, nucleotides set forth in SEQ ID NO: 2, and any variants, alleles, homologs, mutants, derivatives, fragments and complementary sequences thereto. Examples of antisense oligonucleotides are set forth as SEQ ID NOS: 3 to 8 (Figure 4).

[0008] Another embodiment provides a method of modulating function and/or expression of an BDNF polynucleotide in patient cells or tissues *in vivo* or *in vitro* comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to a reverse complement of the an antisense of the BDNF polynucleotide; thereby modulating function and/or expression of the BDNF polynucleotide in patient cells or tissues *in vivo* or *in vitro*.

[0009] Another embodiment provides a method of modulating function and/or expression of an BDNF polynucleotide in patient cells or tissues *in vivo* or *in vitro* comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to an BDNF antisense polynucleotide; thereby modulating function and/or expression of the BDNF polynucleotide in patient cells or tissues *in vivo* or *in vitro*.

[0010] In a preferred embodiment, a composition comprises one or more antisense oligonucleotides which bind to sense and/or antisense BDNF polynucleotides.

[0011] In another preferred embodiment, the oligonucleotides comprise one or more modified or substituted nucleotides.

[0012] In another preferred embodiment, the oligonucleotides comprise one or more modified bonds.

[0013] In yet another embodiment, the modified nucleotides comprise modified bases comprising phosphorothioate, methylphosphonate, peptide nucleic acids, 2'-O-methyl, fluoro- or carbon, methylene or other locked nucleic acid (LNA) molecules. Preferably, the modified nucleotides are locked nucleic acid molecules, including α -L-LNA.

5 [0014] In another preferred embodiment, the oligonucleotides are administered to a patient subcutaneously, intramuscularly, intravenously or intraperitoneally.

[0015] In another preferred embodiment, the oligonucleotides are administered in a pharmaceutical composition. A treatment regimen comprises administering the antisense compounds at least once to patient; however, this treatment can be modified to include
10 multiple doses over a period of time. The treatment can be combined with one or more other types of therapies.

[0016] In another preferred embodiment, the oligonucleotides are encapsulated in a liposome or attached to a carrier molecule (e.g. cholesterol, TAT peptide).

[0017] Other aspects are described *infra*.

15

BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1

Figure 1 A: is a graph of real time PCR results showing the fold change + standard deviation in BDNF mRNA after treatment of HepG2 cells with LNA gapmer phosphorothioate oligonucleotides introduced using Lipofectamine 2000, as compared to control. Real time
20 PCR results show that the levels of the BDNF mRNA in HepG2 cells are significantly increased 48 h after treatment with two of the LNA gapmers with fully phosphothioated backbone designed to BDNF antisense NM_170735 (CUR-0071, P=0.04, CUR-0073, P=0.07, CUR-0075, P=0.03). Bars denoted as CUR-0071, CUR-0072, CUR-0073, CUR-0074, CUR-0075 and CUR-0076 correspond to samples treated with SEQ ID NOS: 6, 7, 8, 3, 4 and 5,
25 respectively.

Figure 1 B: is a graph of real time PCR results showing the fold change + standard deviation in BDNF mRNA after treatment of HepG2 cells with phosphorothioate oligonucleotides introduced using Lipofectamine 2000, as compared to control. Real time PCR results show that the levels of BDNF antisense were significantly decreased after treatment with all oligos except CUR-0072, which is possibly due to different oligos affecting different splice variants
30 of BDNF and/or BDNF antisense NM_170735. Bars denoted as CUR-0071, CUR-0072,

CUR-0073, CUR-0074, CUR-0075 and CUR-0076 correspond to samples treated with SEQ ID NOS: 6, 7, 8, 3, 4 and 5, respectively.

Figure 1 C: is a graph of real time PCR results showing the fold change + standard deviation in BDNF mRNA after treatment of CHP212 cells with LNA gapmer-phosphorothioate oligonucleotides introduced using Lipofectamine 2000, as compared to control. Real time PCR results show that the levels of the BDNF mRNA in CHP212 cells are significantly increased 48 h after treatment with two of the LNA gapmers with fully phosphothioated backbone designed to BDNF antisense NM_170735. Bars denoted as CUR-0071, CUR-0072, and CUR-0076 correspond to samples treated with SEQ ID NOS: 6, 7, and 3, respectively.

10 [0019] Figure 2 shows SEQ ID NO: 1: Homo sapiens brain-derived neurotrophic factor (BDNF), transcript variant 1, mRNA. (NCBI Accession No.: NM_170735) and SEQ ID NO: 11 shows the genomic sequence of BDNF (exons are shown in capital letters, introns in small).

15 [0020] Figure 3 shows SEQ ID NO: 2: Natural BDNF antisense sequence (NR_002832.1) Homo sapiens BDNF opposite strand (non-protein coding) (BDNFOS), non-coding RNA.

[0021] Figure 4 shows the antisense oligonucleotides, SEQ ID NOS: 3 to 8. * indicates phosphothioate bond and + indicates LNA modification.

[0022] Figure 5 shows SEQ ID NOS: 9 and 10.

DETAILED DESCRIPTION

20 [0023] Several aspects of the invention are described below with reference to example applications for illustration. It should be understood that numerous specific details, relationships, and methods are set forth to provide a full understanding of the invention. One having ordinary skill in the relevant art, however, will readily recognize that the invention can be practiced without one or more of the specific details or with other methods. The present invention is not limited by the ordering of acts or events, as some acts may occur in different orders and/or concurrently with other acts or events. Furthermore, not all illustrated acts or events are required to implement a methodology in accordance with the present invention.

25 [0024] All genes, gene names, and gene products disclosed herein are intended to correspond to homologs from any species for which the compositions and methods disclosed herein are applicable. Thus, the terms include, but are not limited to genes and gene products from humans and mice. It is understood that when a gene or gene product from a particular species

30

is disclosed, this disclosure is intended to be exemplary only, and is not to be interpreted as a limitation unless the context in which it appears clearly indicates. Thus, for example, for the genes disclosed herein, which in some embodiments relate to mammalian nucleic acid and amino acid sequences are intended to encompass homologous and/or orthologous genes and gene products from other animals including, but not limited to other mammals, fish, amphibians, reptiles, and birds. In preferred embodiments, the genes or nucleic acid sequences are human.

Definitions

[0025] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms "including", "includes", "having", "has", "with", or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term "comprising."

[0026] The term "about" or "approximately" means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, "about" can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably still up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term "about" meaning within an acceptable error range for the particular value should be assumed.

[0027] As used herein, the term "mRNA" means the presently known mRNA transcript(s) of a targeted gene, and any further transcripts which may be elucidated.

[0028] By "antisense oligonucleotides" or "antisense compound" is meant an RNA or DNA molecule that binds to another RNA or DNA (target RNA, DNA). For example, if it is an RNA oligonucleotide it binds to another RNA target by means of RNA-RNA interactions and alters the activity of the target RNA (Eguchi *et al.*, (1991) *Ann. Rev. Biochem.* 60, 631-652). An antisense oligonucleotide can upregulate or downregulate expression and/or function of a

particular polynucleotide. The definition is meant to include any foreign RNA or DNA molecule which is useful from a therapeutic, diagnostic, or other viewpoint. Such molecules include, for example, antisense RNA or DNA molecules, interference RNA (RNAi), micro RNA, decoy RNA molecules, siRNA, enzymatic RNA, therapeutic editing RNA and agonist and antagonist RNA, antisense oligomeric compounds, antisense oligonucleotides, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other oligomeric compounds that hybridize to at least a portion of the target nucleic acid. As such, these compounds may be introduced in the form of single-stranded, double-stranded, partially single-stranded, or circular oligomeric compounds.

10 [0029] In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. The term "oligonucleotide", also includes linear or circular oligomers of natural and/or modified monomers or linkages, including deoxyribonucleosides, ribonucleosides, substituted and alpha-anomeric forms thereof, peptide nucleic acids (PNA), locked nucleic acids (LNA),
15 phosphorothioate, methylphosphonate, and the like. Oligonucleotides are capable of specifically binding to a target polynucleotide by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, Hoogsteen or reverse Hoogsteen types of base pairing, or the like.

[0030] The oligonucleotide may be "chimeric", that is, composed of different regions. In the
20 context of this invention "chimeric" compounds are oligonucleotides, which contain two or more chemical regions, for example, DNA region(s), RNA region(s), PNA region(s) etc. Each chemical region is made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotides compound. These oligonucleotides typically comprise at least one region wherein the oligonucleotide is modified in order to exhibit one or more desired properties.
25 The desired properties of the oligonucleotide include, but are not limited, for example, to increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. Different regions of the oligonucleotide may therefore have different properties. The chimeric oligonucleotides of the present invention can be formed as mixed structures of two or more oligonucleotides, modified oligonucleotides,
30 oligonucleosides and/or oligonucleotide analogs as described above.

[0031] The oligonucleotide can be composed of regions that can be linked in "register", that is, when the monomers are linked consecutively, as in native DNA, or linked via spacers. The

spacers are intended to constitute a covalent "bridge" between the regions and have in preferred cases a length not exceeding about 100 carbon atoms. The spacers may carry different functionalities, for example, having positive or negative charge, carry special nucleic acid binding properties (intercalators, groove binders, toxins, fluorophores etc.), being lipophilic, inducing special secondary structures like, for example, alanine containing peptides that induce alpha-helices.

[0032] As used herein "BDNF" and "Brain derived neurotrophic factor" are inclusive of all family members, mutants, alleles, fragments, species, coding and noncoding sequences, sense and antisense polynucleotide strands, etc.

10 [0033] As used herein, the words 'Brain derived neurotrophic factor', 'Brain-derived neurotrophic factor' and BDNF, are used interchangeably in the present application.

[0034] As used herein, the term "oligonucleotide specific for" or "oligonucleotide which targets" refers to an oligonucleotide having a sequence (i) capable of forming a stable complex with a portion of the targeted gene, or (ii) capable of forming a stable duplex with a portion of a mRNA transcript of the targeted gene. Stability of the complexes and duplexes can be determined by theoretical calculations and/or in vitro assays. Exemplary assays for determining stability of hybridization complexes and duplexes are described in the Examples below.

20 [0035] As used herein, the term "target nucleic acid" encompasses DNA, RNA (comprising premRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA, coding, noncoding sequences, sense or antisense polynucleotides. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds, which specifically hybridize to it, is generally referred to as "antisense". The functions of DNA to be interfered include, for example, replication and transcription. The functions of RNA to be interfered, include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of an encoded product or oligonucleotides.

30 [0036] RNA interference "RNAi" is mediated by double stranded RNA (dsRNA) molecules that have sequence-specific homology to their "target" nucleic acid sequences (Caplen, N. J.,

et al. (2001) *Proc. Natl. Acad. Sci. USA* 98:9742-9747). In certain embodiments of the present invention, the mediators are 5-25 nucleotide "small interfering" RNA duplexes (siRNAs). The siRNAs are derived from the processing of dsRNA by an RNase enzyme known as Dicer (Bernstein, E., *et al.* (2001) *Nature* 409:363-366). siRNA duplex products are recruited into a multi-protein siRNA complex termed RISC (RNA Induced Silencing Complex). Without wishing to be bound by any particular theory, a RISC is then believed to be guided to a target nucleic acid (suitably mRNA), where the siRNA duplex interacts in a sequence-specific way to mediate cleavage in a catalytic fashion (Bernstein, E., *et al.* (2001) *Nature* 409:363-366; Boutla, A., *et al.* (2001) *Curr. Biol.* 11:1776-1780). Small interfering RNAs that can be used in accordance with the present invention can be synthesized and used according to procedures that are well known in the art and that will be familiar to the ordinarily skilled artisan. Small interfering RNAs for use in the methods of the present invention suitably comprise between about 1 to about 50 nucleotides (nt). In examples of non limiting embodiments, siRNAs can comprise about 5 to about 40 nt, about 5 to about 30 nt, about 10 to about 30 nt, about 15 to about 25 nt, or about 20-25 nucleotides.

[0037] Selection of appropriate oligonucleotides is facilitated by using computer programs that automatically align nucleic acid sequences and indicate regions of identity or homology. Such programs are used to compare nucleic acid sequences obtained, for example, by searching databases such as GenBank or by sequencing PCR products. Comparison of nucleic acid sequences from a range of species allows the selection of nucleic acid sequences that display an appropriate degree of identity between species. In the case of genes that have not been sequenced, Southern blots are performed to allow a determination of the degree of identity between genes in target species and other species. By performing Southern blots at varying degrees of stringency, as is well known in the art, it is possible to obtain an approximate measure of identity. These procedures allow the selection of oligonucleotides that exhibit a high degree of complementarity to target nucleic acid sequences in a subject to be controlled and a lower degree of complementarity to corresponding nucleic acid sequences in other species. One skilled in the art will realize that there is considerable latitude in selecting appropriate regions of genes for use in the present invention.

[0038] By "enzymatic RNA" is meant an RNA molecule with enzymatic activity (Cech, (1988) *J. American. Med. Assoc.* 260, 3030-3035). Enzymatic nucleic acids (ribozymes) act by first binding to a target RNA. Such binding occurs through the target binding portion of an enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the

molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through base pairing, and once bound to the correct site, acts enzymatically to cut the target RNA.

[0039] By "decoy RNA" is meant an RNA molecule that mimics the natural binding domain for a ligand. The decoy RNA therefore competes with natural binding target for the binding of a specific ligand. For example, it has been shown that over-expression of HIV trans-activation response (TAR) RNA can act as a "decoy" and efficiently binds HIV tat protein, thereby preventing it from binding to TAR sequences encoded in the HIV RNA (Sullenger *et al.* (1990) *Cell*, 63, 601- 608). This is meant to be a specific example. Those in the art will recognize that this is but one example, and other embodiments can be readily generated using techniques generally known in the art.

[0040] As used herein, the term "monomers" typically indicates monomers linked by phosphodiester bonds or analogs thereof to form oligonucleotides ranging in size from a few monomeric units, e.g., from about 3-4, to about several hundreds of monomeric units. Analogs of phosphodiester linkages include: phosphorothioate, phosphorodithioate, methylphosphonates, phosphoroselenoate, phosphoramidate, and the like, as more fully described below.

[0041] The term "nucleotide" covers naturally occurring nucleotides as well as nonnaturally occurring nucleotides. It should be clear to the person skilled in the art that various nucleotides which previously have been considered "non-naturally occurring" have subsequently been found in nature. Thus, "nucleotides" includes not only the known purine and pyrimidine heterocycles-containing molecules, but also heterocyclic analogues and tautomers thereof. Illustrative examples of other types of nucleotides are molecules containing adenine, guanine, thymine, cytosine, uracil, purine, xanthine, diaminopurine, 8-oxo- N6-methyladenine, 7-deazaxanthine, 7-deazaguanine, N4,N4-ethanocytosin, N6,N6-ethano-2,6-diaminopurine, 5-methylcytosine, 5-(C3-C6)-alkynylcytosine, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridin, isocytosine, isoguanin, inosine and the "non-naturally occurring" nucleotides described in Benner *et al.*, U.S. Pat No. 5,432,272. The term "nucleotide" is intended to cover every and all of these examples as well as analogues and tautomers thereof. Especially interesting nucleotides are those containing adenine, guanine, thymine, cytosine, and uracil, which are considered as the naturally occurring nucleotides in relation to therapeutic and diagnostic application in humans.

Nucleotides include the natural 2'-deoxy and 2'-hydroxyl sugars, e.g., as described in Kornberg and Baker, DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992) as well as their analogs.

[0042] "Analog" in reference to nucleotides includes synthetic nucleotides having modified base moieties and/or modified sugar moieties (see e.g., described generally by Scheit, Nucleotide Analogs, John Wiley, New York, 1980; Freier & Altmann, (1997) *Nucl. Acid. Res.*, 25(22), 4429-4443, Toulmé, J.J., (2001) *Nature Biotechnology* 19:17-18; Manoharan M., (1999) *Biochemica et Biophysica Acta* 1489:117-139; Freier S. M., (1997) *Nucleic Acid Research*, 25:4429-4443, Uhlman, E., (2000) *Drug Discovery & Development*, 3: 203-213, Herdewin P., (2000) *Antisense & Nucleic Acid Drug Dev.*, 10:297-310); 2'-O, 3'-C-linked [3.2.0] bicycloarabinonucleosides (see e.g. N.K Christensen, *et al*, (1998) *J. Am. Chem. Soc.*, 120: 5458-5463; Prakash TP, Bhat B. (2007) *Curr Top Med Chem.* 7(7):641-9; Cho EJ, *et al*. (2009) *Annual Review of Analytical Chemistry*, 2, 241-264). Such analogs include synthetic nucleotides designed to enhance binding properties, e.g., duplex or triplex stability, specificity, or the like.

[0043] As used herein, "hybridization" means the pairing of substantially complementary strands of oligomeric compounds. One mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoögsteen or reversed Hoögsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleotides) of the strands of oligomeric compounds. For example, adenine and thymine are complementary nucleotides which pair through the formation of hydrogen bonds. Hybridization can occur under varying circumstances.

[0044] An antisense compound is "specifically hybridizable" when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a modulation of function and/or activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and under conditions in which assays are performed in the case of in vitro assays.

[0045] As used herein, the phrase "stringent hybridization conditions" or "stringent conditions" refers to conditions under which a compound of the invention will hybridize to its target sequence, but to a minimal number of other sequences. Stringent conditions are

sequence-dependent and will be different in different circumstances and in the context of this invention, "stringent conditions" under which oligomeric compounds hybridize to a target sequence are determined by the nature and composition of the oligomeric compounds and the assays in which they are being investigated. In general, stringent hybridization conditions
5 comprise low concentrations (<0.15M) of salts with inorganic cations such as Na⁺⁺ or K⁺⁺ (i.e., low ionic strength), temperature higher than 20°C - 25° C. below the T_m of the oligomeric compound:target sequence complex, and the presence of denaturants such as formamide, dimethylformamide, dimethyl sulfoxide, or the detergent sodium dodecyl sulfate (SDS). For example, the hybridization rate decreases 1.1% for each 1% formamide. An
10 example of a high stringency hybridization condition is 0.1X sodium chloride-sodium citrate buffer (SSC)/0.1% (w/v) SDS at 60° C. for 30 minutes.

[0046] "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides on one or two oligomeric strands. For example, if a nucleobase at a certain position of an antisense compound is capable of hydrogen bonding with a nucleobase at a
15 certain position of a target nucleic acid, said target nucleic acid being a DNA, RNA, or oligonucleotide molecule, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be a complementary position. The oligomeric compound and the further DNA, RNA, or oligonucleotide molecule are complementary to each other when a sufficient number of complementary positions in each molecule are
20 occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of precise pairing or complementarity over a sufficient number of nucleotides such that stable and specific binding occurs between the oligomeric compound and a target nucleic acid.

[0047] It is understood in the art that the sequence of an oligomeric compound need not be
25 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, an oligonucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure, mismatch or hairpin structure). The oligomeric compounds of the present invention comprise at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at
30 least about 90%, or at least about 95%, or at least about 99% sequence complementarity to a target region within the target nucleic acid sequence to which they are targeted. For example, an antisense compound in which 18 of 20 nucleotides of the antisense compound are complementary to a target region, and would therefore specifically hybridize, would represent

90 percent complementarity. In this example, the remaining noncomplementary nucleotides may be clustered or interspersed with complementary nucleotides and need not be contiguous to each other or to complementary nucleotides. As such, an antisense compound which is 18 nucleotides in length having 4 (four) noncomplementary nucleotides which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul *et al.*, (1990) *J. Mol. Biol.*, 215, 403-410; Zhang and Madden, (1997) *Genome Res.*, 7, 649-656). Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (*Adv. Appl. Math.*, (1981) 2, 482-489).

[0048] As used herein, the term "Thermal Melting Point (Tm)" refers to the temperature, under defined ionic strength, pH, and nucleic acid concentration, at which 50% of the oligonucleotides complementary to the target sequence hybridize to the target sequence at equilibrium. Typically, stringent conditions will be those in which the salt concentration is at least about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short oligonucleotides (e.g., 10 to 50 nucleotide). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

[0049] As used herein, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene.

[0050] The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to a wild type gene. This definition may also include, for example, "allelic," "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. Of particular utility in the invention are variants of wild type gene products. Variants may

result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes that give rise to variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

[0051] The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs,) or single base mutations in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population with a propensity for a disease state, that is susceptibility versus resistance.

[0052] Derivative polynucleotides include nucleic acids subjected to chemical modification, for example, replacement of hydrogen by an alkyl, acyl, or amino group. Derivatives, e.g., derivative oligonucleotides, may comprise non-naturally-occurring portions, such as altered sugar moieties or inter-sugar linkages. Exemplary among these are phosphorothioate and other sulfur containing species which are known in the art. Derivative nucleic acids may also contain labels, including radionucleotides, enzymes, fluorescent agents, chemiluminescent agents, chromogenic agents, substrates, cofactors, inhibitors, magnetic particles, and the like.

[0053] A "derivative" polypeptide or peptide is one that is modified, for example, by glycosylation, pegylation, phosphorylation, sulfation, reduction/alkylation, acylation, chemical coupling, or mild formalin treatment. A derivative may also be modified to contain a detectable label, either directly or indirectly, including, but not limited to, a radioisotope, fluorescent, and enzyme label.

[0054] As used herein, the term "animal" or "patient" is meant to include, for example, humans, sheep, elks, deer, mule deer, minks, mammals, monkeys, horses, cattle, pigs, goats, dogs, cats, rats, mice, birds, chicken, reptiles, fish, insects and arachnids.

[0055] "Mammal" covers warm blooded mammals that are typically under medical care (e.g., humans and domesticated animals). Examples include feline, canine, equine, bovine, and human, as well as just human.

[0056] "Treating" or "treatment" covers the treatment of a disease-state in a mammal, and includes: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, e.g., arresting its development; and/or (c) relieving the disease-state, e.g., causing regression of the disease state until a desired endpoint is reached. Treating also includes the amelioration of a symptom of a disease (e.g., lessen the pain or discomfort), wherein such amelioration may or may not be directly affecting the disease (e.g., cause, transmission, expression, etc.).

[0057] As used herein, the term "cancer" refers to any malignant tumor, particularly arising in the lung, kidney, or thyroid. The cancer manifests itself as a "tumor" or tissue comprising malignant cells of the cancer. Examples of tumors include sarcomas and carcinomas such as, but not limited to: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma. As noted above, the invention specifically permits differential diagnosis of lung, kidney, and thyroid tumors.

Polynucleotide and Oligonucleotide Compositions and Molecules

[0058] *Targets:* In one embodiment, the targets comprise nucleic acid sequences of Brain derived neurotrophic factor (BDNF), including without limitation sense and/or antisense noncoding and/or coding sequences associated with BDNF.

[0059] Neurotrophins are a class of structurally related growth factors that promote neural survival and differentiation. They stimulate neurite outgrowth, suggesting that they can promote regeneration of injured neurons, and act as target-derived neurotrophic factors to stimulate collateral sprouting in target tissues that produce the neurotrophin (Korsching.,

(1993) *J. Neurosci.*,13: 2739). Brain-derived neurotrophic factor (BDNF) was initially characterized as a basic protein present in brain extracts and capable of increasing the survival of dorsal root ganglia (Leibrock., *et al.*, (1989) *Nature*, 341:149). When axonal communication with the cell body is interrupted by injury, Schwann cells produce neurotrophic factors such as nerve growth factor (NGF) and BDNF. Neurotrophins are released from the Schwann cells and dispersed diffusely in gradient fashion around regenerating axons, which then extend distally along the neurotrophins' density gradient (Ide., (1996) *Neurosci. Res.*, 25:101). Local application of BDNF to transected nerves in neonatal rats has been shown to prevent massive death of motor neurons that follows axotomy (DiStefano., *et al.*, (1992) *Neuron*, 8:983; Oppenheim., *et al.*, (1992) *Nature*, 360:755; Yan., *et al.*, (1992) *Nature*, 360:753). The mRNA titer of BDNF increases to several times the normal level four days after axotomy and reaches its maximum at 4 weeks (Meyer., *et al.*, (1992) *J.Cell Biol.* 119:45). Moreover, BDNF has been reported to enhance the survival of cholinergic neurons in culture (Nonomura, *et al.*, (1995) *Brain Res.* 683:129).

15 [0060] Exemplary Brain derived neurotrophic factor (BDNF) mediated diseases and disorders which can be treated with cell/tissues regenerated from stem cells obtained using the antisense compounds comprise: a disease or a disorder associated with defective neurogenesis; a neurodegenerative disease or disorder (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis etc.); a neuropsychiatric disorder (depression, schizophrenia, schizophreniform disorder, schizoaffective disorder, and delusional disorder; anxiety disorders such as panic disorder, phobias (including agoraphobia), an obsessive-compulsive disorder, a posttraumatic stress disorder, a bipolar disorder, anorexia nervosa, bulimia nervosa, an autoimmune disorder (e.g., multiple sclerosis) of the central nervous system, memory loss, a long term or a short term memory disorder, benign forgetfulness, a childhood learning disorder, close head injury, an attention deficit disorder, neuronal reaction to viral infection, brain damage, narcolepsy, a sleep disorder (e.g., circadian rhythm disorders, insomnia and narcolepsy); severance of nerves or nerve damage, severance of cerebrospinal nerve cord (CNS) and a damage to brain or nerve cells, a neurological deficit associated with AIDS, a motor and tic disorder characterized by motor and/or vocal tics (e.g., Tourette's disorder, chronic motor or vocal tic disorder, transient tic disorder, and stereotypic movement disorder), a substance abuse disorder (e.g., substance dependence, substance abuse and the sequelae of substance abuse/dependence, such as substance-induced psychological disorder, substance withdrawal and substance-induced dementia or amnesic disorder),

traumatic brain injury, tinnitus, neuralgia (e.g., trigeminal neuralgia) pain (e.g. chronic pain, chronic inflammatory pain, pain associated with arthritis, fibromyalgia, back pain, cancer-associated pain, pain associated with digestive disease, pain associated with Crohn's disease, pain associated with autoimmune disease, pain associated with endocrine disease, pain associated with diabetic neuropathy, phantom limb pain, spontaneous pain, chronic post-surgical pain, chronic temporomandibular pain, causalgia, post-herpetic neuralgia, AIDS-related pain, complex regional pain syndromes type I and II, trigeminal neuralgia, chronic back pain, pain associated with spinal cord injury, pain associated with drug intake and recurrent acute pain, neuropathic pain), inappropriate neuronal activity resulting in neurodysthesias in a disease such as diabetes, an MS and a motor neuron disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, Reward deficiency syndrome (RDS), neurotoxicity caused by alcohol or substance abuse (e.g., ecstasy, methamphetamine etc.), mental retardation or cognitive impairment (e.g., nonsyndromic X-linked mental retardation, fragile X syndrome, Down's syndrome, autism), aphasia, Bell's palsy, Creutzfeldt-jacob disease, encephalitis, age related macular degeneration, onidine syndrome, WAGR syndrome, hearing loss, Rett syndrome, epilepsy, spinal cord injury, stroke, hypoxia, ischemia, brain injury, optic nerve injury, diabetic neuropathy, peripheral neuropathy, nerve transplantation complications, motor neuron disease, peripheral nerve injury, obesity, a metabolic syndrome, cancer, asthma, an atopic disease, an allergic inflammation, eczema, a neuro-oncological disease or disorder, neuro-immunological disease or disorder and neuro-otological disease or disorder; and a disease or disorder associated with aging and senescence.

[0061] In a preferred embodiment, the oligonucleotides are specific for polynucleotides of BDNF, which includes, without limitation noncoding regions. The BDNF targets comprise variants of BDNF or BDNFOS; mutants of BDNF or BDNFOS, including SNPs; noncoding sequences of BDNF; alleles, fragments and the like. Preferably the oligonucleotide is an antisense RNA molecule.

[0062] In accordance with embodiments of the invention, the target nucleic acid molecule is not limited to BDNF polynucleotides alone but extends to any of the isoforms, receptors, homologs, non-coding regions and the like of BDNF.

[0063] In another preferred embodiment, an oligonucleotide targets a natural antisense sequence (natural antisense to the coding and non-coding regions) of BDNF targets,

including, without limitation, variants, alleles, homologs, mutants, derivatives, fragments and complementary sequences thereto. Preferably the oligonucleotide is an antisense RNA or DNA molecule.

5 [0064] In another preferred embodiment, the oligomeric compounds of the present invention also include variants in which a different base is present at one or more of the nucleotide positions in the compound. For example, if the first nucleotide is an adenine, variants may be produced which contain thymidine, guanosine, cytidine or other natural or unnatural nucleotides at this position. This may be done at any of the positions of the antisense compound. These compounds are then tested using the methods described herein to determine
10 their ability to inhibit expression of a target nucleic acid.

[0065] In some embodiments, homology, sequence identity or complementarity, between the antisense compound and target is from about 50% to about 60%. In some embodiments, homology, sequence identity or complementarity, is from about 60% to about 70%. In some
15 embodiments, homology, sequence identity or complementarity, is from about 70% to about 80%. In some embodiments, homology, sequence identity or complementarity, is from about 80% to about 90%. In some embodiments, homology, sequence identity or complementarity, is about 90%, about 92%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100%.

[0066] An antisense compound is specifically hybridizable when binding of the compound to
20 the target nucleic acid interferes with the normal function of the target nucleic acid to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired. Such conditions include, i.e., physiological conditions in the case of in vivo assays or therapeutic treatment, and conditions in which assays are performed
25 in the case of in vitro assays.

[0067] An antisense compound, whether DNA, RNA, chimeric, substituted etc, is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound
30 to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

[0068] In another preferred embodiment, targeting of BDNF including without limitation, antisense sequences which are identified and expanded, using for example, PCR, hybridization etc., one or more of the sequences set forth as SEQ ID NO: 2, and the like, modulate the expression or function of BDNF. In one embodiment, expression or function is up-regulated as compared to a control. In another preferred embodiment, expression or function is down-regulated as compared to a control.

[0069] In another preferred embodiment, oligonucleotides comprise nucleic acid sequences set forth as SEQ ID NOS: 3 to 8 including antisense sequences which are identified and expanded, using for example, PCR, hybridization etc. These oligonucleotides can comprise one or more modified nucleotides, shorter or longer fragments, modified bonds and the like. Examples of modified bonds or internucleotide linkages comprise phosphorothioate, phosphorodithioate or the like. In another preferred embodiment, the nucleotides comprise a phosphorus derivative. The phosphorus derivative (or modified phosphate group) which may be attached to the sugar or sugar analog moiety in the modified oligonucleotides of the present invention may be a monophosphate, diphosphate, triphosphate, alkylphosphate, alkanephosphate, phosphorothioate and the like. The preparation of the above-noted phosphate analogs, and their incorporation into nucleotides, modified nucleotides and oligonucleotides, *per se*, is also known and need not be described here.

[0070] The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

[0071] In embodiments of the present invention oligomeric antisense compounds, particularly oligonucleotides, bind to target nucleic acid molecules and modulate the expression and/or function of molecules encoded by a target gene. The functions of DNA to be interfered comprise, for example, replication and transcription. The functions of RNA to be interfered comprise all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or

more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The functions may be up-regulated or inhibited depending on the functions desired.

[0072] The antisense compounds, include, antisense oligomeric compounds, antisense oligonucleotides, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other oligomeric compounds that hybridize to at least a portion of the target nucleic acid. As such, these compounds may be introduced in the form of single-stranded, double-stranded, partially single-stranded, or circular oligomeric compounds.

[0073] Targeting an antisense compound to a particular nucleic acid molecule, in the context of this invention, can be a multistep process. The process usually begins with the identification of a target nucleic acid whose function is to be modulated. This target nucleic acid may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target nucleic acid encodes Brain derived neurotrophic factor (BDNF).

[0074] The targeting process usually also includes determination of at least one target region, segment, or site within the target nucleic acid for the antisense interaction to occur such that the desired effect, e.g., modulation of expression, will result. Within the context of the present invention, the term "region" is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic. Within regions of target nucleic acids are segments. "Segments" are defined as smaller or sub-portions of regions within a target nucleic acid. "Sites," as used in the present invention, are defined as positions within a target nucleic acid.

[0075] In a preferred embodiment, the antisense oligonucleotides bind to the natural antisense sequences of Brain derived neurotrophic factor (BDNF) and modulate the expression and/or function of Brain derived neurotrophic factor (BDNF) (SEQ ID NO: 1). Examples of antisense sequences include SEQ ID NOS: 2 to 8.

[0076] In another preferred embodiment, the antisense oligonucleotides bind to one or more segments of Brain derived neurotrophic factor (BDNF) polynucleotides and modulate the expression and/or function of Brain derived neurotrophic factor (BDNF). The segments comprise at least five consecutive nucleotides of the Brain derived neurotrophic factor (BDNF) sense or antisense polynucleotides.

[0077] In another preferred embodiment, the antisense oligonucleotides are specific for natural antisense sequences of Brain derived neurotrophic factor (BDNF) wherein binding of the oligonucleotides to the natural antisense sequences of Brain derived neurotrophic factor (BDNF) modulate expression and/or function of Brain derived neurotrophic factor (BDNF).

5 [0078] In another preferred embodiment, oligonucleotide compounds comprise sequences set forth as SEQ ID NOS: 3 to 8, antisense sequences which are identified and expanded, using for example, PCR, hybridization etc. These oligonucleotides can comprise one or more modified nucleotides, shorter or longer fragments, modified bonds and the like. Examples of modified bonds or internucleotide linkages comprise phosphorothioate, phosphorodithioate or
10 the like. In another preferred embodiment, the nucleotides comprise a phosphorus derivative. The phosphorus derivative (or modified phosphate group) which may be attached to the sugar or sugar analog moiety in the modified oligonucleotides of the present invention may be a monophosphate, diphosphate, triphosphate, alkylphosphate, alkanephosphate, phosphorothioate and the like. The preparation of the above-noted phosphate analogs, and
15 their incorporation into nucleotides, modified nucleotides and oligonucleotides, per se, is also known and need not be described here.

[0079] Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start
20 codon". A minority of genes has a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG; and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). Eukaryotic and prokaryotic genes may
25 have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA transcribed from a gene encoding Brain derived neurotrophic factor (BDNF), regardless of the sequence(s) of
30 such codons. A translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively).

[0080] The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon. Consequently, the "start codon region" (or "translation initiation codon region") and the "stop codon region" (or "translation termination codon region") are all regions that may be targeted effectively with the antisense compounds of the present invention.

[0081] The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Within the context of the present invention, a targeted region is the intragenic region encompassing the translation initiation or termination codon of the open reading frame (ORF) of a gene.

[0082] Another target region includes the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA (or corresponding nucleotides on the gene). Still another target region includes the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA (or corresponding nucleotides on the gene). The 5' cap site of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap site. Another target region for this invention is the 5' cap region.

[0083] Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. In one embodiment, targeting splice sites, i.e., intron-exon junctions or exon-intron junctions, is particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular splice product is implicated in disease. An aberrant fusion junction due to rearrangement or

deletion is another embodiment of a target site. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as "fusion transcripts". Introns can be effectively targeted using antisense compounds targeted to, for example, DNA or pre-mRNA.

5 [0084] In another preferred embodiment, the antisense oligonucleotides bind to coding and/or non-coding regions of a target polynucleotide and modulate the expression and/or function of the target molecule.

[0085] In another preferred embodiment, the antisense oligonucleotides bind to natural antisense polynucleotides and modulate the expression and/or function of the target molecule.

10 [0086] In another preferred embodiment, the antisense oligonucleotides bind to sense polynucleotides and modulate the expression and/or function of the target molecule.

[0087] Alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants". More specifically, "pre-mRNA variants" are transcripts produced from the same genomic DNA that differ from other
15 transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and exonic sequence.

[0088] Upon excision of one or more exon or intron regions, or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants". Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always
20 produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.

[0089] Variants can be produced through the use of alternative signals to start or stop transcription. Pre-mRNAs and mRNAs can possess more than one start codon or stop codon.
25 Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as "alternative start variants" of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as "alternative stop variants" of that pre-mRNA or mRNA. One specific type of alternative stop variant is the "polyA variant" in which the multiple transcripts produced result from the alternative selection of one of the "polyA stop
30 signals" by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites. Within the context of the invention, the types of variants described herein are also embodiments of target nucleic acids.

[0090] The locations on the target nucleic acid to which the antisense compounds hybridize are defined as at least a 5-nucleotide long portion of a target region to which an active antisense compound is targeted.

5 [0091] While the specific sequences of certain exemplary target segments are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional target segments are readily identifiable by one having ordinary skill in the art in view of this disclosure.

10 [0092] Target segments 5-100 nucleotides in length comprising a stretch of at least five (5) consecutive nucleotides selected from within the illustrative preferred target segments are considered to be suitable for targeting as well.

[0093] Target segments can include DNA or RNA sequences that comprise at least the 5 consecutive nucleotides from the 5'-terminus of one of the illustrative preferred target segments (the remaining nucleotides being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the target segment and continuing until
15 the DNA or RNA contains about 5 to about 100 nucleotides). Similarly preferred target segments are represented by DNA or RNA sequences that comprise at least the 5 consecutive nucleotides from the 3'-terminus of one of the illustrative preferred target segments (the remaining nucleotides being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the target segment and continuing until the
20 DNA or RNA contains about 5 to about 100 nucleotides). One having skill in the art armed with the target segments illustrated herein will be able, without undue experimentation, to identify further preferred target segments.

25 [0094] Once one or more target regions, segments or sites have been identified, antisense compounds are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

[0095] In embodiments of the invention the oligonucleotides bind to an antisense strand of a particular target. The oligonucleotides are at least 5 nucleotides in length and can be synthesized so each oligonucleotide targets overlapping sequences such that oligonucleotides are synthesized to cover the entire length of the target polynucleotide. The targets also include
30 coding as well as non coding regions.

[0096] In one embodiment, it is preferred to target specific nucleic acids by antisense oligonucleotides. Targeting an antisense compound to a particular nucleic acid, is a multistep

process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a non coding polynucleotide such as for example, non coding RNA (ncRNA).

5 [0097] RNAs can be classified into (1) messenger RNAs (mRNAs), which are translated into proteins, and (2) non-protein-coding RNAs (ncRNAs). ncRNAs comprise microRNAs, antisense transcripts and other Transcriptional Units (TU) containing a high density of stop codons and lacking any extensive "Open Reading Frame". Many ncRNAs appear to start from initiation sites in 3' untranslated regions (3'UTRs) of protein-coding loci. ncRNAs are often
10 rare and at least half of the ncRNAs that have been sequenced by the FANTOM consortium seem not to be polyadenylated. Most researchers have for obvious reasons focused on polyadenylated mRNAs that are processed and exported to the cytoplasm. Recently, it was shown that the set of non-polyadenylated nuclear RNAs may be very large, and that many such transcripts arise from so-called intergenic regions (Cheng, J. *et al.* (2005) *Science* 308 (5725), 1149-1154; Kapranov, P. *et al.* (2005). *Genome Res* 15 (7), 987-997). The mechanism by which ncRNAs may regulate gene expression is by base pairing with target transcripts. The RNAs that function by base pairing can be grouped into (1) cis encoded RNAs that are encoded at the same genetic location, but on the opposite strand to the RNAs they act upon and therefore display perfect complementarity to their target, and (2) trans-encoded RNAs
15 (5725), 1149-1154; Kapranov, P. *et al.* (2005). *Genome Res* 15 (7), 987-997). The mechanism by which ncRNAs may regulate gene expression is by base pairing with target transcripts. The RNAs that function by base pairing can be grouped into (1) cis encoded RNAs that are encoded at the same genetic location, but on the opposite strand to the RNAs they act upon and therefore display perfect complementarity to their target, and (2) trans-encoded RNAs
20 that are encoded at a chromosomal location distinct from the RNAs they act upon and generally do not exhibit perfect base-pairing potential with their targets.

[0098] Without wishing to be bound by theory, perturbation of an antisense polynucleotide by the antisense oligonucleotides described herein can alter the expression of the corresponding sense messenger RNAs. However, this regulation can either be discordant (antisense
25 knockdown results in messenger RNA elevation) or concordant (antisense knockdown results in concomitant messenger RNA reduction). In these cases, antisense oligonucleotides can be targeted to overlapping or non-overlapping parts of the antisense transcript resulting in its knockdown or sequestration. Coding as well as non-coding antisense can be targeted in an identical manner and that either category is capable of regulating the corresponding sense
30 transcripts – either in a concordant or discordant manner. The strategies that are employed in identifying new oligonucleotides for use against a target can be based on the knockdown of antisense RNA transcripts by antisense oligonucleotides or any other means of modulating the desired target.

[0099] *Strategy 1:* In the case of discordant regulation, knocking down the antisense transcript elevates the expression of the conventional (sense) gene. Should that latter gene encode for a known or putative drug target, then knockdown of its antisense counterpart could conceivably mimic the action of a receptor agonist or an enzyme stimulant.

5 [00100] *Strategy 2:* In the case of concordant regulation, one could concomitantly knock down both antisense and sense transcripts and thereby achieve synergistic reduction of the conventional (sense) gene expression. If, for example, an antisense oligonucleotide is used to achieve knockdown, then this strategy can be used to apply one antisense oligonucleotide targeted to the sense transcript and another antisense oligonucleotide to the corresponding
10 antisense transcript, or a single energetically symmetric antisense oligonucleotide that simultaneously targets overlapping sense and antisense transcripts.

[00101] According to the present invention, antisense compounds include antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, single- or double-stranded RNA interference (RNAi) compounds such as siRNA
15 compounds, and other oligomeric compounds which hybridize to at least a portion of the target nucleic acid and modulate its function. As such, they may be DNA, RNA, DNA-like, RNA-like, or mixtures thereof, or may be mimetics of one or more of these. These compounds may be single-stranded, doublestranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges,
20 mismatches or loops. Antisense compounds are routinely prepared linearly but can be joined or otherwise prepared to be circular and/or branched. Antisense compounds can include constructs such as, for example, two strands hybridized to form a wholly or partially double-stranded compound or a single strand with sufficient self-complementarity to allow for hybridization and formation of a fully or partially double-stranded compound. The two
25 strands can be linked internally leaving free 3' or 5' termini or can be linked to form a continuous hairpin structure or loop. The hairpin structure may contain an overhang on either the 5' or 3' terminus producing an extension of single stranded character. The double stranded compounds optionally can include overhangs on the ends. Further modifications can include conjugate groups attached to one of the termini, selected nucleotide positions, sugar positions
30 or to one of the internucleoside linkages. Alternatively, the two strands can be linked via a non-nucleic acid moiety or linker group. When formed from only one strand, dsRNA can take the form of a self-complementary hairpin-type molecule that doubles back on itself to form a duplex. Thus, the dsRNAs can be fully or partially double stranded. Specific modulation of

gene expression can be achieved by stable expression of dsRNA hairpins in transgenic cell lines, however, in some embodiments, the gene expression or function is up regulated. When formed from two strands, or a single strand that takes the form of a self-complementary hairpin-type molecule doubled back on itself to form a duplex, the two strands (or duplex-forming regions of a single strand) are complementary RNA strands that base pair in Watson-Crick fashion.

[00102] Once introduced to a system, the compounds of the invention may elicit the action of one or more enzymes or structural proteins to effect cleavage or other modification of the target nucleic acid or may work via occupancy-based mechanisms. In general, nucleic acids (including oligonucleotides) may be described as "DNA-like" (i.e., generally having one or more 2'-deoxy sugars and, generally, T rather than U bases) or "RNA-like" (i.e., generally having one or more 2'-hydroxyl or 2'-modified sugars and, generally U rather than T bases). Nucleic acid helices can adopt more than one type of structure, most commonly the A- and B-forms. It is believed that, in general, oligonucleotides which have B-form-like structure are "DNA-like" and those which have A-formlike structure are "RNA-like." In some (chimeric) embodiments, an antisense compound may contain both A- and B-form regions.

[00103] In another preferred embodiment, the desired oligonucleotides or antisense compounds, comprise at least one of: antisense RNA, antisense DNA, chimeric antisense oligonucleotides, antisense oligonucleotides comprising modified linkages, interference RNA (RNAi), short interfering RNA (siRNA); a micro, interfering RNA (miRNA); a small, temporal RNA (stRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); small activating RNAs (saRNAs), or combinations thereof.

[00104] dsRNA can also activate gene expression, a mechanism that has been termed "small RNA-induced gene activation" or RNAa. dsRNAs targeting gene promoters induce potent transcriptional activation of associated genes. RNAa was demonstrated in human cells using synthetic dsRNAs, termed "small activating RNAs" (saRNAs). It is currently not known whether RNAa is conserved in other organisms.

[00105] Small double-stranded RNA (dsRNA), such as small interfering RNA (siRNA) and microRNA (miRNA), have been found to be the trigger of an evolutionary conserved mechanism known as RNA interference (RNAi). RNAi invariably leads to gene silencing via remodeling chromatin to thereby suppress transcription, degrading complementary mRNA, or blocking protein translation. However, in instances described in detail in the examples section

which follows, oligonucleotides are shown to increase the expression and/or function of the Brain derived neurotrophic factor (BDNF) polynucleotides and encoded products thereof. dsRNAs may also act as small activating RNAs (saRNA). Without wishing to be bound by theory, by targeting sequences in gene promoters, saRNAs would induce target gene
5 expression in a phenomenon referred to as dsRNA-induced transcriptional activation (RNAa).

[00106] In a further embodiment, the "preferred target segments" identified herein may be employed in a screen for additional compounds that modulate the expression of Brain derived neurotrophic factor (BDNF) polynucleotides. "Modulators" are those compounds that decrease or increase the expression of a nucleic acid molecule encoding Brain derived
10 neurotrophic factor (BDNF) and which comprise at least a 5-nucleotide portion that is complementary to a preferred target segment. The screening method comprises the steps of contacting a preferred target segment of a nucleic acid molecule encoding sense or natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF) with one or more candidate modulators, and selecting for one or more candidate modulators which decrease or
15 increase the expression of a nucleic acid molecule encoding Brain derived neurotrophic factor (BDNF) polynucleotides, e.g. SEQ ID NOS: 3 to 8. Once it is shown that the candidate modulator or modulators are capable of modulating (e.g. either decreasing or increasing) the expression of a nucleic acid molecule encoding Brain derived neurotrophic factor (BDNF) polynucleotides, the modulator may then be employed in further investigative studies of the
20 function of Brain derived neurotrophic factor (BDNF) polynucleotides, or for use as a research, diagnostic, or therapeutic agent in accordance with the present invention.

[00107] Targeting the natural antisense sequence preferably modulates the function of the target gene. For example, the BDNF gene (e.g. accession number NM_170735, Fig. 2). In a preferred embodiment, the target is an antisense polynucleotide of the BDNF gene. In a
25 preferred embodiment, an antisense oligonucleotide targets sense and/or natural antisense sequences of Brain derived neurotrophic factor (BDNF) polynucleotides (e.g. accession number NM_170735, Fig.2), variants, alleles, isoforms, homologs, mutants, derivatives, fragments and complementary sequences thereto. Preferably the oligonucleotide is an antisense molecule and the targets include coding and noncoding regions of antisense and/or
30 sense BDNF polynucleotides.

[00108] The preferred target segments of the present invention may be also be combined with their respective complementary antisense compounds of the present invention to form stabilized double-stranded (duplexed) oligonucleotides.

[00109] Such double stranded oligonucleotide moieties have been shown in the art to modulate target expression and regulate translation as well as RNA processing via an antisense mechanism. Moreover, the double-stranded moieties may be subject to chemical modifications (Fire *et al.*, (1998) *Nature*, 391, 806-811; Timmons and Fire, (1998) *Nature*, 395, 854; Timmons *et al.*, (2001) *Gene*, 263, 103-112; Tabara *et al.*, (1998) *Science*, 282, 430-431; Montgomery *et al.*, (1998) *Proc. Natl. Acad. Sci. USA*, 95, 15502-15507; Tuschl *et al.*, (1999) *Genes Dev.*, 13, 3191-3197; Elbashir *et al.*, (2001) *Nature*, 411, 494-498; Elbashir *et al.*, (2001) *Genes Dev.* 15, 188-200). For example, such double-stranded moieties have been shown to inhibit the target by the classical hybridization of antisense strand of the duplex to the target, thereby triggering enzymatic degradation of the target (Tijsterman *et al.*, (2002) *Science*, 295, 694-697).

[00110] In a preferred embodiment, an antisense oligonucleotide targets Brain derived neurotrophic factor (BDNF) polynucleotides (e.g. accession number NM_170735), variants, alleles, isoforms, homologs, mutants, derivatives, fragments and complementary sequences thereto. Preferably the oligonucleotide is an antisense molecule.

[00111] In accordance with embodiments of the invention, the target nucleic acid molecule is not limited to Brain derived neurotrophic factor (BDNF) alone but extends to any of the isoforms, receptors, homologs and the like of Brain derived neurotrophic factor (BDNF) molecules.

[00112] In another preferred embodiment, an oligonucleotide targets a natural antisense sequence of BDNF polynucleotides, for example, polynucleotides set forth as SEQ ID NO: 2, and any variants, alleles, homologs, mutants, derivatives, fragments and complementary sequences thereto. Examples of antisense oligonucleotides are set forth as SEQ ID NOS: 3 to 8.

[00113] In one embodiment, the oligonucleotides are complementary to or bind to nucleic acid sequences of Brain derived neurotrophic factor (BDNF) antisense, including without limitation noncoding sense and/or antisense sequences associated with Brain derived neurotrophic factor (BDNF) polynucleotides and modulate expression and/or function of Brain derived neurotrophic factor (BDNF) molecules.

[00114] In another preferred embodiment, the oligonucleotides are complementary to or bind to nucleic acid sequences of BDNF natural antisense, set forth as SEQ ID NO: 2 and modulate expression and/or function of BDNF molecules.

5 [00115] In a preferred embodiment, oligonucleotides comprise sequences of at least 5 consecutive nucleotides of SEQ ID NOS: 3 to 8 and modulate expression and/or function of Brain derived neurotrophic factor (BDNF) molecules.

10 [00116] The polynucleotide targets comprise BDNF, including family members thereof, variants of BDNF; mutants of BDNF, including SNPs; noncoding sequences of BDNF; alleles of BDNF; species variants, fragments and the like. Preferably the oligonucleotide is an antisense molecule.

[00117] In another preferred embodiment, the oligonucleotide targeting Brain derived neurotrophic factor (BDNF) polynucleotides, comprise: antisense RNA, interference RNA (RNAi), short interfering RNA (siRNA); micro interfering RNA (miRNA); a small, temporal RNA (stRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); or, small activating RNA (saRNA).

15 [00118] In another preferred embodiment, targeting of Brain derived neurotrophic factor (BDNF) polynucleotides, e.g. SEQ ID NO: 2, modulates the expression or function of these targets. In one embodiment, expression or function is up-regulated as compared to a control. In another preferred embodiment, expression or function is down-regulated as compared to a control.

[00119] In another preferred embodiment, antisense compounds comprise sequences set forth as SEQ ID NOS: 3 to 8. These oligonucleotides can comprise one or more modified nucleotides, shorter or longer fragments, modified bonds and the like.

25 [00120] In another preferred embodiment, SEQ ID NOS: 3 to 8 comprise one or more LNA nucleotides.

[00121] Table 1 shows exemplary antisense oligonucleotides useful in the methods of the invention.

Table 1

Sequence ID	Oligo Name	Sequence
SEQ ID NO:3	CUR-0076	C*+T*+T*G*A*A*T*T*G*T*T*T*+G*+T*+A
SEQ ID NO:4	CUR-0075	A*+G*+T*T*G*C*A*A*G*A*G*T*+T*+G*+G
SEQ ID NO:5	CUR-0074	A*+T*+C*T*G*T*T*C*T*G*C*T*+G*+T*+C
SEQ ID NO:6	CUR-0071	C*+A*+T*A*T*T*C*T*T*G*G*A*+C*+G*+A
SEQ ID NO:7	CUR-0072	T*+G*+T*G*C*T*G*T*T*G*T*A*+A*+G*+A
SEQ ID NO:8	CUR-0073	T*+G*+A*C*A*G*A*G*G*A*G*T*+A*+T*+T

[00122] The modulation of a desired target nucleic acid can be carried out in several ways known in the art. For example, antisense oligonucleotides, siRNA etc. Enzymatic nucleic acid molecules (e.g., ribozymes) are nucleic acid molecules capable of catalyzing one or more of a variety of reactions, including the ability to repeatedly cleave other separate nucleic acid molecules in a nucleotide base sequence-specific manner. Such enzymatic nucleic acid molecules can be used, for example, to target virtually any RNA transcript (Zaug *et al.*, 324, *Nature* 429 1986; Cech, 260 *JAMA* 3030, 1988; and Jefferies *et al.*, 17 *Nucleic Acids Research* 1371, 1989).

[00123] Because of their sequence-specificity, trans-cleaving enzymatic nucleic acid molecules show promise as therapeutic agents for human disease (Usman & McSwiggen, (1995) *Ann. Rep. Med. Chem.* 30, 285-294; Christoffersen and Marr, (1995) *J. Med. Chem.* 38, 2023-2037). Enzymatic nucleic acid molecules can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the mRNA non-functional and abrogates protein expression from that RNA. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited.

[00124] In general, enzymatic nucleic acids with RNA cleaving activity act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its

ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

[00125] Several approaches such as in vitro selection (evolution) strategies (Orgel, (1979) *Proc. R. Soc. London*, B 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing a variety of reactions, such as cleavage and ligation of phosphodiester linkages and amide linkages, (Joyce, (1989) *Gene*, 82, 83-87; Beaudry *et al.*, (1992) *Science* 257, 635-641; Joyce, (1992) *Scientific American* 267, 90-97; Breaker *et al.*, (1994) *TIBTECH* 12, 268; Bartel *et al.*, (1993) *Science* 261:1411- 1418; Szostak, (1993) *TIBS* 17, 89-93; Kumar *et al.*, (1995) *FASEB J.*, 9, 1183; Breaker, (1996) *Curr. Op. Biotech.*, 7, 442).

[00126] The development of ribozymes that are optimal for catalytic activity would contribute significantly to any strategy that employs RNA-cleaving ribozymes for the purpose of regulating gene expression. The hammerhead ribozyme, for example, functions with a catalytic rate (kcat) of about 1 min⁻¹ in the presence of saturating (10 mM) concentrations of Mg²⁺ cofactor. An artificial "RNA ligase" ribozyme has been shown to catalyze the corresponding self-modification reaction with a rate of about 100 min⁻¹. In addition, it is known that certain modified hammerhead ribozymes that have substrate binding arms made of DNA catalyze RNA cleavage with multiple turn-over rates that approach 100 min⁻¹. Finally, replacement of a specific residue within the catalytic core of the hammerhead with certain nucleotide analogues gives modified ribozymes that show as much as a 10-fold improvement in catalytic rate. These findings demonstrate that ribozymes can promote chemical transformations with catalytic rates that are significantly greater than those displayed in vitro by most natural self-cleaving ribozymes. It is then possible that the structures of certain selfcleaving ribozymes may be optimized to give maximal catalytic activity, or that entirely new RNA motifs can be made that display significantly faster rates for RNA phosphodiester cleavage.

[00127] Intermolecular cleavage of an RNA substrate by an RNA catalyst that fits the "hammerhead" model was first shown in 1987 (Uhlenbeck, O. C. (1987) *Nature*, 328: 596-600). The RNA catalyst was recovered and reacted with multiple RNA molecules, demonstrating that it was truly catalytic.

[00128] Catalytic RNAs designed based on the "hammerhead" motif have been used to cleave specific target sequences by making appropriate base changes in the catalytic RNA to

maintain necessary base pairing with the target sequences (Haseloff and Gerlach, (1988) *Nature*, 334, 585; Walbot and Bruening, (1988) *Nature*, 334, 196; Uhlenbeck, O. C. (1987) *Nature*, 328: 596-600; Koizumi, M., *et al.* (1988) *FEBS Lett.*, 228: 228-230). This has allowed use of the catalytic RNA to cleave specific target sequences and indicates that catalytic RNAs designed according to the "hammerhead" model may possibly cleave specific substrate RNAs in vivo. (see Haseloff and Gerlach, (1988) *Nature*, 334, 585; Walbot and Bruening, (1988) *Nature*, 334, 196; Uhlenbeck, O. C. (1987) *Nature*, 328: 596-600).

[00129] RNA interference (RNAi) has become a powerful tool for modulating gene expression in mammals and mammalian cells. This approach requires the delivery of small interfering RNA (siRNA) either as RNA itself or as DNA, using an expression plasmid or virus and the coding sequence for small hairpin RNAs that are processed to siRNAs. This system enables efficient transport of the pre-siRNAs to the cytoplasm where they are active and permit the use of regulated and tissue specific promoters for gene expression.

[00130] In a preferred embodiment, an oligonucleotide or antisense compound comprises an oligomer or polymer of ribonucleic acid (RNA) and/or deoxyribonucleic acid (DNA), or a mimetic, chimera, analog or homolog thereof. This term includes oligonucleotides composed of naturally occurring nucleotides, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring portions which function similarly. Such modified or substituted oligonucleotides are often desired over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for a target nucleic acid and increased stability in the presence of nucleases.

[00131] According to the present invention, the oligonucleotides or "antisense compounds" include antisense oligonucleotides (e.g. RNA, DNA, mimetic, chimera, analog or homolog thereof), ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, single- or double-stranded RNA interference (RNAi) compounds such as siRNA compounds, saRNA, aRNA, and other oligomeric compounds which hybridize to at least a portion of the target nucleic acid and modulate its function. As such, they may be DNA, RNA, DNA-like, RNA-like, or mixtures thereof, or may be mimetics of one or more of these. These compounds may be single-stranded, double-stranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges, mismatches or loops. Antisense compounds are routinely prepared linearly but can be joined or otherwise prepared to be circular and/or branched. Antisense compounds can include

constructs such as, for example, two strands hybridized to form a wholly or partially double-stranded compound or a single strand with sufficient self-complementarity to allow for hybridization and formation of a fully or partially double-stranded compound. The two strands can be linked internally leaving free 3' or 5' termini or can be linked to form a continuous hairpin structure or loop. The hairpin structure may contain an overhang on either the 5' or 3' terminus producing an extension of single stranded character. The double stranded compounds optionally can include overhangs on the ends. Further modifications can include conjugate groups attached to one of the termini, selected nucleotide positions, sugar positions or to one of the internucleoside linkages. Alternatively, the two strands can be linked via a non-nucleic acid moiety or linker group. When formed from only one strand, dsRNA can take the form of a self-complementary hairpin-type molecule that doubles back on itself to form a duplex. Thus, the dsRNAs can be fully or partially double stranded. Specific modulation of gene expression can be achieved by stable expression of dsRNA hairpins in transgenic cell lines (Hammond *et al.*, (1991) *Nat. Rev. Genet.*, 2, 110-119; Matzke *et al.*, (2001) *Curr. Opin. Genet. Dev.*, 11, 221-227; Sharp, (2001) *Genes Dev.*, 15, 485-490). When formed from two strands, or a single strand that takes the form of a self-complementary hairpin-type molecule doubled back on itself to form a duplex, the two strands (or duplex-forming regions of a single strand) are complementary RNA strands that base pair in Watson-Crick fashion.

[00132] Once introduced to a system, the compounds of the invention may elicit the action of one or more enzymes or structural proteins to effect cleavage or other modification of the target nucleic acid or may work via occupancy-based mechanisms. In general, nucleic acids (including oligonucleotides) may be described as "DNA-like" (i.e., generally having one or more 2'-deoxy sugars and, generally, T rather than U bases) or "RNA-like" (i.e., generally having one or more 2'-hydroxyl or 2'-modified sugars and, generally U rather than T bases). Nucleic acid helices can adopt more than one type of structure, most commonly the A- and B-forms. It is believed that, in general, oligonucleotides which have B-form-like structure are "DNA-like" and those which have A-formlike structure are "RNA-like." In some (chimeric) embodiments, an antisense compound may contain both A- and B-form regions.

[00133] The antisense compounds in accordance with this invention can comprise an antisense portion from about 5 to about 80 nucleotides (i.e. from about 5 to about 80 linked nucleosides) in length. This refers to the length of the antisense strand or portion of the antisense compound. In other words, a single-stranded antisense compound of the invention comprises from 5 to about 80 nucleotides, and a double-stranded antisense compound of the

invention (such as a dsRNA, for example) comprises a sense and an antisense strand or portion of 5 to about 80 nucleotides in length. One of ordinary skill in the art will appreciate that this comprehends antisense portions of 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 5 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleotides in length, or any range therewithin.

[00134] In one embodiment, the antisense compounds of the invention have antisense portions of 10 to 50 nucleotides in length. One having ordinary skill in the art will appreciate that this embodies oligonucleotides having antisense portions of 10, 11, 12, 13, 14, 15, 16, 17, 10 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length, or any range therewithin. In some embodiments, the oligonucleotides are 15 nucleotides in length.

[00135] In one embodiment, the antisense or oligonucleotide compounds of the invention have antisense portions of 12 or 13 to 30 nucleotides in length. One having ordinary skill in 15 the art will appreciate that this embodies antisense compounds having antisense portions of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length, or any range therewithin.

[00136] In another preferred embodiment, the oligomeric compounds of the present invention also include variants in which a different base is present at one or more of the nucleotide 20 positions in the compound. For example, if the first nucleotide is an adenosine, variants may be produced which contain thymidine, guanosine or cytidine at this position. This may be done at any of the positions of the antisense or dsRNA compounds. These compounds are then tested using the methods described herein to determine their ability to inhibit expression of a target nucleic acid.

25 [00137] In some embodiments, homology, sequence identity or complementarity, between the antisense compound and target is from about 40% to about 60%. In some embodiments, homology, sequence identity or complementarity, is from about 60% to about 70%. In some 30 embodiments, homology, sequence identity or complementarity, is from about 70% to about 80%. In some embodiments, homology, sequence identity or complementarity, is from about 80% to about 90%. In some embodiments, homology, sequence identity or complementarity, is about 90%, about 92%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100%.

[00138] In another preferred embodiment, the antisense oligonucleotides, such as for example, nucleic acid molecules set forth in SEQ ID NOS: 2 to 8 comprise one or more substitutions or modifications. In one embodiment, the nucleotides are substituted with locked nucleic acids (LNA).

5 [00139] In another preferred embodiment, the oligonucleotides target one or more regions of the nucleic acid molecules sense and/or antisense of coding and/or non-coding sequences associated with BDNF and the sequences set forth as SEQ ID NOS: 1, 2. The oligonucleotides are also targeted to overlapping regions of SEQ ID NOS: 1, 2.

[00140] Certain preferred oligonucleotides of this invention are chimeric oligonucleotides.
10 "Chimeric oligonucleotides" or "chimeras," in the context of this invention, are oligonucleotides which contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, for example, increased nuclease resistance, increased uptake into cells, increased binding affinity for the target) and a region that is a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids.
15 By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of antisense modulation of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when
20 chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art. In one preferred embodiment, a chimeric oligonucleotide comprises at least one region modified to increase target binding affinity, and, usually, a region that acts as a
25 substrate for RNase H. Affinity of an oligonucleotide for its target (in this case, a nucleic acid encoding ras) is routinely determined by measuring the T_m of an oligonucleotide/target pair, which is the temperature at which the oligonucleotide and target dissociate; dissociation is detected spectrophotometrically. The higher the T_m , the greater is the affinity of the oligonucleotide for the target.

30 [00141] Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotides mimetics as described above. Such; compounds have also been

referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures comprise, but are not limited to, US patent nos. 5,013,830; 5,149,797; 5, 220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, each of which is herein incorporated by
5 reference.

[00142] In another preferred embodiment, the region of the oligonucleotide which is modified comprises at least one nucleotide modified at the 2' position of the sugar, most preferably a 2'-O-alkyl, 2'-O-alkyl-O-alkyl or 2'-fluoro-modified nucleotide. In other preferred embodiments, RNA modifications include 2'-fluoro, 2'-amino and 2' O-methyl modifications on the ribose of
10 pyrimidines, abasic residues or an inverted base at the 3' end of the RNA. Such modifications are routinely incorporated into oligonucleotides and these oligonucleotides have been shown to have a higher T_m (i.e., higher target binding affinity) than; 2'-deoxyoligonucleotides against a given target. The effect of such increased affinity is to greatly enhance RNAi oligonucleotide inhibition of gene expression. RNase H is a cellular endonuclease that
15 cleaves the RNA strand of RNA:DNA duplexes; activation of this enzyme therefore results in cleavage of the RNA target, and thus can greatly enhance the efficiency of RNAi inhibition. Cleavage of the RNA target can be routinely demonstrated by gel electrophoresis. In another preferred embodiment, the chimeric oligonucleotide is also modified to enhance nuclease resistance. Cells contain a variety of exo- and endo-nucleases which can degrade nucleic
20 acids. A number of nucleotide and nucleoside modifications have been shown to make the oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide. Nuclease resistance is routinely measured by incubating oligonucleotides with cellular extracts or isolated nuclease solutions and measuring the extent of intact oligonucleotide remaining over time, usually by gel electrophoresis.
25 Oligonucleotides which have been modified to enhance their nuclease resistance survive intact for a longer time than unmodified oligonucleotides. A variety of oligonucleotide modifications have been demonstrated to enhance or confer nuclease resistance. Oligonucleotides which contain at least one phosphorothioate modification are presently more preferred. In some cases, oligonucleotide modifications which enhance target binding affinity
30 are also, independently, able to enhance nuclease resistance. Some desirable modifications can be found in De Mesmaeker *et al.* (1995) *Acc. Chem. Res.*, 28:366-374.

[00143] Specific examples of some preferred oligonucleotides envisioned for this invention include those comprising modified backbones, for example, phosphorothioates,

phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are oligonucleotides with phosphorothioate backbones and those with heteroatom backbones, particularly $\text{CH}_2\text{--NH--O--CH}_2$, $\text{CH}_2\text{--N(CH}_3\text{)--O--CH}_2$ [known as a methylene(methylimino) or MMI backbone], $\text{CH}_2\text{--O--N(CH}_3\text{)--CH}_2$, $\text{CH}_2\text{--N(CH}_3\text{)--N(CH}_3\text{)--CH}_2$ and $\text{O--N(CH}_3\text{)--CH}_2\text{--CH}_2$ backbones, wherein the native phosphodiester backbone is represented as O--P--O--CH_2 .) The amide backbones disclosed by De Mesmaeker *et al.* (1995) *Acc. Chem. Res.* 28:366-374 are also preferred. Also preferred are oligonucleotides having morpholino backbone structures (Summerton and Weller, U.S. Pat. No. 5,034,506). In other preferred embodiments, such as the peptide nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen *et al.* (1991) *Science* 254, 1497). Oligonucleotides may also comprise one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH, SH, SCH₃, F, OCN, OCH₃, O(CH₂)_nCH₃, O(CH₂)_nNH₂ or O(CH₂)_nCH₃ where n is from 1 to about 10; C₁ to C₁₀ lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF₃; OCF₃; O--, S--, or N-alkyl; O--, S--, or N-alkenyl; SOCH₃; SO₂CH₃; ONO₂; NO₂; N₃; NH₂; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy [2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl)] (Martin *et al.*, (1995) *Helv. Chim. Acta*, 78, 486). Other preferred modifications include 2'-methoxy (2'-O--CH₃), 2'-propoxy (2'-OCH₂CH₂CH₃) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group.

[00144] Oligonucleotides may also include, additionally or alternatively, nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleotides include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleotides include nucleotides found only infrequently or

transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2' deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, as well as synthetic nucleotides, e.g., 2-aminoadenine, 2-(methylamino)adenine, 2-(imidazolylalkyl)adenine, 2-(aminoalkylamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 7-deazaguanine, N⁶-(6-aminohexyl)adenine and 2,6-diaminopurine. (Kornberg, A., DNA Replication, W. H. Freeman & Co., San Francisco, 1980, pp75-77; Gebeyehu, G., (1987) *et al. Nucl. Acids Res.* 15:4513). A "universal" base known in the art, e.g., inosine, may be included. 5-Me-C substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C. (Sanghvi, Y. S., in Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions.

[00145] Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety, a cholesteryl moiety (Letsinger *et al.*, (1989) *Proc. Natl. Acad. Sci. USA* 86, 6553), cholic acid (Manoharan *et al.* (1994) *Bioorg. Med. Chem. Lett.* 4, 1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660, 306; Manoharan *et al.* (1993) *Bioorg. Med. Chem. Lett.* 3, 2765), a thiocholesterol (Oberhauser *et al.*, (1992) *Nucl. Acids Res.* 20, 533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras *et al.* EMBO J. 1991, 10, 111; Kabanov *et al.* (1990) *FEBS Lett.* 259, 327; Svinarchuk *et al.* (1993) *Biochimie* 75, 49), a phospholipid, e.g., dihexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan *et al.* (1995) *Tetrahedron Lett.* 36, 3651; Shea *et al.* (1990) *Nucl. Acids Res.* 18, 3777), a polyamine or a polyethylene glycol chain (Manoharan *et al.* (1995) *Nucleosides & Nucleotides*, 14, 969), or adamantane acetic acid (Manoharan *et al.* (1995) *Tetrahedron Lett.* 36, 3651). Oligonucleotides comprising lipophilic moieties, and methods for preparing such oligonucleotides are known in the art, for example, U.S. Pat. Nos. 5,138,045, 5,218,105 and 5,459,255.

[00146] It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide.

The present invention also includes oligonucleotides which are chimeric oligonucleotides as hereinbefore defined.

[00147] In another embodiment, the nucleic acid molecule of the present invention is conjugated with another moiety including but not limited to abasic nucleotides, polyether, polyamine, polyamides, peptides, carbohydrates, lipid, or polyhydrocarbon compounds. Those skilled in the art will recognize that these molecules can be linked to one or more of any nucleotides comprising the nucleic acid molecule at several positions on the sugar, base or phosphate group.

[00148] The oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of one of ordinary skill in the art. It is also well known to use similar techniques to prepare other oligonucleotides such as the phosphorothioates and alkylated derivatives. It is also well known to use similar techniques and commercially available modified amidites and controlled-pore glass (CPG) products such as biotin, fluorescein, acridine or psoralen-modified amidites and/or CPG (available from Glen Research, Sterling VA) to synthesize fluorescently labeled, biotinylated or other modified oligonucleotides such as cholesterol-modified oligonucleotides.

[00149] In accordance with the invention, use of modifications such as the use of LNA monomers to enhance the potency, specificity and duration of action and broaden the routes of administration of oligonucleotides comprised of current chemistries such as MOE, ANA, FANA, PS etc (Uhlman, *et al.* (2000) *Current Opinions in Drug Discovery & Development* Vol. 3 No 2). This can be achieved by substituting some of the monomers in the current oligonucleotides by LNA monomers. The LNA modified oligonucleotide may have a size similar to the parent compound or may be larger or preferably smaller. It is preferred that such LNA-modified oligonucleotides contain less than about 70%, more preferably less than about 60%, most preferably less than about 50% LNA monomers and that their sizes are between about 5 and 25 nucleotides, more preferably between about 12 and 20 nucleotides.

[00150] Preferred modified oligonucleotide backbones comprise, but not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3'alkylene

phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

[00151] Representative United States patents that teach the preparation of the above phosphorus containing linkages comprise, but are not limited to, US patent nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5, 177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 10 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455, 233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563, 253; 5,571,799; 5,587,361; and 5,625,050, each of which is herein incorporated by reference.

[00152] Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing 20 backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

[00153] Representative United States patents that teach the preparation of the above oligonucleosides comprise, but are not limited to, US patent nos. 5,034,506; 5,166,315; 25 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264, 562; 5, 264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596, 086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623, 070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.

[00154] In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent 30

hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.

5 Representative United States patents that teach the preparation of PNA compounds comprise, but are not limited to, US patent nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen, *et al.* (1991) *Science* 254, 1497-1500.

[00155] In another preferred embodiment of the invention the oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular- CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- known as a methylene (methylimino) or MMI backbone, -CH₂-O-N(CH₃)-CH₂-, -CH₂N(CH₃)-N(CH₃)CH₂- and -O-N(CH₃)-CH₂-CH₂- wherein the native phosphodiester backbone is represented as -O-P-O-CH₂- of the above referenced US patent no. 5,489,677, and the amide backbones of the above referenced
 10 US patent no. 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced US patent no. 5,034,506.

[00156] Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C to CO alkyl or C₂ to CO alkenyl and alkynyl. Particularly preferred are O(CH₂)_nOmCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON(CH₂)_nCH₃)₂ where n and m can be from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C to CO, (lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar
 25 properties. A preferred modification comprises 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin *et al.*, (1995) *Helv. Chim. Acta*, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification comprises 2'-dimethylaminoethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as
 30

described in examples herein below, and 2'- dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'- DMAEEOE), i.e., 2'-O-CH₂-O-CH₂-N (CH₂)₂.

[00157] Other preferred modifications comprise 2'-methoxy (2'-O CH₃), 2'-aminopropoxy (2'-O CH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other
5 positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures comprise, but are not limited to, US patent nos. 4,981,957;
10 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514, 785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646, 265; 5,658,873; 5,670,633; and 5,700,920, each of which is herein incorporated by reference.

[00158] Oligonucleotides may also comprise nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleotides
15 comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleotides comprise other synthetic and natural nucleotides such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2- aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and
20 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylquanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-
25 deazaguanine and 3-deazaadenine.

[00159] Further, nucleotides comprise those disclosed in United States Patent No. 3,687,808, those disclosed in 'The Concise Encyclopedia of Polymer Science And Engineering', pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch *et al.*, 'Angewandle Chemie, International Edition', 1991, 30, page 613, and those disclosed by
30 Sanghvi, Y.S., Chapter 15, 'Antisense Research and Applications', pages 289-302, Crooke, S.T. and Lebleu, B. ea., CRC Press, 1993. Certain of these nucleotides are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These

comprise 5-substituted pyrimidines, 6- azapyrimidines and N-2, N-6 and 0-6 substituted purines, comprising 2-aminopropyladenine, 5- propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds, 'Antisense Research and Applications', CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

[00160] Representative United States patents that teach the preparation of the above noted modified nucleotides as well as other modified nucleotides comprise, but are not limited to, US patent nos. 3,687,808, as well as 4,845,205; 5,130,302; 5,134,066; 5,175, 273; 5, 367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,596,091; 5,614,617; 5,750,692, and 5,681,941, each of which is herein incorporated by reference.

[00161] Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates, which enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide.

[00162] Such moieties comprise but are not limited to, lipid moieties such as a cholesterol moiety (Letsinger *et al.*, (1989) *Proc. Natl. Acad. Sci. USA*, 86, 6553-6556), cholic acid (Manoharan *et al.*, (1994) *Bioorg. Med. Chem. Lett.*, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan *et al.*, (1992) *Ann. N. Y. Acad. Sci.*, 660, 306-309; Manoharan *et al.*, (1993) *Bioorg. Med. Chem. Lett.*, 3, 2765-2770), a thiocholesterol (Oberhauser *et al.*, (1992) *Nucl. Acids Res.*, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Kabanov *et al.*, (1990) *FEBS Lett.*, 259, 327-330; Svinarchuk *et al.*, (1993) *Biochimie* 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan *et al.*, (1995) *Tetrahedron Lett.*, 36, 3651-3654; Shea *et al.*, (1990) *Nucl. Acids Res.*, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Mancharan *et al.*, (1995) *Nucleosides & Nucleotides*, 14, 969-973), or adamantane acetic acid (Manoharan *et al.*, (1995) *Tetrahedron Lett.*, 36, 3651-3654), a palmityl moiety (Mishra *et al.*, (1995) *Biochim. Biophys. Acta*, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-t oxysterol moiety (Crooke *et al.*, (1996) *J. Pharmacol. Exp. Ther.*, 277, 923-937).

[00163] Representative United States patents that teach the preparation of such oligonucleotides conjugates comprise, but are not limited to, US patent nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552, 538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486, 603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762, 779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082, 830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5, 245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391, 723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5, 565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 10 5,599, 928 and 5,688,941, each of which is herein incorporated by reference.

[00164] *Drug discovery:* The compounds of the present invention can also be applied in the areas of drug discovery and target validation. The present invention comprehends the use of the compounds and preferred target segments identified herein in drug discovery efforts to elucidate relationships that exist between Brain derived neurotrophic factor (BDNF) 15 polynucleotides and a disease state, phenotype, or condition. These methods include detecting or modulating Brain derived neurotrophic factor (BDNF) polynucleotides comprising contacting a sample, tissue, cell, or organism with the compounds of the present invention, measuring the nucleic acid or protein level of Brain derived neurotrophic factor (BDNF) polynucleotides and/or a related phenotypic or chemical endpoint at some time after 20 treatment, and optionally comparing the measured value to a non-treated sample or sample treated with a further compound of the invention. These methods can also be performed in parallel or in combination with other experiments to determine the function of unknown genes for the process of target validation or to determine the validity of a particular gene product as a target for treatment or prevention of a particular disease, condition, or phenotype.

25 *Assessing Up-regulation or Inhibition of Gene Expression:*

[00165] Transfer of an exogenous nucleic acid into a host cell or organism can be assessed by directly detecting the presence of the nucleic acid in the cell or organism. Such detection can be achieved by several methods well known in the art. For example, the presence of the exogenous nucleic acid can be detected by Southern blot or by a polymerase chain reaction 30 (PCR) technique using primers that specifically amplify nucleotide sequences associated with the nucleic acid. Expression of the exogenous nucleic acids can also be measured using conventional methods including gene expression analysis. For instance, mRNA produced

from an exogenous nucleic acid can be detected and quantified using a Northern blot and reverse transcription PCR (RT-PCR).

[00166] Expression of RNA from the exogenous nucleic acid can also be detected by measuring an enzymatic activity or a reporter protein activity. For example, antisense modulatory activity can be measured indirectly as a decrease or increase in target nucleic acid expression as an indication that the exogenous nucleic acid is producing the effector RNA. Based on sequence conservation, primers can be designed and used to amplify coding regions of the target genes. Initially, the most highly expressed coding region from each gene can be used to build a model control gene, although any coding or non coding region can be used. Each control gene is assembled by inserting each coding region between a reporter coding region and its poly(A) signal. These plasmids would produce an mRNA with a reporter gene in the upstream portion of the gene and a potential RNAi target in the 3' non-coding region. The effectiveness of individual antisense oligonucleotides would be assayed by modulation of the reporter gene. Reporter genes useful in the methods of the present invention include acetohydroxyacid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucuronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), horseradish peroxidase (HRP), luciferase (Luc), nopaline synthase (NOS), octopine synthase (OCS), and derivatives thereof. Multiple selectable markers are available that confer resistance to ampicillin, bleomycin, chloramphenicol, gentamycin, hygromycin, kanamycin, lincomycin, methotrexate, phosphinothricin, puromycin, and tetracycline. Methods to determine modulation of a reporter gene are well known in the art, and include, but are not limited to, fluorometric methods (e.g. fluorescence spectroscopy, Fluorescence Activated Cell Sorting (FACS), fluorescence microscopy), antibiotic resistance determination.

[00167] BDNF protein and mRNA expression can be assayed using methods known to those of skill in the art and described elsewhere herein. For example, immunoassays such as the ELISA can be used to measure protein levels. BDNF ELISA kits are available commercially, e.g., from R&D Systems (Minneapolis, MN).

[00168] In embodiments, BDNF expression (e.g., mRNA or protein) in a sample (e.g., cells or tissues in vivo or in vitro) treated using an antisense oligonucleotide of the invention is evaluated by comparison with BDNF expression in a control sample. For example,

expression of the protein or nucleic acid can be compared using methods known to those of skill in the art with that in a mock-treated or untreated sample. Alternatively, comparison with a sample treated with a control antisense oligonucleotide (e.g., one having an altered or different sequence) can be made depending on the information desired. In another embodiment, a difference in the expression of the BDNF protein or nucleic acid in a treated vs an untreated sample can be compared with the difference in expression of a different nucleic acid (including any standard deemed appropriate by the researcher, e.g., a housekeeping gene) in a treated sample vs an untreated sample.

[00169] Observed differences can be expressed as desired, e.g., in the form of a ratio or fraction, for use in a comparison with control. In embodiments, the level of BDNF mRNA or protein, in a sample treated with an antisense oligonucleotide of the present invention, is increased or decreased by about 1.25-fold to about 10-fold or more relative to an untreated sample or a sample treated with a control nucleic acid. In embodiments, the level of BDNF mRNA or protein is increased or decreased by at least about 1.25-fold, at least about 1.3-fold, at least about 1.4-fold, at least about 1.5-fold, at least about 1.6-fold, at least about 1.7-fold, at least about 1.8-fold, at least about 2-fold, at least about 2.5-fold, at least about 3-fold, at least about 3.5-fold, at least about 4-fold, at least about 4.5-fold, at least about 5-fold, at least about 5.5-fold, at least about 6-fold, at least about 6.5-fold, at least about 7-fold, at least about 7.5-fold, at least about 8-fold, at least about 8.5-fold, at least about 9-fold, at least about 9.5-fold, or at least about 10-fold or more.

Kits, Research Reagents, Diagnostics, and Therapeutics

[00170] The compounds of the present invention can be utilized for diagnostics, therapeutics, and prophylaxis, and as research reagents and components of kits. Furthermore, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes or to distinguish between functions of various members of a biological pathway.

[00171] For use in kits and diagnostics and in various biological systems, the compounds of the present invention, either alone or in combination with other compounds or therapeutics, are useful as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

[00172] As used herein the term "biological system" or "system" is defined as any organism, cell, cell culture or tissue that expresses, or is made competent to express products of the

Brain derived neurotrophic factor (BDNF) genes. These include, but are not limited to, humans, transgenic animals, cells, cell cultures, tissues, xenografts, transplants and combinations thereof.

5 [00173] As one non limiting example, expression patterns within cells or tissues treated with one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence
10 of other compounds that affect expression patterns.

[00174] Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, (2000) *FEBS Lett.*, 480, 17-24; Celis, *et al.*, (2000) *FEBS Lett.*, 480, 2-16), SAGE (serial analysis of gene expression) (Madden, *et al.*, (2000) *Drug Discov. Today*, 5, 415- 425), READS (restriction enzyme amplification of digested
15 cDNAs) (Prashar and Weissman, (1999) *Methods Enzymol.*, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, *et al.*, (2000) *Proc. Natl. Acad. Sci. U.S.A.*, 97, 1976-81), protein arrays and proteomics (Celis, *et al.*, (2000) *FEBS Lett.*, 480, 2-16; Jungblut, *et al.*, *Electrophoresis*, 1999, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, *et al.*, *FEBS Lett.*, 2000, 480, 2-16; Larsson, *et al.*, *J. Biotechnol.*, 2000, 80, 143-57), subtractive
20 RNA fingerprinting (SuRF) (Fuchs, *et al.*, (2000) *Anal. Biochem.* 286, 91-98; Larson, *et al.*, (2000) *Cytometry* 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, (2000) *Curr. Opin. Microbiol.* 3, 316-21), comparative genomic hybridization (Carulli, *et al.*, (1998) *J. Cell Biochem. Suppl.*, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, (1999) *Eur. J. Cancer*, 35, 1895-904) and
25 mass spectrometry methods (To, Comb. (2000) *Chem. High Throughput Screen*, 3, 235-41).

[00175] The compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding Brain derived neurotrophic factor (BDNF). For example, oligonucleotides that hybridize with such efficiency and under such conditions as disclosed herein as to be effective Brain derived neurotrophic factor (BDNF)
30 modulators are effective primers or probes under conditions favoring gene amplification or detection, respectively. These primers and probes are useful in methods requiring the specific detection of nucleic acid molecules encoding Brain derived neurotrophic factor (BDNF) and

in the amplification of said nucleic acid molecules for detection or for use in further studies of Brain derived neurotrophic factor (BDNF). Hybridization of the antisense oligonucleotides, particularly the primers and probes, of the invention with a nucleic acid encoding Brain derived neurotrophic factor (BDNF) can be detected by means known in the art. Such means
5 may include conjugation of an enzyme to the oligonucleotide, radiolabeling of the oligonucleotide, or any other suitable detection means. Kits using such detection means for detecting the level of Brain derived neurotrophic factor (BDNF) in a sample may also be prepared.

[00176] The specificity and sensitivity of antisense are also harnessed by those of skill in the
10 art for therapeutic uses. Antisense compounds have been employed as therapeutic moieties in the treatment of disease states in animals, including humans. Antisense oligonucleotide drugs have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that antisense compounds can be useful therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells,
15 tissues and animals, especially humans.

[00177] For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of Brain derived neurotrophic factor (BDNF) polynucleotides is treated by administering antisense compounds in accordance with this invention. For example, in one non-limiting embodiment, the methods
20 comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of Brain derived neurotrophic factor (BDNF) modulator. The Brain derived neurotrophic factor (BDNF) modulators of the present invention effectively modulate the activity of the Brain derived neurotrophic factor (BDNF) or modulate the expression of the Brain derived neurotrophic factor (BDNF) protein. In one embodiment, the activity or
25 expression of Brain derived neurotrophic factor (BDNF) in an animal is inhibited by about 10% as compared to a control. Preferably, the activity or expression of Brain derived neurotrophic factor (BDNF) in an animal is inhibited by about 30%. More preferably, the activity or expression of Brain derived neurotrophic factor (BDNF) in an animal is inhibited by 50% or more. Thus, the oligomeric compounds modulate expression of Brain derived
30 neurotrophic factor (BDNF) mRNA by at least 10%, by at least 50%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100% as compared to a control.

- 5 [00178] In one embodiment, the activity or expression of Brain derived neurotrophic factor (BDNF) and/or in an animal is increased by about 10% as compared to a control. Preferably, the activity or expression of Brain derived neurotrophic factor (BDNF) in an animal is increased by about 30%. More preferably, the activity or expression of Brain derived neurotrophic factor (BDNF) in an animal is increased by 50% or more. Thus, the oligomeric compounds modulate expression of Brain derived neurotrophic factor (BDNF) mRNA by at least 10%, by at least 50%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100% as compared to a control.
- 10 [00179] For example, the reduction of the expression of Brain derived neurotrophic factor (BDNF) may be measured in serum, blood, adipose tissue, liver or any other body fluid, tissue or organ of the animal. Preferably, the cells contained within said fluids, tissues or organs being analyzed contain a nucleic acid molecule encoding Brain derived neurotrophic factor (BDNF) peptides and/or the Brain derived neurotrophic factor (BDNF) protein itself.
- 15 [00180] The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of a compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the compounds and methods of the invention may also be useful prophylactically.

Conjugates

- 20 [00181] Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates that enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter
- 25 molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of
- 30 this invention, include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve

uptake, distribution, metabolism or excretion of the compounds of the present invention. Representative conjugate groups are disclosed in International Patent Application No. PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. No. 6,287,860, which are incorporated herein by reference. Conjugate moieties include, but are not limited to, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-5- tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-Hphosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety. Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

[00182] Representative United States patents that teach the preparation of such oligonucleotides conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941.

25 *Formulations*

[00183] The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as foreexample, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S. Pat. Nos. 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,165; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556;

5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

[00184] Although, the antisense oligonucleotides do not need to be administered in the context of a vector in order to modulate a target expression and/or function, embodiments of the invention relates to expression vector constructs for the expression of antisense oligonucleotides, comprising promoters, hybrid promoter gene sequences and possess a strong constitutive promoter activity, or a promoter activity which can be induced in the desired case.

[00185] In an embodiment, invention practice involves administering at least one of the foregoing antisense oligonucleotides with a suitable nucleic acid delivery system. In one embodiment, that system includes a non-viral vector operably linked to the polynucleotide. Examples of such nonviral vectors include the oligonucleotide alone (e.g. any one or more of SEQ ID NOS: 3 to 8) or in combination with a suitable protein, polysaccharide or lipid formulation.

[00186] Additionally suitable nucleic acid delivery systems include viral vector, typically sequence from at least one of an adenovirus, adenovirus-associated virus (AAV), helper-dependent adenovirus, retrovirus, or hemagglutinin virus of Japan-liposome (HVJ) complex. Preferably, the viral vector comprises a strong eukaryotic promoter operably linked to the polynucleotide e.g., a cytomegalovirus (CMV) promoter.

[00187] Additionally preferred vectors include viral vectors, fusion proteins and chemical conjugates. Retroviral vectors include Moloney murine leukemia viruses and HIV-based viruses. One preferred HIV-based viral vector comprises at least two vectors wherein the gag and pol genes are from an HIV genome and the env gene is from another virus. DNA viral vectors are preferred. These vectors include pox vectors such as orthopox or avipox vectors, herpesvirus vectors such as a herpes simplex I virus (HSV) vector [Geller, A.I. *et al.*, (1995) *J. Neurochem*, 64: 487; Lim, F., *et al.*, in *DNA Cloning: Mammalian Systems*, D. Glover, Ed. (Oxford Univ. Press, Oxford England) (1995); Geller, A.I. *et al.*, (1993) *Proc Natl. Acad. Sci.: U.S.A.*:90 7603; Geller, A.I., *et al.*, (1990) *Proc Natl. Acad. Sci USA*: 87:1149], Adenovirus Vectors (LeGal LaSalle *et al.*, *Science*, 259:988 (1993); Davidson, *et al.*, (1993) *Nat. Genet.* 3: 219; Yang, *et al.*, (1995) *J. Virol.* 69: 2004) and Adeno-associated Virus Vectors (Kaplitt, M.G., *et al.*, (1994) *Nat. Genet.* 8:148).

[00188] The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof.

5 [00189] The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. For oligonucleotides, preferred examples of pharmaceutically acceptable salts and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein
10 by reference.

[00190] The present invention also includes pharmaceutical compositions and formulations that include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be
15 topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular,
20 administration.

[00191] For treating tissues in the central nervous system, administration can be made by, e.g., injection or infusion into the cerebrospinal fluid. Administration of antisense RNA into cerebrospinal fluid is described, e.g., in U.S. Pat. App. Pub. No. 2007/0117772, "Methods for slowing familial ALS disease progression," incorporated herein by reference in its entirety.

25 [00192] When it is intended that the antisense oligonucleotide of the present invention be administered to cells in the central nervous system, administration can be with one or more agents capable of promoting penetration of the subject antisense oligonucleotide across the blood-brain barrier. Injection can be made, e.g., in the entorhinal cortex or hippocampus. Delivery of neurotrophic factors by administration of an adenovirus vector to motor neurons
30 in muscle tissue is described in, e.g., U.S. Pat. No. 6,632,427, "Adenoviral-vector-mediated gene transfer into medullary motor neurons," incorporated herein by reference. Delivery of vectors directly to the brain, e.g., the striatum, the thalamus, the hippocampus, or the

substantia nigra, is known in the art and described, e.g., in U.S. Pat. No. 6,756,523, “Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain,” incorporated herein by reference. Administration can be rapid as by injection or made over a period of time as by slow infusion or administration of slow release formulations.

The subject antisense oligonucleotides can also be linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties. For example, the antisense oligonucleotide can be coupled to any substance, known in the art to promote penetration or transport across the blood-brain barrier, such as an antibody to the transferrin receptor, and administered by intravenous injection. The antisense compound can be linked with a viral vector, for example, that makes the antisense compound more effective and/or increases the transport of the antisense compound across the blood-brain barrier. Osmotic blood brain barrier disruption can also be accomplished by, e.g., infusion of sugars including, but not limited to, meso erythritol, xylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, myo-inositol, L(-) fructose, D(-) mannitol, D(+) glucose, D(+) arabinose, D(-) arabinose, cellobiose, D(+) maltose, D(+) raffinose, L(+) rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, and L(-) lyxose, or amino acids including, but not limited to, glutamine, lysine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tyrosine, valine, and taurine. Methods and materials for enhancing blood brain barrier penetration are described, e.g., in U. S. Patent No. 4,866,042, “Method for the delivery of genetic material across the blood brain barrier,” 6,294,520, “Material for passage through the blood-brain barrier,” and 6,936,589, “Parenteral delivery systems,” all incorporated herein by reference in their entirety.

[00193] The subject antisense compounds may be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. For example, cationic lipids may be included in the formulation to facilitate oligonucleotide uptake. One such composition shown to facilitate uptake is LIPOFECTIN (available from GIBCO-BRL, Bethesda, MD).

[00194] Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration. Pharmaceutical compositions and formulations for

topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

5 [00195] The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association
10 the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[00196] The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be
15 formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

[00197] Pharmaceutical compositions of the present invention include, but are not limited to,
20 solutions, emulsions, foams and liposome-containing formulations. The pharmaceutical compositions and formulations of the present invention may comprise one or more penetration enhancers, carriers, excipients or other active or inactive ingredients.

[00198] Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. Emulsions may contain additional
25 components in addition to the dispersed phases, and the active drug that may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Microemulsions are included as an embodiment of the present invention. Emulsions and their uses are well known in the art and are further described in U.S. Pat. No. 6,287,860.

[00199] Formulations of the present invention include liposomal formulations. As used in the
30 present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior

that contains the composition to be delivered. Cationic liposomes are positively charged liposomes that are believed to interact with negatively charged DNA molecules to form a stable complex. Liposomes that are pH-sensitive or negatively-charged are believed to entrap DNA rather than complex with it. Both cationic and noncationic liposomes have been used to
5 deliver DNA to cells.

[00200] Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids. When incorporated into liposomes, these specialized lipids result in liposomes with enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized
10 liposomes are those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. Liposomes and their uses are further described in U.S. Pat. No. 6,287,860.

[00201] The pharmaceutical formulations and compositions of the present invention may also
15 include surfactants. The use of surfactants in drug products, formulations and in emulsions is well known in the art. Surfactants and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein by reference.

[00202] In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides. In addition to
20 aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs. Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating nonsurfactants. Penetration enhancers and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein by reference.

[00203] One of skill in the art will recognize that formulations are routinely designed
25 according to their intended use, i.e. route of administration.

[00204] Preferred formulations for topical administration include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred
30 lipids and liposomes include neutral (e.g. dioleoyl-phosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g.

dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoyl-phosphatidyl ethanolamine DOTMA).

[00205] For topical or other administration, oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters, pharmaceutically acceptable salts thereof, and their uses are further described in U.S. Pat. No. 6,287,860.

[00206] Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitables. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts and fatty acids and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein by reference. Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein by reference.

[00207] Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions that may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

[00208] Certain embodiments of the invention provide pharmaceutical compositions containing one or more oligomeric compounds and one or more other chemotherapeutic agents that function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to cancer chemotherapeutic drugs such as daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bischloroethyl- nitrosurea, busulfan,

mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5- azacytidine, 5 hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclo-phosphoramidate, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. Combinations of antisense compounds and other non-antisense drugs are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

[00209] In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. For example, the first target may be a particular antisense sequence of Brain derived neurotrophic factor (BDNF), and the second target may be a region from another nucleotide sequence. Alternatively, compositions of the invention may contain two or more antisense compounds targeted to different regions of the same Brain derived neurotrophic factor (BDNF) nucleic acid target. Numerous examples of antisense compounds are illustrated herein and others may be selected from among suitable compounds known in the art. Two or more combined compounds may be used together or sequentially.

Dosing:

The formulation of therapeutic compositions and their subsequent administration (dosing) is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is

achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC50s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 μg to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 μg to 100 g per kg of body weight, once or more daily, to once every 20 years. In embodiments, a patient is treated with a dosage of drug that is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100 mg/kg body weight. Certain injected dosages of antisense oligonucleotides are described, e.g., in U.S. Pat. No. 7,563,884, "Antisense modulation of PTP1B expression," incorporated herein by reference in its entirety.

[00210] While various embodiments of the present invention have been described above, it should be understood that they have been presented by way of example only, and not limitation. Numerous changes to the disclosed embodiments can be made in accordance with the disclosure herein without departing from the spirit or scope of the invention. Thus, the breadth and scope of the present invention should not be limited by any of the above described embodiments.

[00211] All documents mentioned herein are incorporated herein by reference. All publications and patent documents cited in this application are incorporated by reference for all purposes to the same extent as if each individual publication or patent document were so individually denoted. By their citation of various references in this document, Applicants do not admit any particular reference is "prior art" to their invention. Embodiments of inventive compositions and methods are illustrated in the following examples.

EXAMPLES

[00212] The following non-limiting Examples serve to illustrate selected embodiments of the invention. It will be appreciated that variations in proportions and alternatives in elements of the components shown will be apparent to those skilled in the art and are within the scope of
5 embodiments of the present invention.

Example 1: Design of antisense oligonucleotides specific for a nucleic acid molecule antisense to a Brain derived neurotrophic factor (BDNF) polynucleotide and/or a sense strand of Brain derived neurotrophic factor (BDNF) polynucleotide

[00213] As indicated above the term "oligonucleotide specific for" or "oligonucleotide
10 targets" refers to an oligonucleotide having a sequence (i) capable of forming a stable complex with a portion of the targeted gene, or (ii) capable of forming a stable duplex with a portion of an mRNA transcript of the targeted gene.

[00214] Selection of appropriate oligonucleotides is facilitated by using computer programs that automatically align nucleic acid sequences and indicate regions of identity or homology.
15 Such programs are used to compare nucleic acid sequences obtained, for example, by searching databases such as GenBank or by sequencing PCR products. Comparison of nucleic acid sequences from a range of species allows the selection of nucleic acid sequences that display an appropriate degree of identity between species. In the case of genes that have not been sequenced, Southern blots are performed to allow a determination of the degree of
20 identity between genes in target species and other species. By performing Southern blots at varying degrees of stringency, as is well known in the art, it is possible to obtain an approximate measure of identity. These procedures allow the selection of oligonucleotides that exhibit a high degree of complementarity to target nucleic acid sequences in a subject to be controlled and a lower degree of complementarity to corresponding nucleic acid sequences
25 in other species. One skilled in the art will realize that there is considerable latitude in selecting appropriate regions of genes for use in the present invention.

[00215] An antisense compound is "specifically hybridizable" when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a modulation of function and/or activity, and there is a sufficient degree of complementarity
30 to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in

the case of in vivo assays or therapeutic treatment, and under conditions in which assays are performed in the case of in vitro assays

[00216] The hybridization properties of the oligonucleotides described herein can be determined by one or more in vitro assays as known in the art. For example, the properties of the oligonucleotides described herein can be obtained by determination of binding strength between the target natural antisense and a potential drug molecules using melting curve assay.

[00217] The binding strength between the target natural antisense and a potential drug molecule (Molecule) can be estimated using any of the established methods of measuring the strength of intermolecular interactions, for example, a melting curve assay.

[00218] Melting curve assay determines the temperature at which a rapid transition from double-stranded to single-stranded conformation occurs for the natural antisense/Molecule complex. This temperature is widely accepted as a reliable measure of the interaction strength between the two molecules.

[00219] A melting curve assay can be performed using a cDNA copy of the actual natural antisense RNA molecule or a synthetic DNA or RNA nucleotide corresponding to the binding site of the Molecule. Multiple kits containing all necessary reagents to perform this assay are available (e.g. Applied Biosystems Inc. MeltDoctor kit). These kits include a suitable buffer solution containing one of the double strand DNA (dsDNA) binding dyes (such as ABI HRM dyes, SYBR Green, SYTO, etc.). The properties of the dsDNA dyes are such that they emit almost no fluorescence in free form, but are highly fluorescent when bound to dsDNA.

[00220] To perform the assay the cDNA or a corresponding oligonucleotide are mixed with Molecule in concentrations defined by the particular manufacturer's protocols. The mixture is heated to 95 °C to dissociate all pre-formed dsDNA complexes, then slowly cooled to room temperature or other lower temperature defined by the kit manufacturer to allow the DNA molecules to anneal. The newly formed complexes are then slowly heated to 95 °C with simultaneous continuous collection of data on the amount of fluorescence that is produced by the reaction. The fluorescence intensity is inversely proportional to the amounts of dsDNA present in the reaction. The data can be collected using a real time PCR instrument compatible with the kit (e.g. ABI's StepOne Plus Real Time PCR System or LightTyper instrument, Roche Diagnostics, Lewes, UK).

[00221] Melting peaks are constructed by plotting the negative derivative of fluorescence with respect to temperature ($-d(\text{Fluorescence})/dT$) on the y-axis) against temperature (x-axis) using

appropriate software (for example LightTyper (Roche) or SDS Dissociation Curve, ABI). The data is analyzed to identify the temperature of the rapid transition from dsDNA complex to single strand molecules. This temperature is called T_m and is directly proportional to the strength of interaction between the two molecules. Typically, T_m will exceed 40 °C.

5 *Example 2: Modulation of BDNF polynucleotides*

Treatment of HepG2 cells with antisense oligonucleotides:

[00222] HepG2 cells from ATCC (cat# HB-8065) were grown in growth media (MEM/EBSS (Hyclone cat #SH30024, or Mediatech cat # MT-10-010-CV) +10% FBS (Mediatech cat# MT35- 011-CV)+ penicillin/streptomycin (Mediatech cat# MT30-002-CI)) at 37°C and 5%
10 CO₂. One day before the experiment the cells were replated at the density of 1.5×10^5 /ml into 6 well plates and incubated at 37°C and 5% CO₂. On the day of the experiment the media in the 6 well plates was changed to fresh growth media. All antisense oligonucleotides were diluted to the concentration of 20 µM. Two µl of this solution was incubated with 400 µl of Opti-MEM media (Gibco cat#31985-070) and 4 µl of Lipofectamine 2000 (Invitrogen cat#
15 11668019) at room temperature for 20 min and applied to each well of the 6 well plates with HepG2 cells. A Similar mixture including 2 µl of water instead of the oligonucleotide solution was used for the mock-transfected controls. After 3-18 h of incubation at 37°C and 5% CO₂ the media was changed to fresh growth media. 48 h after addition of antisense oligonucleotides the media was removed and RNA was extracted from the cells using SV
20 Total RNA Isolation System from Promega (cat # Z3105) or RNeasy Total RNA Isolation kit from Qiagen (cat# 74181) following the manufacturers' instructions. 600 ng of RNA was added to the reverse transcription reaction performed using Verso cDNA kit from Thermo Scientific (cat#AB1453B) or High Capacity cDNA Reverse Transcription Kit (cat# 4368813) as described in the manufacturer's protocol. The cDNA from this reverse transcription
25 reaction was used to monitor gene expression by real time PCR using ABI Taqman Gene Expression Mix (cat#4369510) and primers/probes designed by ABI (Applied Biosystems Taqman Gene Expression Assay by Applied Biosystems Inc., Foster City CA). The following PCR cycle was used: 50°C for 2 min, 95°C for 10 min, 40 cycles of (95°C for 15 seconds, 60°C for 1 min) using StepOne Plus Real Time PCR Machine (Applied Biosystems).

30 [00223] Fold change in gene expression after treatment with antisense oligonucleotides was calculated based on the difference in 18S-normalized dCt values between treated and mock-transfected samples.

[00224] Detection oligos for BDNF antisense:

ABI assay ID Hs00417345_m1

Context sequence GCACACCTGGAGATACTCTATTATA (SEQ ID No.: 9)

[00225] Detection oligos for BDNF:

5 ABI assay ID Hs00542425_s1

CCTGCAGAATGGCCTGGAATTACAA (SEQ ID No.: 10)

Results:

[00226] Real time PCR results show that the levels of the BDNF mRNA in HepG2 cells are significantly increased 48 h after treatment with two of the LNA gapmers with fully phosphothioated backbone designed to BDNF antisense (CUR-71, P=0.04, CUR-73, P=0.07, CUR-76, P=0.03) (Fig. 1A). In the same samples the levels of BDNF antisense were significantly decreased after treatment with all oligos except CUR-72, which is possibly due to different oligos affecting different splice variants of BDNF and/or BDNF antisense (Fig. 1B).

15 *Treatment of CHP212 cells with antisense oligonucleotides:*

[00227] CHP212 cells from ATCC (cat# CRL-2273) were grown in growth media (MEM/F12 (ATCC cat # 30-2003 and Mediatech cat# 10-080-CV) +10% FBS (Mediatech cat# MT35-011-CV)+ penicillin/streptomycin (Mediatech cat# MT30-002-CI)) at 37°C and 5% CO₂. One day before the experiment the cells were replated at the density of 1.5×10^5 /ml into 6 well plates and incubated at 37°C and 5% CO₂. On the day of the experiment the media in the 6 well plates was changed to fresh growth media. All antisense oligonucleotides were diluted to the concentration of 20 μM. Two μl of this solution was incubated with 400 μl of Opti-MEM media (Gibco cat#31985-070) and 4 μl of Lipofectamine 2000 (Invitrogen cat# 11668019) at room temperature for 20 min and applied to each well of the 6 well plates with CHP212 cells. Similar mixture including 2 μl of water instead of the oligonucleotide solution was used for the mock-transfected controls. After 3-18 h of incubation at 37°C and 5% CO₂ the media was changed to fresh growth media. 48 h after addition of antisense oligonucleotides the media was removed and RNA was extracted from the cells using SV Total RNA Isolation System from Promega (cat # Z3105) or RNeasy Total RNA Isolation kit from Qiagen (cat# 74181) following the manufacturers' instructions. 600 ng of RNA was added to the reverse transcription reaction performed using Verso cDNA kit from Thermo Scientific (cat#AB1453B) or High Capacity cDNA Reverse Transcription Kit (cat# 4368813) as

described in the manufacturer's protocol. The cDNA from this reverse transcription reaction was used to monitor gene expression by real time PCR using ABI Taqman Gene Expression Mix (cat#4369510) and primers/probes designed by ABI (Applied Biosystems Taqman Gene Expression Assay: Hs00542425_s1 by Applied Biosystems Inc., Foster City CA). The following PCR cycle was used: 50°C for 2 min, 95°C for 10 min, 40 cycles of (95°C for 15 seconds, 60°C for 1 min) using StepOne Plus Real Time PCR Machine (Applied Biosystems). [00228] Fold change in gene expression after treatment with antisense oligonucleotides was calculated based on the difference in 18S-normalized dCt values between treated and mock-transfected samples.

10 *Results:*

[00229] Real time PCR results show that the levels of the BDNF mRNA in CHP212 cells are significantly increased 48 h after treatment with three of the oligos designed to BDNF antisense (Fig. 1C).

15 *Example 3: Antisense Modulation of BDNF polynucleotide and protein product and effect on memory and learning in amyloid-transgenic mice*

[00230] Antisense oligonucleotides specific for BDNF-AS (e.g., oligonucleotides identified by SEQ ID NOS 3-8) are administered to J20 mice, which express the human amyloid precursor protein (APP) transgene bearing both the Swedish and Indiana APP mutations. As described by, e.g., Nagahara, et al., 2009, "Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease," Nature Medicine 15(3): 331-337, incorporated herein by reference, these mice show cortical plaques and progressive cell loss in the entorhinal cortex beginning at age 2-3 months, and cognitive decline by 6-7 months. Pre-treatment blood samples are collected several days before dosing by collecting 4-7 drops from the tail vein. Each antisense oligonucleotide is dissolved in PBS and administered into a mouse by injection into the entorhinal cortex or the hippocampus at about 10 mg/kg. Control mice (age-matched WT littermates) are administered the same volume of PBS alone. One month later, spatial memory is tested in the Morris water maze in treated and control mice, and their performance compared. Restorative effects are also tested by measuring hippocampal-dependent and hippocampal-independent learning. After testing, the mice are sacrificed and brain tissues (entorhinal cortex and hippocampal dentate gyrus) are collected for analysis of expression of BDNF protein and mRNA. Human BDNF protein

concentration and secretion levels are determined using an enzyme linked immunosorbent assay (ELISA) kit (available commercially, e.g., Quantikine human BDNF, R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. mRNA is assayed using RT-PCR, as described elsewhere herein.

5

Example 4: Antisense modulation of BDNF polynucleotide and protein product and effect on memory and learning in SAM-P8 mice.

[00231] The P8 strain of senescence accelerated mice (SAM), as described, e.g., in U.S. Pat. No. 6,310,048, "Antisense modulation of amyloid beta protein expression," incorporated
10 herein by reference, show an age-related increase in impaired learning (acquisition) and memory (retention) as well as an age-related increase in the accumulation of amyloid precursor protein and A β P. SAM-P8 mice have a median life span of 17.2 months, as opposed to a normal life span of 24 months for standard R1 mice.

15 [00232] SAM-P8 mice are divided into seven groups of 10 mice each. At 11 months of age (4 weeks prior to training) one group is given 0.2 microliters of calf serum by intracerebral ventricular injection (ICV), while the other six groups are given one or two 0.2 microliter injections (each of 2 microliters and having 60 ng of oligonucleotide) ICV of antisense oligonucleotides of the present invention. Administration is performed by drilling a hole
20 through the skull over the third ventricle (-0.5 relative to bregma; 0.5 mm right of central suture). The scalp is closed and the mice are returned to their cages. Two weeks after this first injection, one of the groups of treated mice and the group that had received serum are injected with the saline vehicle that is used as the carrier for the antisense oligonucleotides. At this same time (two weeks before training), each one of the oligonucleotides is administered
25 in saline ICV to all of the mice in one group. Each administration contains 0.2 microliter (60 ng of oligonucleotide per injection).

[00233] Two weeks after the last injection, when the mice are 12 months of age, they are trained on footshock avoidance in a T-maze. The training and testing procedures are the same
30 as described by Flood et al., *Physiology & Behavior*, 58:819-822 (1995); and Flood et al., *Neurobiology of Aging*, 14:159-166 (1993), and U.S. Pat. No. 6,310,048, all incorporated by reference herein. All mice are trained until they make their first avoidance response. Retention

test scores when tested 1 hr after training and one week later are compared. One week after original training, retention for both 4 and 12 month-old mice is tested by continuing the training until each mouse makes 5 avoidances in 6 consecutive training trials. Results are expressed as means and with a standard error of the means. The trials to first avoidance, or to a criterion of 5 avoidances in 6 consecutive trials are analyzed in separate one way ANOVAs. Statistical differences between the means of the 12 month-old mice that received antisense oligonucleotides are compared to the means of the 12 month-old mice that received the saline solution vehicle using Dunnett's T-test.

10 [00234] Samples are recovered from the amygdala, hippocampal, and septum regions of the brains of each of four mice, two treated with the saline vehicle and the other two treated with the antisense oligonucleotides. The samples are tested for BDNF protein expression by ELISA or immuno-blotting against an antibody that specifically hybridizes to BDNF.

15 *Example 5: Antisense modulation of BDNF polynucleotide and protein product and effect on disease progression in patients with Amyotrophic Lateral Sclerosis*

[00235] A pharmaceutical composition comprising an antisense oligonucleotide of the present invention (e.g., an oligonucleotide identified by any of SEQ ID NOS: 3-8) is administered to the cerebrospinal fluid of an individual suffering from familial ALS. A Medtronic SyncroMed II pump is used to deliver the composition to the cerebrospinal fluid. The pump is surgically implanted according to the manufacturer instructions. The pump reservoir is loaded with the pharmaceutical composition in phosphate-buffered saline. The pharmaceutical composition is administered at an amount that yields an infusion of 8 mg to 12 mg/day of the antisense oligonucleotide into the cerebrospinal fluid. Antisense oligonucleotide is infused, for at least 28 days. The drug is pumped at a programmed dose into a catheter that is surgically intrathecally implanted.

[00236] Disease progression is measured by methods routine in the art and described herein, for example, using indicators including ALSFSR-R, and measurements of FEV₁, FVC, and muscle strength. These methods are used by a physician to assess disease state at initiation of treatment, and to provide a baseline for disease state. Subsequent assessments are performed at intervals, as determined by the physician, during the delivery period. Expression of BDNF

protein and mRNA in cerebrospinal fluid is assayed. Human BDNF protein concentration and secretion levels are determined using an enzyme linked immunosorbent assay (ELISA) kit (e.g., Quantikine human BDNF, R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. mRNA is assayed using RT-PCR, as described elsewhere herein.

5 [00237] Although the invention has been illustrated and described with respect to one or more implementations, equivalent alterations and modifications will occur to others skilled in the art upon the reading and understanding of this specification and the annexed drawings. In addition, while a particular feature of the invention may have been disclosed with respect to only one of several implementations, such feature may be combined with one or more other
10 features of the other implementations as may be desired and advantageous for any given or particular application.

[00238] The Abstract of the disclosure will allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the following claims.

CLAIMS

What is claimed is:

1. A method of modulating a function of and/or the expression of a Brain derived neurotrophic factor (BDNF) polynucleotide in patient cells or tissues *in vivo* or *in vitro* comprising:

contacting said cells or tissues with at least one antisense oligonucleotide of 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising about 5 to about 30 consecutive nucleotides within nucleotides 1 to 3175 of SEQ ID NO: 2 (Figure 3);

thereby modulating a function of and/or the expression of the Brain derived neurotrophic factor (BDNF) polynucleotide in patient cells or tissues *in vivo* or *in vitro*.

2. A method of modulating a function of and/or the expression of a Brain derived neurotrophic factor (BDNF) polynucleotide in patient cells or tissues *in vivo* or *in vitro* comprising:

contacting said cells or tissues with at least one antisense oligonucleotide of 5 to 30 nucleotides in length wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a natural antisense of a Brain derived neurotrophic factor (BDNF) polynucleotide;

thereby modulating a function of and/or the expression of the Brain derived neurotrophic factor (BDNF) polynucleotide in patient cells or tissues *in vivo* or *in vitro*.

3. A method of modulating a function of and/or the expression of a Brain derived neurotrophic factor (BDNF) polynucleotide in patient cells or tissues *in vivo* or *in vitro* comprising:

contacting said cells or tissues with at least one antisense oligonucleotide of 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to the Brain derived neurotrophic factor (BDNF) polynucleotide;

thereby modulating a function of and/or the expression of the Brain derived neurotrophic factor (BDNF) polynucleotide in patient cells or tissues *in vivo* or *in vitro*.

4. A method of modulating a function of and/or the expression of a Brain derived neurotrophic factor (BDNF) polynucleotide in patient cells or tissues *in vivo* or *in vitro* comprising:

contacting said cells or tissues with at least one antisense oligonucleotide that targets a region of a natural antisense oligonucleotide of the Brain derived neurotrophic factor (BDNF) polynucleotide;

thereby modulating a function of and/or the expression of the Brain derived neurotrophic factor (BDNF) polynucleotide in patient cells or tissues *in vivo* or *in vitro*.

5. The method of claim 4, wherein a function of and/or the expression of the Brain derived neurotrophic factor (BDNF) is increased *in vivo* or *in vitro* with respect to a control.

6. The method of claim 4, wherein the at least one antisense oligonucleotide targets a natural antisense sequence of a Brain derived neurotrophic factor (BDNF) polynucleotide.

7. The method of claim 4, wherein the at least one antisense oligonucleotide targets a nucleic acid sequence comprising coding and/or non-coding nucleic acid sequences of a Brain derived neurotrophic factor (BDNF) polynucleotide.

8. The method of claim 4, wherein the at least one antisense oligonucleotide targets overlapping and/or non-overlapping sequences of a Brain derived neurotrophic factor (BDNF) polynucleotide.

9. The method of claim 4, wherein the at least one antisense oligonucleotide comprises one or more modifications selected from: at least one modified sugar moiety, at least one modified internucleoside linkage, at least one modified nucleotide, and combinations thereof.

10. The method of claim 9, wherein the one or more modifications comprise at least one modified sugar moiety selected from: a 2'-O-methoxyethyl modified sugar moiety, a

2'-methoxy modified sugar moiety, a 2'-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and combinations thereof.

11. The method of claim 9, wherein the one or more modifications comprise at least one modified internucleoside linkage selected from: a phosphorothioate, 2'-
5 Omethoxyethyl (MOE), 2'-fluoro, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.
12. The method of claim 9, wherein the one or more modifications comprise at least one modified nucleotide selected from: a peptide nucleic acid (PNA), a locked nucleic acid
10 (LNA), an arabino-nucleic acid (FANA), an analogue, a derivative, and combinations thereof.
13. The method of claim 1, wherein the at least one oligonucleotide comprises at least one of the oligonucleotide sequences set forth as SEQ ID NOS: 3 to 8.
14. A method of modulating a function of and/or the expression of a Brain derived
15 neurotrophic factor (BDNF) gene in mammalian cells or tissues *in vivo* or *in vitro* comprising:
- contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide about 5 to about 30 nucleotides in length, said at least one siRNA oligonucleotide being specific for an antisense polynucleotide of a Brain derived
20 neurotrophic factor (BDNF) polynucleotide, wherein said at least one siRNA oligonucleotide has at least about 50% sequence identity to a complementary sequence of at least about five consecutive nucleic acids of the antisense and/or sense nucleic acid molecule of the Brain derived neurotrophic factor (BDNF) polynucleotide; and,
- modulating a function of and/or the expression of Brain derived neurotrophic factor
25 (BDNF) in mammalian cells or tissues *in vivo* or *in vitro*.
15. The method of claim 14, wherein said oligonucleotide has at least 80% sequence identity to a sequence of at least about five consecutive nucleic acids that is complementary to the antisense and/or sense nucleic acid molecule of the Brain derived neurotrophic factor (BDNF) polynucleotide.

16. A method of modulating a function of and/or the expression of Brain derived neurotrophic factor (BDNF) in mammalian cells or tissues *in vivo* or *in vitro* comprising:
- 5 contacting said cells or tissues with at least one antisense oligonucleotide of about 5 to about 30 nucleotides in length specific for noncoding and/or coding sequences of a sense and/or natural antisense strand of a Brain derived neurotrophic factor (BDNF) polynucleotide wherein said at least one antisense oligonucleotide has at least 50% sequence identity to at least one of the nucleic acid sequences set forth as SEQ ID NOS: 1 and 2; and,
- 10 modulating the function and/or expression of the Brain derived neurotrophic factor (BDNF) in mammalian cells or tissues *in vivo* or *in vitro*.
17. A synthetic, modified oligonucleotide comprising at least one modification wherein the at least one modification is selected from: at least one modified sugar moiety; at least one modified internucleotide linkage; at least one modified nucleotide, and combinations thereof; wherein said oligonucleotide is an antisense compound which hybridizes to and modulates the function and/or expression of a Brain derived neurotrophic factor (BDNF) gene *in vivo* or *in vitro* as compared to a normal control.
- 15
18. The oligonucleotide of claim 17, wherein the at least one modification comprises an internucleotide linkage selected from the group consisting of: phosphorothioate, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.
- 20
19. The oligonucleotide of claim 17, wherein said oligonucleotide comprises at least one phosphorothioate internucleotide linkage.
- 25
20. The oligonucleotide of claim 17, wherein said oligonucleotide comprises a backbone of phosphorothioate internucleotide linkages.
21. The oligonucleotide of claim 17, wherein the oligonucleotide comprises at least one modified nucleotide, said modified nucleotide selected from: a peptide nucleic acid, a locked nucleic acid (LNA), analogue, derivative, and a combination thereof.
- 30
22. The oligonucleotide of claim 17, wherein the oligonucleotide comprises a plurality of modifications, wherein said modifications comprise modified nucleotides selected

from: phosphorothioate, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and a combination thereof.

23. The oligonucleotide of claim 17, wherein the oligonucleotide comprises a plurality of
5 modifications, wherein said modifications comprise modified nucleotides selected from: peptide nucleic acids, locked nucleic acids (LNA), analogues, derivatives, and a combination thereof.
24. The oligonucleotide of claim 17, wherein the oligonucleotide comprises at least one
10 modified sugar moiety selected from: a 2'-O-methoxyethyl modified sugar moiety, a 2'-methoxy modified sugar moiety, a 2'-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and a combination thereof.
25. The oligonucleotide of claim 17, wherein the oligonucleotide comprises a plurality of
15 modifications, wherein said modifications comprise modified sugar moieties selected from: a 2'-O-methoxyethyl modified sugar moiety, a 2'-methoxy modified sugar moiety, a 2'-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and a combination thereof.
26. The oligonucleotide of claim 17, wherein the oligonucleotide is of at least about 5 to
20 about 30 nucleotides in length and hybridizes to an antisense and/or sense strand of a Brain derived neurotrophic factor (BDNF) polynucleotide wherein said oligonucleotide has at least about 20% sequence identity to a complementary sequence of at least about five consecutive nucleic acids of the antisense and/or sense coding and/or noncoding nucleic acid sequences of the Brain derived neurotrophic factor (BDNF) polynucleotide.
27. The oligonucleotide of claim 17, wherein the oligonucleotide has at least about 80%
25 sequence identity to a complementary sequence of at least about five consecutive nucleic acids of the antisense and/or sense coding and/or noncoding nucleic acid sequence of the Brain derived neurotrophic factor (BDNF) polynucleotide.
28. The oligonucleotide of claim 17, wherein said oligonucleotide hybridizes to and
30 modulates expression and/or function of at least one Brain derived neurotrophic factor (BDNF) polynucleotide *in vivo* or *in vitro*, as compared to a normal control.

29. The oligonucleotide of claim 17, wherein the oligonucleotide comprises the sequences set forth as SEQ ID NOS: 3 to 8.
30. A composition comprising one or more oligonucleotides specific for one or more Brain derived neurotrophic factor (BDNF) polynucleotides, said polynucleotides comprising antisense sequences, complementary sequences, alleles, homologs, isoforms, variants, derivatives, mutants, fragments, or combinations thereof.
31. The composition of claim 30, wherein the one or more oligonucleotides have at least about 40% sequence identity as compared to any one of the nucleotide sequences set forth as SEQ ID NOS: 3 to 8.
32. The composition of claim 30, wherein the at least one of the one or more oligonucleotides comprises one of the nucleotide sequences set forth as SEQ ID NOS: 3 to 8.
33. The composition of claim 32, wherein the oligonucleotides set forth as SEQ ID NOS: 3 to 8 comprise one or more modifications or substitutions.
34. The composition of claim 33, wherein the one or more modifications are selected from: phosphorothioate, methylphosphonate, peptide nucleic acid, locked nucleic acid (LNA) molecules, and combinations thereof.
35. A method of preventing or treating a disease associated with at least one Brain derived neurotrophic factor (BDNF) polynucleotide and/or at least one encoded product thereof, comprising:
administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide that binds to a natural antisense sequence of said at least one Brain derived neurotrophic factor (BDNF) polynucleotide and modulates expression of said at least one Brain derived neurotrophic factor (BDNF) polynucleotide; thereby preventing or treating the disease associated with the at least one Brain derived neurotrophic factor (BDNF) polynucleotide and/or at least one encoded product thereof.
36. The method of claim 35, wherein a disease associated with the at least one Brain derived neurotrophic factor (BDNF) polynucleotide is selected from: a disease or a disorder associated with defective neurogenesis; a neurodegenerative disease or disorder (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease,


amyotrophic lateral sclerosis etc.); a neuropsychiatric disorder (depression, schizophrenia, schizofreniform disorder, schizoaffective disorder, and delusional disorder); an anxiety disorder such as panic disorder, phobias (including agoraphobia), an obsessive-compulsive disorder, a posttraumatic stress disorder, a bipolar disorder, anorexia nervosa, bulimia nervosa, an autoimmune disorder (e.g., multiple sclerosis) of the central nervous system, memory loss, a long term or a short term memory disorder, benign forgetfulness, a childhood learning disorder, close head injury, an attention deficit disorder, neuronal reaction to viral infection, brain damage, narcolepsy, a sleep disorder (e.g., circadian rhythm disorders, insomnia and narcolepsy); severance of nerves or nerve damage, severance of cerebrospinal nerve cord (CNS) and a damage to brain or nerve cells, a neurological deficit associated with AIDS, a motor and tic disorder characterized by motor and/or vocal tics (e.g., Tourette's disorder, chronic motor or vocal tic disorder, transient tic disorder, and stereotypic movement disorder), a substance abuse disorder (e.g., substance dependence, substance abuse and the sequelae of substance abuse/dependence, such as substance-induced psychological disorder, substance withdrawal and substance-induced dementia or amnestic disorder), traumatic brain injury, tinnitus, neuralgia (e.g., trigeminal neuralgia) pain (e.g chronic pain, chronic inflammatory pain, pain associated with arthritis, fibromyalgia, back pain, cancer-associated pain, pain associated with digestive disease, pain associated with Crohn's disease, pain associated with autoimmune disease, pain associated with endocrine disease, pain associated with diabetic neuropathy, phantom limb pain, spontaneous pain, chronic post-surgical pain, chronic temporomandibular pain, causalgia, post-herpetic neuralgia, AIDS-related pain, complex regional pain syndromes type I and II, trigeminal neuralgia, chronic back pain, pain associated with spinal cord injury, pain associated with drug intake and recurrent acute pain, neuropathic pain), inappropriate neuronal activity resulting in neurodysthesis in a disease such as diabetes, an MS and a motor neuron disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, Reward deficiency syndrome (RDS), neurotoxicity caused by alcohol or substance abuse (e.g., ecstasy, methamphetamine etc.), mental retardation or cognitive impairment (e.g., nonsyndromic X-linked mental retardation, fragile X syndrome, Down's syndrome, autism), aphasia, Bell's palsy, Creutzfeldt-jacob disease, encephalitis, age related macular degeneration, Ondine syndrome, WAGR syndrome, hearing loss, Rett

syndrome, epilepsy, spinal cord injury, stroke, hypoxia, ischemia, brain injury, optic nerve injury, diabetic neuropathy, peripheral neuropathy, nerve transplantation complications, motor neuron disease, peripheral nerve injury, obesity, a metabolic syndrome, cancer, asthma, an atopic disease, an allergic inflammation, eczema, a
5 a neuro-oncological disease or disorder, neuro-immunological disease or disorder and neuro-otological disease or disorder; and a disease or disorder associated with aging and senescence.

37. A method of identifying and selecting at least one oligonucleotide for *in vivo* administration comprising: selecting a target polynucleotide associated with a disease
10 state; identifying at least one antisense oligonucleotide comprising at least five consecutive nucleotides which are complementary to the selected target polynucleotide or to a polynucleotide that is antisense to the selected target polynucleotide; measuring the thermal melting point of a hybrid of the antisense oligonucleotide and the target polynucleotide or the polynucleotide that is antisense to
15 the selected target polynucleotide under stringent hybridization conditions; and selecting at least one oligonucleotide for *in vivo* administration based on the information obtained.

FIGURE 1

A



B




FIGURE 1 (cont.)

C




FIGURE 2

(SEQ ID NO: 1)

>gi|219842286|ref|NM_170735| Homo sapiens brain-derived neurotrophic factor (BDNF), transcript variant 1, mRNA.

CACACACACACACACACAGAGAGAACATCTCTAGTAAAAAGAAAAGTTGAGCTTTCTTAGCTAGATGTGTGTATT
AGCCAGAAAAAGCCAAGGAGTGAAGGGTTTTAGAGAAGTGGAGGAGATAAAGTGGAGTCTGCATATGGGAGGCATTT
GAAATGGACTTAAATGTCTTTTTAATGCTGACTTTTTTCAGTTTTCTCCTTACCAGACACATTGTTTTTCATGACATTA
GCCCCAGGCATAGACACATCATTAAATGAACATGTCAAAAAATGATTTCTGTTTAGAAAATAAGCAAAAACATTTTCA
GTTGTGACCACCCAGGTGTAGAATAAAGAACAGTGGAAATTGGGAGCCCTGAGTTCTAACATAAACTTTCTTCATGAC
ATAAGGCAAGTCTTCTATGGCCTTTGGTTTTCTTACCTGTAAAACAGGATGGCTCAATGAAATTATCTTTCTCTTTT
GCTATAATAGAGTATCTCTGTGGGAAGAGGAAAAAAAAGTCAATTTAAAGGCTCCTTATAGTTCCCCAACTGCTGT
TTTATTGTGCTATTCATGCCTAGACATCACATAGCTAGAAAAGGCCATCAGACCCCTCAGGCCACTGCTGTTCCCTGT
CACACATTCCTGCAAAGGACCATGTTGCTAAGTTGAAAAAATTAATTAATTACACTTGCAGTTGTTGCTTAGTA
ACATTTATGATTTTGTGTTTCTCGTGACAGCATGAGCAGAGATCATTAAAAATTAACCTTACAAAGCTGCTAAAAGTG
GGAAGAAGGAGAAGTTGAAGCCACAATTTTTGCACTTGCTTAGAAGCCATCTAATCTCAGGTTATATGCTAGATCTT
GGGGGCAAACACTGCATGTCTCTGGTTTATATTAACCACATACAGCACACTACTGACACTGATTTGTGTCTGGTGC
AGCTGGAGTTTATCACCAAGACATAAAAAACCTTGACCCCTGCAGAATTGGCCTGGAATTACAATCAGATGGGCCACA
TGCCATCCCGTGAAAGAAAGCCCTAACCCAGTTTTCTGTCTTGTCTTCTGCTTTCTCCCTACAGTCCACCAGGTGAG
AAGAGTGTGACCATCTTTTCTTACTATGTTTATTTTACTACTTTGGTTGCATGAAGGCTGCCCCCATGAAAGAAG
CAAACATCCGAGGACAAGGTGGCTTGGCCACCAGGTGTGCGGACCCATGGGACTCTGGAGAGCGTGAATGGGCC
AAGGCAGGTTCAAGAGGCTTGACATCATTGGCTGACACTTTTCAACACGTGATAGAAGAGCTGTTGGATGAGGACCA
GAAAGTTCGGCCCAATGAAGAAAACAATAAGGACGCAGACTTGTACACGTCCAGGGTGTATGCTCAGTAGTCAAGTGC
CTTTGGAGCCTCCTCTTCTTTCTGCTGGAGGAATACAAAAATTACCTAGATGCTGCAACATGTCCATGAGGGTC
CGGCGCCACTCTGACCCTGCCCGCCGAGGGGAGCTGAGCGTGTGTGACAGTATTAGTGAGTGGGTAACGGCGGCAGA
CAAAAAGACTGCAGTGGACATGTGCGGCGGGACGGTACAGTCTTTGAAAAGGTCCCTGTATCAAAAAGGCCAACTGA
AGCAATACTTCTACGAGACCAAGTGAATCCCATGGGTTACACAAAAGAAGGCTGCAGGGGCATAGACAAAAGGCAT
TGGAACCCCAGTGCCGAACCTACCCAGTCTGACGTGCGGGCCCTTACCATGGATAGCAAAAAGAGAATTGGCTGGCG
ATTATAAGGATAGACACTTCTTGTGTATGTACATTGACCATTAAAAGGGGAAGATAGTGGATTTATGTTGTATAGA
TTAGATTATATTGAGACAAAATTAATCTATTTGTATATATACATAACAGGGTAAATTAATTCAGTTAAGAAAAAATA
ATTTTATGAAGTGCATGTATAAATGAAGTTTATACAGTACAGTGGTTCTACAATCTATTTATTGGACATGTCCATGA
CCAGAAGGGAAACAGTCAATTTGCGCACAACTTAAAAAGTCTGCATTACATTCCTTGATAATGTTGTGGTTTTGTTGCC
GTTGCCAAGAAGTGAACATAAAAAAGTTAAAAAAAATAATAAATTGCATGCTGCTTTAATTGTGAATTGATAATAA
ACTGTCTCTTTTTCAGAAAACAGAAAAAACACACACACACACAAAAAATTTGAACCAAAACATTCCGTTTACATT
TTAGACAGTAAGTATCTTCGTTCTTGTTAGTACTATATCTGTTTTACTGCTTTTAACTTCTGATAGCGTTGGAATTA
AAACAATGTCAAGGTGCTGTTGTCTATTGCTTTACTGGCTTAGGGGATGGGGGATGGGGGATATTTTTGTTTGTGTT
TGTGTTTTTTTTTTCGTTTTGTTTTGTTTTTACTTCCACAGGGAGTAGAGATGGGGAAAGAATTCGATAAATA
TATATCTGGCTGATAAAAGATACATTTGTATGTTGTGAAGATGTTTGCATATCGATCAGATGACTGAAAGTGA
TAAAAATTAAGGCAACTGAACAAAAAATGCTCACACTCCACATCCCGTGTGACCTCCCAGGCCCGCTCATTCT
TTGGGCGTTGGTCAAGTGTGCTTTTGTGACGGAAGGACCTATGTTTGTGCTCAGAACACATTTCTTTCCCCCCTCCC
CCTCTGGTCTCCTCTTTGTTTTGTTTTAAGGAAGAAAAATCAGTTGCGGTTTCTGAAATATTTTACCCTGCTGTGA
ACAAGTGAACACATTGTGTACATCATGACACTCGTATAAGCATGGAGAACAGTGAATTTTTTTTTTAGAACAGAAAAAC
AACAAAAATAACCCCAAATGAAGATTATTTTTTATGAGGAGTGAACATTTGGGTAAATCATGGCTAAGCTTAAAA
AAACTCATGGTGAGGCTTAACAATGTCTTGTAAAGCAAAGGTAGAGCCCTGTATCAACCCAGAAACACCTAGATCA
GAACAGGAATCCACATTGCCAGTGAACAGCCAAATGGAGGCTATGTGGAGTTGGCATTGCATTTAC
CGGCAGTGGGGAGGAATTTCTGAGTGGCCATCCCAAGGTCTAGGTGGAGGTGGGGCATGGTATTTGAGACATTTCA
AAACGAAGGCCCTTGAAGGACCTTCCAGAGGTGGCTCTGGAATGACATGTGTCAAGCTGCTTGGACCTCGTGTCTTA
AGTGCCATACATTATCTAACTGTGCTCAAGAGGTTCTCGACTGGAGGACCACACTCAAGCCGACTTATGCCACCATC
CCACCTCTGGATAATTTTGCATAAAATTTGGATTAGCCTGGAGCAGGTTGGGAGCCAAATGTGGCATTGTTGATCATG
AGATTGATGCAATGAGATAGAAGATGTTTGTACCTGAACACTTATTGCTTTGAACTAGACTTGGAGAAAACAGGG
TTTATCTTTTGGAACTTTTGGTAAGGGAAAAGGGAACAGGAAAAGAAACCCCAACTCAGGCCGAATGATCAAGGG
GACCCATAGGAAATCTTGTCCAGAGACAAGACTTCCGGAAAGGTGTCTGGACATTCAGAACACCAAGACTTGAAGGTG
CCTTGTCTCAATGGAAGAGGCCAGGACAGAGCTGACAAAATTTTGTCTCCCAAGTGAAGGCCACAGCAACCTTCTGCC
ATCTGTCTTCTTCTGGAGAGGTTCCCTGCCTCACCTCTGCCATTTTGGGTTAGGAGAAGTCAAGTTGGGAGCTTGA
AATAGTGGTTCTTGGAAAAATGGATCCCAAGTGAACACTAGAGCTTAAAGCCATTACGCCCATTTACACCTGAAA
ATGTTAGTGATCACCATTGGACCAGCATCTTAAAGTATCAGAAAAGCCCAAGCAATTGCTGCATCTTAGTAGGGTG
AGGGATAAGCAAAGAGGATGTTTACCATAACCCAGGAATGAAGATACCATCAGCAAAGAATTTCAATTTGTTTCAGT

CTTTCATTTAGAGCTAGTCTTTTACAGTACCATCTGAATACCTCTTTGAAAGAAGGAAGACTTTACGTAGTGTAGAT
TTGTTTTGTGTTGTTTTGAAAATATTATCTTTGTAATTATTTTTAATATGTAAGGAATGCTTGAATATCTGCTATAT
GTCAACTTTATGCAGCTTCCTTTTGGAGGACAAATTTAAACAAACAACCCCCCATCACAACTTAAAGGATTGCAA
GGGCCAGATCTGTTAAGTGGTTTTATAGGAGACACATCCAGCAATTGTGTGGTCAGTGGCTCTTTTACCCAATAAGA
TACATCACAGTCACATGCTTGATGGTTTTATGTTGACCTAAGATTTATTTTGTAAATCTCTCTCTGTTGTGTTCGT
TCTTGTTCGTTTTGTTTTGTTTTTTAAAGTCTTGCTGTGGTCTCTTTGTGGCAGAAGTGTTCATGCATGGCAGCA
GGCCTGTTGCTTTTTTATGGCGATTCCCATTTGAAAATGTAAGTAAATGTCTGTGGCCTTGTTCCTCTATGGTAAAG
ATATTATTCACCATGTAAAACAAAAACAATATTTATTGTATTTTAGTATATTTATATAATTATGTTATTGAAAAAA
ATTGGCATTAAACTTAACCGCATCAGAACCTATTGTAATAACAAGTTCTATTTAAGTGTACTAATTAACATATAAT
ATATGTTTTAAATATAGAATTTTTAATGTTTTTAAATATATTTTCAAAGTACATAAAA

(SEQ ID NO: 11)

>hg18_knownGene_uc009yjg.1 range=chr11:27633018-27679176 5'pad=0 3'pad=0
strand=- repeatMasking=none
GTAAACCAATAGCCCCATGCTCTGTGCGATTTCATTGTGTGCTCGCGTTTCGCAAGCTCCGTAAGTGCAGGAAGGTGC
GGGAAGgtgtgtctgtggcccggaacgcacgcctctcccagagaacttgggtgctgggatggggaggaagggga
gagttgaaagctaggggagcgagacctcggggcgctgcatctctactcgtccctcccggcccagcggccacagccg
gggttctgcagagggcgcgggacgcggggttccccggggctgaggtggggctggaaccccctcgaagccgcggg
cgtcctgtccaaggcggccagggagggcgaggactcgcagggcgatgtcgcggggccctaggggagggaggtgagga
caggccccggggagcggggagtccggggcgcccctcgggttccccgcgcgagggaaaagacgcggcggtccctttaag
cggccgcctcgaacgggtatcggtagcggggcgagcggggagcggggggcgggggggggggggggggggcggcgc
cgtttgaccaatcgaagctcaaccgaagagctaaataatgtctgaccggggcgcaaggcgcagcctggagctccggg
tccccgacgtgcccggcggcgcccggggcgaccccggcgtcgtctcccgcgaccccgtagcgcctcgggctc
ccgggcccagacagaggagccagcccgggtgcgcccctccacctcctgctcggggggctttaatgagacaccaccgct
gctgtggggccggcggggagcagcaccgcgacggggaccggggctgggcgctggagccagaatcggaaaccagatgt
gactccgcccgggggacccgtgaggtttgtgtggaccccaggttaggcaagcgtgggaatggggcttggtgcagg
agctgcccgctccgcccggagagagttgactgggggatccccaccccaagttgtgggacgagggccagctcctctct
tctccccctccggtagaagggacgatttgaggttactcttggggagttttctccccatccccacaaccagaaaggtc
agccggcaccaccagggaaaaagggaccgggggaagtcacgaagtagaggaggggaaggcctggaggagaccagagc
tgctgatgggagcaaacgcggcagccggggatccctcgcagccctccccagcccaggagtagtcgagagagact
tagggggccagagctgtcgagggtcctgactgaggggaggggtgctggggctaggctaggaatccttccaggggggtg
gtggtccccgcgcccacttgccgggggagtgaggaggaagcttgccgcttcagcccgcacccctccccggagctgc
acagggctacctctcccaggaattgagactgaagtggacttacaagtcogaagccaatgtagcttggaaaacttg
ggagcggaaatctcactcggctgggaactgaaagggctgcgacactctcgggcaggccgaaccacatctctacca
tcctgcccctctctgaagcggcctccagggaggttaagagtttgacttccggggagtggttggaaactgactg
gggattcttgactcgggttagtctctggggatgcagagcgggaagaggaatgggtgagtgagttactcctggaaa
gaaatagctgaggattgggggctctgtgcctgacgggcaagaagaaggggagattacagactaggggcatccctaag
gaagaagcctcggggctgcgaggggtgaactggaggatgcagtggtttgtgtgttgggggtagagcggggatgagggac
cgggggtggaggggagggcagggagggaggggaggggacccagagaacgaagctagggaaggttagaggggtgccctctgccg
ccatgctccaagagcagctactgggggcccggaggctgggggtgggggaagtggttaaaggaaggttttgccggatccc
ttagagagctggtaggggacttggtgaatggtgctgctgactccagctcgggtggggcgctgcgactcgtcgtcgg
ggattttgactcctcgttcttggcttctatgcaagtttctcgcgctgggggagctttgataagcctcgatt
ggcgggtgtgtagggcttcttgatcttattttagggctcctctagttatcctgcacttactccttaatgtcagtagc
aaccaagaacatccccgacaagcagcaggaatgttcttggccagaagcaagaaagggcatatctctgagtggtt
attaatcctcctagtaatcttttaaagcaagtaatatgtaattgggaacggttgattttctaactgcataataaagg
cgacatgatattaatgagaccctccctactgactcaatatcctgcaaaatctctctctccccctttattattatgg
aaaaatctatttttatagagtttgttgaaggtcaaaagccattttgggtcttacaatttgatagttctttacattt
taacttattgaggcataattacagatttaatttgtatgaacgtgtgtgccttcaatgcttatctcatgcaacataat
tttaggttgagatctctgatgttatggcatgtagcgtttcaaggcattacacataataggtaacatagcatggtg
aaattacaccacaaagttttgaccctgggaacagcaccttttaaaacaatcactaaactcctgttctctgtttctg
attttgcaaatgccttgcttaagacttt
caggagaggttaaaaaaaggaagagacacttgttgaatgttaaccataaccttactggaatttaaaacatgttgg
tcaccattactggaattccagggccataaagtcggttctttttttcttctacttcattttgtaaaatgtgataaa
tgtttgtaaatatagaccagtagtaagtattatgacactaaaagcattatgtatgtggaactattttaagttattac
agaacatcttctatttataaatgatataagcagaaagaaatgatttccagataaacaaggcttacgtacatgttttg
aagcattagaacattgcagacactcttagacatcacattttttaagcaaaataacagtaatttttcacataccttt
ggagcctttcatagcccattcagagctgagttagtagctggaagtttcttttatttttaaggtgatatttttaaacca
tttaacatgtatagtaggtcaacattgggtgcatccagaaaatgaagcatttaggaaatctgtttcagtgcttttca

gcaatgggttgaggggacttggaaatgcatgacttagggacaagaaaacttaggctggaatggcaagtgggttttgaat
gttgggttgagaagaattctaaaactgtgaaggattagtaaaaaataacattcagattgctaatagcctactgtggctg
ggagattagagtgtcaacatgtgtgatgtatTTTTGACATCCTTATTTTgaggatgggcttcaaagatttgacgaac
tgtcataagtgtaatTTGTGTTGCTCAGACAGCAGTCTAGAACCAATGATGTAAATTTAGATACTCTACATGGTA
gttagaaaactttccattaatttaatttagcaaatattgaaatgctcactgcatacagagcactttatttagaggaata
tataataaagaaaaagaggctggtgtgggtggctcatgcctgtaatcccagcactctgggaggctgaggtgggagg
atcacttgagcccaggagatcattacgagctctggacaacatagcaagaccccatctttacaaaagacaaaaaaatt
atccaagcctggtgacagggcacttgtagtcccagctacttgggaggctgaggcagtaggatcggttgagcccaggag
gttggggctgcagtgagccgtgattgtcccactgctcttcagcctgggtgacagagtgagaccccgttggagggaag
gaaggaaggaaggaagaaaggttaggaaggctgaaatgaaacccttttagaaatgacactaaaatgggagggttgag
taaggtatTTTCTGAAGTGCCTTTGTACTTGTTTTTTCTAATGCATTGGCCATAAGTCTGCTCCTTATTTATAGTC
cataaacaatcctaatagagaacagttatataTTTCTGCTTTGAATCATCTACTTGAAGTGTTTAGCATCATGAATT
gagatcagaaaatccctcccatttctttgcaaagcgtgtatTTTACTTTCTTATTGTATACAGATTCTCAAAA
ttggctatTTTCTTTGGGTAGACAGAACAAGTGTCTGGAAAAAAAGTCTTATCAAATTCAGGTGCCAAAT
tgcttaagaaattaactTTTgaggttatTTTTTTTtagggttcagtagctaaactaagaaaacttctcaccgttcac
cttcaactTTTgaaaccacaaaatcttcagatattacagttttccaaagagtTCTCTTTTTaaataaaactaaaa
ggaattgactcctcccccaactccctcaggcctcagcatggatagagttactTTTTTCTTTAATAATTTATTATA
acttTTTTGCTCTTCTGTAGAACAGCTGGAGATTAAGCAACATGGCCATGACATAAAATGCAAGTTAGACCATAAG
atgagcagcccactccaagtatgaaatgagtagtacttattctTTGTGATCTCTCATACTGCTTTAGGTATTAATAGTGT
cagtcagcaaagcaaacagtttaataTTTACATCTCCTTTAGGATATCATATAGTTTATAGTTTGTATGTGTTCTTG
CGTGTATGTTTTCTCTGTTTTCAAATCTTTTTTCTTAAAGTAAGAATGTTATATGTAGCAAATGGTCTTTCTTA
attcatttgtaattcaccgtgcatttaattgagtgcccagtgagtgctcaggcactgggctacttggatttctTTTCC
ctgtattgatccatatacttccaggtgctccttgatatggctctccattgactctctcatataaggctttcattacc
tattcacatactccctcccaaagaggactggtccaaaagtaaaatcttgagcaagttctctgagttatttcagaact
cttggcccccaactgtatTTTTAATTATTGACTGGTAGCATTTTGGAAATAACTTACCTCTCTTTTTAAAGATTGA
agttctttatcctctctgattttcaggtgtcagtttgtgtacaaattgagacaataaaaaatggttggtagacatTTT
cttaaagcattttgctatgtgagaatctttcatgaagaactctTTTTAACAATGACTCTATAGCAGAAGCCACAGTA
gagggagaactactgaaatcaaagatgggtgtttgagtagtatgattttatgatggattTTTTTTTTTTTTTACATACAAG
gatatgcatgggtctTTTtagtattcaggaatctgttcttcaacttgacagtagttataaaattgtgtgtttccccctaa
aaaaacttaattgtgagaatgcttccatttactagaagttgggttaattgattatgccaataaggaataaagacag
aaaaactcagtttagtgaatactatTTTGCCTTTAAATTTAGTAATTTAGTAACAGTATCTCTTTGGGGTTACTAGA
aaccactTTTTAATCCAATAGGTCTCTTTCAATTGTAAGTCAGGAGGTGATTTGTCTAAATGTGTAGTATAGGAAT
ctatatgtgggtttcaaggatcatgtaaatatgctgatataatcggagcacagtttggcatcattaactcagaaata
tttaaactcttgcataacaacatggaagcaaaccttgtgcatagtttgtgtgtgtgtgtgtgtgaaatctcaaaaaa
agaaaaaatcacaggatcaggaagtcggaataggtcccactTTTTCTCTAGTACCAAACCTACAGCCATGTTCTTA
gccttctctTTTactccaagcaagacagacaggcaaatgaccatcctgctgcccatttctgtgtatattcacttgc
attgagagttgtattcacctgcttgttgagagtagttcacaaatggtaacctgataaagtagatacttctTTAAACATG
tgaattTTTTTGCATTGTATAATGTTTAGAAATAATCATGTATAAATGGTTGAATATAACAGGATTGCCTTATC
aagtattttataatcattaaaatgtgggtgtcatttaatacaatttattTTTAAAGTGCTTTTCTAAAATACCAGATTA
TTTTCTGATTTTCACATCCCTGACAATGACTTTCTTAAACTTGGTAGCCAGGAACAGAAAACCTAACACTGCATGT
tctcaactcataagtgggagctgaacagagagaacacatggactcagggaggggaaccacacacactggggcctggag
cagggggcaggggaagggagagagtagcgtcaggacaacagacaaatagctaatagcatgagcagccttaatacctagg
tgatgggttgataggtgcagcaaacaccatgacacatatttacctatgtaacaaacctgcacattctgcacatgta
tcccggaaacttaaagtaaaaaataataataaaaaataaaacttagtagcatctattgttccagagcctgt
aattgctcttcaggcagctctacataaaaaacctaggagaaccttcaactgtcactgttccatgaggtgttaggaaaac
ttgctctactgcagtgccccagtaggcatttggtagtactgagacaaaattcagctgggttgggttactacgattccta
cgtgatttcaacttgtcatgtagacaagattgcacacttcaataataatcttgtccaaatgtgtgggtattccatacat
tttaaaatgcattcacataatctcatttccattttagctcctacaataactctataaaaaagattggcagacattattt
ctataaacagagaggaaactggagcttagagaagctaaatagcaatccaaaatgcacagctgtagaaccagagca
aggatgatagcccagtgacttcacctaacctagctccccttaccaccactccagctgtctataaccaaaccctgcagt
attcaagtaagaaccatatttgccttgatgcatttaattgtgagacctggagcaggaacaggctgatattgtcacc
ctggcctactgtccaccttTGTCTCCAGCAGAGACTGGTACCCTTCTGTGTGCCAAGGAATAAAGTGGTAATGGGAA
gattaaaaatgtTTTTTCCAAGGAGTTTTTAAATTTTAAATTTTTTAAAAAGAAAAAactcttagagggaataatga
atataatgacttttgatgtattgttcccttagtaacttagttataTTTTTacttAAACCTGAGACTCTTGTAAAGTGA
tgattagaaatattaggtggctggccagatggcaaataggaacagctgcagctctgcagctcccagagagatcaatgc
agaaggtgggtgatttctgcatttccaactgaggtaccgggctcatctcattgggactgggttagacagtggggtgcag
ccatggagggtgagccaaagcaggggtggagcattgcctcactcaggaagcgcaggggtcaggggaactccctccc
ctagccaaggaagccctgagggactgtgccatgagggacagtgctatctggcccagatactacacatttccctacag
tctttgcagccggcagaccaggagattcccttgggtgcctacaccaccagggccctgggtttcaagtacaaaactgg
gtggccatttgggcagacaccagtttagctgcaggagttTTTTTCTCATACCCAGTGGCACCTGAAATTCAGTGAAG

acagaaccattcactccccggaaggggctgaaggccagggcagccaagtgatctagctcagcagatccccccca
tggagcacggcaaggttaagatctgctgggttgaattctcactgccagcacagctgcctgaagtcaacctgggatgc
tccagcttggctcgggggaggggcatccgccattactgaggcttgagtaggctgttttctctcacaatgtaacaaa
gccactgggaagtttgaactgggtggagcctaccacagctcagcaaagccctgtagccagattgcctctctagatt
ctccctctctgggcagggcatctgggaaagaaagggcagcagccccagtcaggggcttatagataaaactcccatctc
atgggacagagcacctgggagagggggtggctgtggggccagcttcagcagacttaaagtgtctttgctgttggt
gtgaagagagcagtggtatctcccagcacagcacttgagctctgctaagggacagactgccttcttaagcaggtccct
gacctcgtgattcctgagtgaggagacacctcccagcaggggtcgacagacacttcatacaggagagctctggctgg
catctggtgggtgcccctctgggacaaaacctccagaggaaggaacagggcagcagcttttgctgttctgcagcttct
gctggtgatacccaggcaaacagggctctggagtgacctccaccaaattccagcagacctgcagcagaggggctga
ctgttagaaggaactaacaacaggaatagcatcaacatcaacaaaaaggatgtccacacgaaaaccccgtaaa
aggtcgccaacatcaaagatcaaacatagataaatccacaaggatgagggaaaatccagcacaacaaaggctgaaaatt
ccaaaaccagaatgcctcttctcctccaagggagcacaactctttgcccagcaaggaacaaaactggatggagaat
gagtttgatgaattgacagaagatgcttcagaaaagtggttaaaaacagactcctccaagctaaaggagcagctct
aacccaatgcaagaagctaagaaccttgaaaaagggttgagggaattgctaactagaataactagtttagagaaga
acataaatgacctaattggagctgaaaaacacagcacgagaactctgtgaagcatacacaaagcttcaataactgaatc
gataaagcagaggaaggtatcagagattgaagatcaatttaagtaaaatgaagcagatgaagacaagattagagaaaa
aaagaatgaaaaggaaggaacaaagcctccaagaaatgtgggactatgtgaaaagacaaacctacatttctgggt
gtacctgaaagtggcggggacaatggaaccaagttggaaaacactccttaggatattatccaggagaacttccccaa
actagcaagacaagccaacattcaaattcaggaaatcacagagaacaccacaaagatacccctcaagaagagcaaac
caagacatgtaattgtcagattcaccaaggttgaaatgcaggaaaaaaagtttaagggcagcgagagagaaaggctcg
gttacccaaaaagggaagcccatcagactaacagtggtctctcagcagaaaacctacaagcctacaagccagaaga
gagtgggggccaatattcaacattcttaagaaaagaattttcaaccagaatttcatatccagccaactaagcttc
agaagtgaagtagaataaaatcctttacagacgagcaaatgctgagagattttgtcaccaccaggcatgccttaca
agagctcctgaaggaagtaactaaataaggaaaggaacacgggtaccagccactgcagaaacataccaaattgtaaa
gaccattgaaactatgaagaaactgcatcaactaatgggcaaaaataaccagctaacatcataatgacaggatcaaat
tcacacataacaatattaaccttaaatataaatgggctaaatgcccacattaaaagaccacagactggcaaatggga
taaagagtcaagaccatcagtggtgctgtgttctggagacccatctcacatgcaaagacacacataggctgaaaata
aaggatggaggaagatctaccaagcaaatggaaagcaaaaaaaaaagcaggggttgcaatcctagtctctgataaaa
cagacttaaaccaacaagaatcaaaagagacaaagaaggccattacataatgataaagggtcaattcaacaagaa
gagctaacttctaacaatataatgcaccaatcacagggacccagattcataaagcaagttcttagagaccaca
aagagaccaagactcccacacaataatagtgtagactttaacacccaatgtcaatattaggtcaacgagacagaa
aattaacaagcatattcaggatttgaactcagctctggaccagtggaactaatagacatctacagaactctccacc
ccatatcaacagaatatacattcttctcagcaccacatcacacttattctaaaattgaccacataattggaagtaaa
acactcctcagcaaatgcaaaagaatggaaatcatacaaacagctctctcagaccaaagtgcaattaaattagaact
caggattaagaaactaactcaaaaccatacaactacagtggaactgaacaacctgctcctgaatgactactgagta
aatacaaaaagaaggcagaaataaatacatttttgagaccaatgagaataaagatacaacataccagaatctctg
ggacacagctaaaacagtggttaggggaaattcatagcaataaatgcccacaggagaaagcaggaaagagctaaaat
caacacttaacatcacaattaaaggaactagagaagcaagagcaaacacattcaaaagctagcagaagacaagaaa
taactaagatcagagcagaactgaaggagattagagacacaaaaaaccttcaaaaaatcagtgaaatccagaagct
ggttttttgaaaagattaacaaaatagatagaatgctagccagattgataaagaagaaaagagagaagaatcaata
gacgcaataaaagatgataaagaggatcaccactgatcccacaaaaatacaatctaccatcagagaacactataa
acacctctatgcaataaactagaaaatctagaagaaatgaataaattcctggacacatacaccctcctaagactaa
aggaagaagtcaaattcctgaatagaccaataataagttctgaaatcgagggcagtaattaacagcctaccaacaaa
aaaagcccaggaccagacggattcacagctgaattctaccagaagtacaaagaagagctggtaccattccttctgaa
actattccaatcaatagaaaaggagggaatcctccctaactcattttatgagtcgggcatcatcctgatacaaaaac
aaactggtaactgaatccagcagcacatcaaaaagcttatctaccatgataaatttggtctcctccctgggatgcaa
ggctgggtcaacatagcaaatcaataagataatccatcacataaagagaaccaatgcaaaaaaccacatgattat
ttcaatagatgcagaaaaggcctttcataaaattcaacagcccttcatgctaaaaactctcaataaactaggtattg
atggaacatattcaaaaataaagagctattttatgagaaacccacagccaatatcactgaatgggcaaaaagctg
gaagcattcatttgaiaaccggcacaaaaaaggatgccctctgtcaccactcctattcaacatagatttgacggtt
ctagccagggcaatcaggcaatagaaagaaataaagcatattcaaataggaagagaggaagtcaaattgtctctggt
tgcagatgacatgattgtatatttagaaaacccatcatctcagcccaaaaatctccttaagctgataagcaacttca
gcaagctcaggatacaaaaatcaatgtgcaaaaatcacgagcattcctatacaccaataatgacaaaacagccaagt
catgagtgaaactcccattcacaattgctacaaagagaataaaatgcctaggaatacaacttacaagggatgtgaagg
acctctttaaagagaactacaaccactgctcaatgaaataagagaggacacaaacaaatggaagaacattccattc
tcatggataggaagaatcaatctgtgaaaatggccatactgccaaaagtaatttatagatccaatgctatccccat
caagctaccattgactttcttcatagaattagaaaaaactactttaaatttcatatggaacaaaaaacagcccgtat
tagccaagacaatcctaagcaaatgaacaagctggaggcatcatgctacctgacttcaactatactacaaggcta

cagtaacccaaaacatcatgggtactgggtacataaacagatagatagaccaatggaacagaaacagaggcctcagaaata
acgccacacatctacaaccatctgatctttgacaaaacatgacaaaaacaagcaatgcagaaaggattccctatttaa
taaattgggtgctgggaaaactgggttagccattttgcagaaaactgaaactggaccoccttcttacacggtatatacaaaa
ttaatcaagatggattaaagacttaaacataaaaacataaaaaccataaaaaccctagaagaaaacctaggcaatacc
attcaggacataggcatggcaagacttcatgactaaaataccaaaagcaatggcaacaaaagccaaaattgacaaa
tgggatctaattaaactaaagagcttctgcacagcaaaaagaaactaacatcagagtgaacaggcaaccgacagaatg
ggtgaaatTTTTTgcaacgtatccatctgacaaaaggctaataatccagaatctacaaggaacctaaacaagtttaca
agaaaaaaaaacaaccccatcaaaaagtgggccaagggtatgaacagatgcttctcaaaaagaagaaatttatgctgcc
aacaacatacgaagaaaagctcatcatcactgggtcattagagaaatgcaaatcaaaaaccacagtgagataccatct
tatgccagttagaatggcgatcattaaaaagtgcaggaaacaacagatgcaggagaggatgtagagaaataggaacac
ttttacactggttgggtgggagtgtaaattagttcaaccattgtggaagacagtggtgattcctcaaggatctagaa
ccagaaatatctttgaccagccatcccattactgggtatatactcaaaggattataaatcatgctactataaaga
cacatgcacatgtagtttattgtggcactattcacaatagcaagacttggaaaccaatccgaatgccatcaatga
tagactggataaagaaaatgtgacacacataccacattggaataactatgcagccataaaaaaggatgagttcatgtcc
tttgacgggacatggatgaagctggaacccatcattcttggcaaggtaaacacaggaacagaaaacccaaacaccacat
gttctcactcataagtgggagttgaacagtgagaacacatggacactgggaggagaacatcacacactggggcctgt
caggggtgtaggaggctaggggaggatagcattaggagaaatacctaattgtagatgacaagttgatgagtgacgcaa
accaccatggcatctgtatacctaggtacaacacctgcacgttctgcacatgtacccagaacttaaaagtattatt
attattattataataataataaaaagaaatacaataaaaatagaatgcagcatacagcagtgattctcaaacacat
tcagcatcagaattacccttgaatctttaaaatatatacatatgagatcttagtctccaagatttgaagtgttg
tattgggtccctgggctatgttgggttagaaacttctacagatgggttggatgtagggacagtttaagaatcgc
tgaactaaaatcaataaaactgaatatcctgtgatttagagagacttatcgtttatttccactatccaagtacttgca
ttagagcgtggctagaagggatttgcagccttgtaataatcagaaatcagacatcttgagatgagagaactgctg
aagattttattctgacttgaataaaattttctaattagaaacttccaggtgagagcaaggcctggaacaatattcc
tgagccagaggaggatcgagtttgactccaggcctaacacttactaggtctatgacctggggtcagtaatttaaat
ctctgtatctcaacctctcaacagggtatttggtagggattaaatgtgttagtctctgtgaagtgttagagcagtg
ttggcatagtaaatgcttaatgaatttcagccactgtttttatttttagtactttccagctcccccaaaaagatact
tttttagacttgtattaagacaataaaaagtttaatcagcatgcttcatacctaataatgcttccactttatagcaa
agtttacaagactaaaactgttttggttgtaattctctgagctctcatgtgtttattaatgattttttctgctgtttat
tcactgtaattctactcattcttcaagacctagctggaatcctgtttctagaaagactctgcccataataaaaac
ctgcccatactgagttcctaggtgctgtacctcataaatttggtaatttaattgtatataatgataatacaaaaac
attattgtgtgcttttctgtatcagattctaggctggaagttgtagatatgatgtttttgctagaaaaatgttct
agaatgtcctactcaggacagctgtgtgactttaagacacatttccataaacagacacttcatgaggcagcccagc
ctgtacctgtgttctctggacctgatgatcaagtttgatttaagcctcaccacttactagctctgtgattttgggcaa
gttacttgaattctctgtgtgtagatagaacaatgttgagggaaatccctttccccatccttgtgtttccacaagg
gaacttgcttccataaagtaaacactttcaggggaatattctaggcccttctcttatccccattacttgttctttct
gtgaaaagaggagaggttaatctgatggatgaaatccttaatctttcatctctggactgtagagcctgtgaaccaa
agcaatggaccacttgcactgaaattgaggctgacctgtattttgattcttattttggcaacttatttctattctgt
tcccaattcaaaaatcccaaggggagaaggaagataattgattaccagaagtatgtaattgggtgtaggaagttgaata
aatggtaactttttaaaagttgcatgagatatagtccttatcccagagaagctaagtttgcctttcttctctcat
gtatttttagtattttctacaattagattgtaaaccttttaaaagcaagaatatttctacattttcttactcctga
tagcacacagtagactgctgggcacatacatagtaggtggctctgttaggtacttgctaaatgattcaacatgttttt
ccctcatggaaaagaaagatttcagatattgttcttatcagcttaggaaggcactctgaataggaaatcagttctaggc
aggtatccataaatgggttatgatttccaacttacttgccccagaggctcgtaatgttgaaactcttcatgggtact
ttgtcttgcctcatgagctatacatgctaaggggttagcagatcatataatcttttgatctacaaaatatgatcttt
attgaacaaaaacttgggccaaggcctttctcctttgcccacttctcctcttttcttcttttttgggaatg
ccctttgtgcatgttagttacagcatgtaccacattgcactgtatttgttgggtttttgggtctaaccacccttaaca
ctgcagtcaccaagggcagaaattcagctctcattcattttgatgtcctcagtgccctgtgctcagagaataatctatta
tttgaaaaaatagtgcaaaagtaaattttaggagactacatcacactcatctaaactgcaagtttgacaagttgaca
tccaaaagaaaggctctcctaataaacctcgccacagaaatttgggtgacctttgtagctctggagaaagcagaggc
aaaaatgaaacctaaaatttttgggttttttaaaaaatgttttctcatggagttaaaggctacagctgagttct
ttcatatgagggaatgacagaaacacagctgggtctgactttcagcttcaactgagcagaccagagctctgctgggtg
aaacaggaacttgtattgtgcccctgacgtgcaccttgaagggtgcagctcattgtccctttgttcacataaatagt
tttttaagaattgtttttgatcttgtgagcctctaactaaatgattaaacctgcaagttggccatttggggttaata
ctgaagcacttctcttgagggtatttgacaggtgggaatgtgcccacctccttgggtctctgggttttcatgtcatac
ttgcaaatcagtgacagtttaacttggggcaatcacttagcaagctcattgagttaccaagtttaattattccact
ttgcatgaagcaaccttgaaaatgattttcctaagcaagtaacatccaaactcagtaaccttctaataacctttgc
tgaatgaataaatgactaattcataaaaaatgtaacatatcttaattcttacttacgggcagtttaagcctctgt
gtaagaggaggcctcggcttgagataacataggatagtaagcctcctagagaaatttctatatggaaacatgggtctg
ctatgaagctagaagtgagaggacattatatttgaccattatatttggcttcagagcttctcaacatggggcccaaaa

gtcaagggtcccttggtttcattaagaggaggtccaggagtgcatgacacccatcagactactgagaccagctggaac
taggcaccttgacaggggcttgccctaatcaaaatagttcttattttttctgagttccaagtaactagtttccctaa
cccagtgctggtatagtagtgccaagtgaggagtagccttcaatgaacttctcatgaggttatttctagcctattgga
atgtttcgtttaggagggtaggaagggagagtccttgaatttttgtgcttagtttaatggtgtgatacagctttgac
catccgtttaatgggagatctggtttccagatgactatacatgtggaaaggagaagttttttgagtggttttttaa
ccccttttaagaatggtttttcatttagtctctacatttgggggtaaaagggtcctctagggagacttttcaaaagt
atgtgaagtttgcatctgatttcagaggtgagttggaggcctatctgtgtatgacagacacatgtctccaacaacta
tatgttcacaaggactaagagccatccttttgggtccatcattcaacattgatctcacattcgtgttcgtatcagta
tctttacagtgcgctcccagttacatctccctaatttcccttagtaggcttcacagaatttgcagtgatgcaatgg
cagatgaccacatgtggagtcatttaaccacatcttccactgcaagtcagcccgcctcttgatgtctgtttatgttta
gattccatcttttggagatttccattcctctgcaactatctcagatctcagatgcttttgagactgggtccttttcc
cctcctatggttggccatggccacccctcagggttggtgtgtgtgtttcacagctgctgtttgtagggttgacctta
caatgtacaaagctctttcccatatggtgacaatccctgggtgtgagtgctgagttaggcaggggtgtgtatacgtgt
cctcatcattacagtggttaaggcaacaggggttttgaatttgatcaccatgaatttgctcaatttgttggtaaa
aaatggtcatgtatcagcgtttcacagggtcagcttaataagaaagtgagggttaggcagaccagaattcaggact
tcagccccgggtcccaggactattctctatacccaattgtcccacctgaaatcagtttcttctagggaaatatctc
caaaactgagatggcaccacaggacttcttaattgtagtcattaccaggaaaaacaagcaaaaggaaactgggtgtaa
tctctgttttgggtgattgggtggagatttggagattgtcttgtgtcaaaagtaaaagccactagattaaatgtttgt
taataaattgggttatttttaatttattttgacagtttaatttaccattttcaaaaatcaaaaataaaatttaaaag
aagtttactgaaaagcttggcccacttataccctgctcacctcagtatcccccaatacataccatctataaggt
gatcatttgtattagtttcttgtgaatccttgatagtggttttatatagatacaggtaaatatgagtatgtactat
tatttccccccaccaccctgtttttttttgagacggagtcctcgctctgtcgcccaggctggagtgagtgga
cgatctcggctcaccgcaagctccaccattttccccatttttaaaacaaaaggtagtagccatatacactattt
tacacctgttttatcacttaataatataaccagagagctttccatcattttgtacatatgcacctatactgtca
attattcccagaagtgaattgctgggtcagcaggaaaaatcatgtataattttgataggtattgcctaattgtcct
gcacagggcttgaattgtttgactcccaccttagtgatgagaagacctgtttctccatagcctcatcaaacaga
gtgtgtgagattagatgagaaataggaggtgagcagtcctttaccocatccgtagtttgcagtggaacactgcaca
gttgcaagagctgggtgcaggtatcagattagttccagtggaacgctgcctcaccatggccatgggttgcgccagc
tctagtgcacacacgggaatggaccacgctggccacttgcagaatttctctgtagcagaaagttgaacatgcatc
tattcatctaactagccatgctggatctaaagagcacaacagtggttttttagaaccaaaaagaaaattgtttcacta
caacacactgtgataaggctttcaatgctctttctcagctattaacattattttcaggactagttcaagagatg
tatcccaaatcacaggtatgtcttggtaagcttggaaacttctactcaagggatgcttttttgaggaatgattta
cacttactcaacatttgaattaaataatttagtactttataagataaaatttaactgtccaagtacaatataaacat
tgaactatgatgcattattgctagactttttccttaaagttgccaagtggtttcctgcattaggcaaataggggatc
atataaaaatgccatgatttacggcctagataaacatctccaccatttgagcagcatalatccagggtcatccccaca
taactccttaccattctcattagaaaggttgattcttagtcttatttttctctgaggacagcaaaaaaaaaatccc
cttcagttccactgcatagaaaagtggtgtaaatggagccgggacacagtggttatttaatttaaatggacaatattt
ttatagaattttgacagggccactgtataggggaaagtcactcctcttcccctttatagaagagttgcacctggac
agttgcattgatgactgtatccagctacacaagaggtcattcctgggcataagaatggactgccaaaatctagctg
aaacaccattgacaaatagacattttcttttggtaataatccctgtgaaggcttccataacagacatttccagttt
gttctcaggctccttgacagctgctcctctaaaagtggtgctctcttccaagagctgacaatggccagaagcaaggtg
tctgtcttttgtgccatcatcatcacttgccacacacatttgggatgtcagcctaggtataggttttgtatccac
tcagtatggcttgtgggtctggttgcctttgttattcatgctgagggcctctgggcatcagtttgggtgtgagagaac
ccattccatgaccctccttcccttggctgttttgactcgatggctctgttggcacagctctgtgagtgctgatgct
ctatccatgcccggaccatctgttctgctgtctctgtgggtctgaagtogttttctgaaactattccttgataataaatt
tgagatgatcttgttctacctttcttttcaagtcacatcttagcccttagccacattcccgaagaacatgacaaat
ggatgggtcacaagtcacgtagcataggggtgtcagaccacgaggctttgaagggattctgttgggtgctaaaagaa
agatttgggtgaccacagatttttttaaggcatgttgacacttaggccttaattgaaagcgttcttactcaagta
gagttgacagagagattttggtagtcggttggcttgaagagcatgtggttctgtttcaatgcccataatgaga
tcttctcacgggaaaatgttctgacatctcaacaaatgacctcatgcatagtttgacaaaataccctattaagt
atgcatatatggttggtagcttggtaataattcaatactggaacagagtagcaacaaagaaacattaggggtat
atthaacctctgtggaattagtggtgtaacaaactgcttatcagaaatgctcatatggggctttgtttaaataaata
agaaactggcatalatagggctctgcaggatatttctgccaagtagacctccctcacattataagacaccacatctatgt
ctgaccccatatggaaagagggcatagcaagccagcactgggtcataltccctctccaccacataatgggtatgtgat
cttagggaatccaccgaaactctctgggcctcagtttctcagctataaatgggtggataatcaaatattttacctca
ccattaataaattgttagctattttttttatcaagtttaatacaaaagagaaacattttacttatttttccagctatc
cagagcatcttcaaaaatcctatcaccacaaatactgtattgtattttatagcaactatgtaaaaatggagtc
ctgtcctatgcttagatgaaatattgttggattttgagtttgatgtctctataggaatcagtggttagtgaaaacg
gggtggagataaacagatgttttcacagtcctgttggttcacagtagcccaaatgaaatgtttccatataaggtgcatt
ctaattggcttaaatgatgcagatattttctggccagccatattggatcttttctcatctaaagatggttaattttcct

gatgcgggctcttttttggttccatatgaactttaaagtagtttttttccaattctgtggagaaagtcattggtagc
ttgatggggatggcattgaatctataaattacctgggtagtatggccattttcatgatattgattcttctacc
tgagaatggaatgttcttccattttggttgcgctctcttttatttctcttgagcagtggtttgtagttctccttgaaga
ggtcttccacatcccttgaagttggattcctaagtattttatttctcttgaacaattgtgaatgggagttcactc
atgatttggctctctgtttgtctgttattgggtgataggaatgcttgtgatttttgcacattgattttgtatcctga
gactttgctgaagttgcttatcagcttaaggagattttgggctgagatgatggggtttctaaatatacaatcatgt
catctgcaaacagagacaatttgacttccctctcttctctatttgaatatcctttatttcttctattgacctgattgcc
ctggctagaacgtccaatactatgttgaataggagtggtgacagaggacatccttgttttgtgccagtttcaaagg
gaatgcttccagcttttggccattcagatgacattggctgtgggtttgtcgtgaatagctcttattattttgagat
atgtcccacataacactagtttatttagagtttttagcacaaggctgttgaattttgtcaaaggccttttctgcat
ctattgagataatcatggtttttgtctttgattctgtttatgatggtattatatttattgatttgcataatgttga
ccagccttgcacccaggatgaagccaacttgatcatggtggataagctttttgatgttctgctggattcggtttg
ccagtttttactgagatttttccatcgatcttcatcagggatattggcctgaaattctctttttgttgtgtct
ctgtcaggctgtggtatcaggatgctgctggcctcataaaatgagttaggaggattccctcttttctattgatta
gaatagtttcagaatggtaccagctcctccttatacctctggtagaattcagctgtgaatccatctggctcctgatgg
attttttggttggtaggctattaattattgctcaatttcagagcctgttattgggtctattaagagattcaacttc
ttcctggtttagtctggagggtgtgtgtgtccaggaatttataaatttcttttaggttttctagtttatttgc
agaagtgtttatagtgctctctgatggttagtttgtatttctgtgggattgggtggtgataccccctttatcaccttt
attgcatctatttgaattcttttctcttttcttttatttagtcttgcctagtgatctatcaattttgttgcattttt
aaaaaaccagctcctgggttccattgattttttgaaggagttttctgtctctatctccttcagttctactctgatct
tagttatttcttctgtctctctgctagcttttgaatgtgtttgctcttgcctctctaaattgtgatgtaggggtgcaat
tttagatctttcctgctttctcttgtgggcattttagtctataaatttccctctacacactgctttaaagtgtgcc
agagattctggatggtgtgtctttgttctcattgggttcaaagaacatctttatttctgccttccacttctgtaagt
accagtagtccactcaggagcaggttgcctcagtttccatgtagttgagtggttctgagtgagtttcttaactcctgag
ttctagtttgaaagcactgtagctctgagaggcagtttgttataatttctgttcttttacatttgcctgaggagtgctt
tacttccaactatgtagtcaatttttggaaataagtggtgatgtggtgcccagagaagaatgtatattctgttgatttga
gtggagagttctgtagatgtctattaggtccgcttgggtgcagagctgagttcaatttctggatattcttggtaattt
tctgtcttggtagctgtctaatattgaccgtgggggtgataaagctctccattattattgtgtgggagctctaaagtct
ctttgtaggtctctaaggacttgctttgtgaatctggtgctcctgtattaggtgcataatatttttaggatagttagc
tcttcttgttagaattgatccctttatcattatgtaattggccttctttgtctctttttgatctttgttggtttaaagtc
tgtttatcagagactaggattgcaactcctgcttttttggctttccatttcccttggtagatcttccctccatccct
ttattttgagcctatgtgctctctgcacatgagatgggtctgctgaatacagcacactgtgggtcttgcactctt
atccaatttggcagtcctatgtcttttaactggagcatttagccatttaccatttaagggttaatttgttatgtgtga
atttgatcctgtcattatgatgttagctggttattttgctcgttagttgatgcagtttcttccctagcctcaatgatc
ttacaatttggcatgtttttgcagtggtggtactggttggttccctttccatgttttagtgcttccctcaggagctct
tgtaaggcaggcctgggtggtgacaaaatctctcagcatttgccttctgtgtaaaggattttatttctccttccattat
gaagcttagtttggctggatataaaattctgggttgaatttcttttctttaaagaatgttgaatattggccccact
ctcttctggctttagagtttctgccgaaagatgctgttagtctgatggacttccctttgtgggtaacctgcccttt
ctctctcgtgcacttaattgtttttccttccatttcaactttgggtgaatctgacaattatgtgtctttgagttactc
ttcttggaggatatttgcggcattctctgtatttccctgaatttgaatgctggcctgcctcactagattgggggaag
ttctcctggataatctcctgcagagcgttttccaacttgggttccattctccccatcacttccaggtacaccaatcag
atgtagatttggctttttcacatagtcacatatttcttggaggctttgttccatttctttttactcttttttctctaa
acttctcttcttgccttccatttccatttccatttgcatttccatccctttcttccacttgattgaatcagctactgaagct
tgtgcatgtgtcacatagttctcgtgcccattggttttccagctccatcaggctcatttaagggtcttctctatgctgtttt
ttctagttagccattcgtctaatgttttttcaagggttttttagcttctttgtctaaaagggttcaaacatcctcctttag
ctcggaggagtttggttattactgatcatctgaagccttcttctctcaacttgtgaaagtcatttctctgtccagcttt
gttccattgtcggcaggagctgcattcctttggaggagaagacgtgctctgattttttagaattttcagcttctctg
ctctggtttctccccatcttattgggttttcttacccttttggctttttagatgatggtgacgtacagatgggggttttgg
gtgagatttctttctttttagtttttcttacccttcaacagtcaggaccctcagctgcaggtctgttggagtttctg
aggctcactccagaccctgtttgcttgggtatcaccagcagaggctgcagaacagcaaatattgcagaacggcaaat
gttgcctcctgattgttctctggaagcttctctcagaggggacacctggccgtatgaggtgtcagtcggccccctac
tgggagggtgctcccagttaggctactcaggggtcaggaaccacttgaagaggcagactgtccattctcagatatac
atattccatgctgggaggaccctactcttttcaaagctgtcagacagggacatttaagctctgcagaagtttctgct
gtcttttggttcagctgtgcccctgcccctagagggtggagctctacagaggcaggcaggcctcctttagctgctgggtggg
tccaccatttctgagcttcttggctgtctttgtttaccctactcaagctctcagcaatggtggacacccctccccagcc
tcgctgctgctttgcagttcgatctcagactgctgtgctagcagtgagccaggctccgtgggcatgggacccctccga
gccaggcctgggacataatctcctgggtgtgcccgtttgctaagaccattggaaaagcagctattaggggtggggagtg
tcttgattttccaggtaccgtcagctcatggcttcccttggctaggaagggaattccccaacccttgtgcttctctg
ggtgaggtgatccccaccctgctttggctcatgctccgtgggttgtaccactgtctgacaagccccagtgagatg
aaccggtagctcagttggaatgcagaatcaccctgcttctgcatcactcacgctgggggctgtagactggagct

gttcatatattggccatcttggaaacctccctttccaagttctttattacagagtgggctcaactgaaacttcatggaaca
aattggaaattatcttcttaattaatgtcactgtctaccatgtatgggaatttggtaaataattatggtttcaata
acatagtagatagaacattgtcfaatctaaacttcagtgaaattgtaacagatcccacctgaaattctaaagaaaca
gaattctaatgaagagggttaacttttacaggggaatgtcaactgccatttgggtcctgtaaacaaaaaactgtttt
taaaaaagtaactttaaaagtatcttcagatgacctcatttgcctatccaagtggcttgagtagcttgatgctaa
gacttctttgttacagactggagatgtgtgctactggggcagtggttgcctgtgacaaggaggcagaggatgagggc
aaggttcagatgtgactgtgaattctgggtggctctggctatcgggagccttcattgattacagcaaacagttgctt
tcttagggcaatagtgctctgtcaccaggctggagttcagtgggcatgatcaatcgctcactgtagcctcaacttc
ttagactcaagtaacctcccacctcagcctcccaagtagctgaaactacaggtgtgcaccaccacacctaattttt
ttaatttttaagttttttagagacatggctcactgtgttggccagggtgatctcgaattcctgggctctagtgat
cctcccgcctcggcctcccaaagtgttgggattacaaatgtgagccactgcacctggcccttggcaaccttcttgac
aatgcattcctttattccctaactggaagtaacttcttctctttataaaaattgtatctgtacctttctgggtcat
tctacctttatattctagttacgtatgtcctacctccctcctaggggagggaagtaagactggaagtagact
tcatgtgtgatgaatgaacaaaagggaagcttaacatattgatatagtcactggatgcaaattaaaaaattttt
aaatattgatttgaagatttcatthaaggtaactccttaatagtttgtatcatatattgtaggaaccaaataat
aacttctcagcattaccattatctttataggactgtctaaaatgagcagccatattctttaaactgtgtttctctg
attacagctcacaggtaaaacccaaaggggctgggaacaaacaagacttttttttttctgtatgcctgaattat
ctgtactgttgcctgttttcccaccttggccatagaaacttagttctaactgctacaatttttgcagttctttct
cttagaaaaagaccacattgtctgaaatctcatccatttaagtaatcaagccttaaagttgaaggatcttggctatg
attaatctagacctacaagtagtatcttaatggcactccttttagaaagttagggtccaggacacacatagctgca
gtgtccacattttgtaagctccttcgttgtcacagccactctctctctgtggctgatattctaaaactggcaacac
atcctgatggtaaaagcttgggttcaggagacagggtgacctactagctttatggcatttgacaggttacctaacctct
ctgacgcataattgcctcatctatataatggggataataatcccacctcctgtctccttgtaaaaatcaaattagatg
acgctgtgaatgttctatagctctcttagacaaatgtaagttatgactacagcaagagtaaaagagcatgttgttat
ggacattctttcagtgaaatgtctaagacttgtgagtcacacttaaagctaaacttgataatctacttcatgatttt
cttttttagttctatgtactatattgaatctcctgacagtggggctatgaaagccttcctagcattttatagatgtgg
ttgaattaatggctgtaagccttaaagcagaatttagacagcatcaatgaatttattaagtataaataaataataat
ctgcttagcaatattacacagcctctttatcttatgtgtgataaaagagtcacccgaagggtgaaaatgagaattgt
cctggaagctcttacttaactttttatttttcttaataacagtatataaaaattactcattgaaagcttagcagaata
agaacaagaagtataaaaggctgaaaactcaaaatttgtctatttatttatttatttacttccaagctctcttattga
tctgttagaaaatgagactacacaggaatgttaggcatttagtatgtgtgtggttagtctgctcttttaattatca
agtaaggttttattccattagaggaactcaagaagttgggtcatggctgataattgctatctgtcaaatccttagag
cagggatccgcaacaccaggccatggattgttaccagtcctggcctgttaggaaccaggctgcacagtaggaagt
gagcggcgggtgagcaaacattgccatctgagctctgtctcctttcagatcagcagcagcattagattctcatagaa
gcatgagccctgttgtgaaactgcacatgcaaggatctagggtgtgtgtccttatgagaatccaattccttatgat
aatttaactgatgatctaagggtggaaccatttcatccaaaaccatccaccctgctactcccagaccgtggaaaaat
tgtcttccacaaaactgggttctgctgccaaaagggttgggaccactgccttagagtttataatttgggggttagcac
agcctatatttacctgagaatttcaatgggttactgatctttccaaatgaaaaggcttcttacgaaaattatattcc
aaactgtcttttctcttagtttaataaacctatcagtaagtttttactgagtactgctattacatttttctctgtta
agcattatgggggctcagacatgatccattccctcaaagaacttacctttcagctgaagactgactagaatgagcaa
atagcgttaacaattaacaagttagtaggagcagctcggccaacatgggtgaaacctgtctctactaaaaatacaaaa
attagccgggcatggtggtgggagcctgtaatcccagctacctcctgtctgaggcaggagaattgcttgaaccaggga
ggtggagattgcagtgagccgagattgcaccattgcactccagcctgggagacagagcaagactctgtcttgggaaa
aaaacaaaacaaaacaagtgaaggggaatcaagtaactacgtaagatgtaattgtggaatttttagggaaaggaaggcag
tgtatgctggagtaattagagaaaggggcatgcatgatttgatgcttgaactggatcatgaaggataagcaagattt
tggcagcaagtgaaggggagagaggagtgtgtcagaggaatggaacaagttaggagggcagtaattgtgtacggcactc
caaggactctgtcctgatcggagcagaagtgatgaagcatttagtagtttgagaaagttagctaagaaggggtgaggg
cagatgttgagagagtttagtatcagagagaagacatttagatttgagcagatagaacaaaaatgccattgccagtt
tttgtgaagagaatagatttaggggttaccaggaagtggtcatcagagttgaatggagcagaaagagtgctctg
atacagcatcgggagcttgtggtcacaataatgaggtggtgagggctgagccaagatgggtggcagtgggatggataaa
aagggtgagccaggacaaatattttaaaggaaaaatcaacaggacatctttactgactggattggaaggctatgcag
gaaatataattgtcaaacttgattccaggattttctatcctatgcctgggttggccaaaatatacagggaaccattgtta
gaaaaggtaggagataaccactgttccaacaaaagatttaggtttgggtgttgacccacttaacttcaaggccttac
aagttagtagacagtttagttagaattgcagaagtggcactcagagagcagggcttgcattgtgggggttggactttgt
caccattgtgttaattcctaattctatgcagatgctcagcttgagggaatacccatgtttgggcttcagaatgaaagc
caagtaataatttactcagatgccaaatttccctctgaaatatttgcctcatggaactgagagaacaataataaagca
ttaattatattttctcataaagttattaataaaaagataagatcagtgaaaggcagagtaaaactagaagccaagtata
gaaaatggatcattcaagactcattactgtagtggtgaaaacaaaacaatttccaacagcttaagatgcctcag
tattttggaccatttttaagtagtttagtggggcacttagtaaatatgtattaaactatagttcattaattctttt
ttttttttttgagatggagtttactctggtcaccaggctgcatttttgccttcttagtgatataataaatgtcag

agtttcacaatgatgggtatcttagatgattgattaaatatgggtattaaaaaatagctgatcacagaaagtctctaccag
tgtgatgtagatggctaaagatattccacatttgcaaaccttttattgacctaaataagaggtgccccttgggttgttt
ttatttggactgggaatattaggagaaagctttttcattcagtggtgtaagtacaatctaccagaaatagaaaccccc
atggacgatctatttctttgatgggtacaggactcagaacattcacaagatttagttgtagcggaaatagacatctg
tattttattcaaaccaattttcccttcctaactctgagaacattgtgcaatctaagcagttctaagcatgtttgctat
tcgtgcaaagtgagagtaaactctaaaagaaatttttttgtgtgttttagGGATGGTAATAAAGTCTCTTAGTGGTTGA
AAATGTTATTTCTTACAAAAGTGGAGAACATTTGCTTTTCAATACCAGAGTTTTTCAGCCATTTCTGCATTCTGACCT
ATTGACTGGAGgttaggttgcctttgaattcagtaaaacttcatgggcagaaacacagttcccttttccactattttg
gatatcatgatggccattgcatgtatgtgtctttttgtaagtccatgcctcagaactgagaagtaggaataaaatta
gggtcagggctggggatgctactctttgctgctgagaaacacaatgcttcaggtaagtgattctgaagtccttcacc
acctgacggtaaccttgggttgggtccataggtatgttttcttttctttgcttgcctccatttttaattggcttccaga
gcatgctttagatgtagagccaaattagagtagagcaacctctggcaaacaggaagagattaattttgtggat
gcttttaaggacttcccaggaacttcaaaagcagaaaaagaagcactagctgcctattccaaaatgtgtaaaaca
ccactcagctttttaaaagaaaactcaaaactcagagcgcgcgcacacgcgcgcacacacacacacacacacacaga
gagaactctctagtaaaaaagaaagttagcttttcttagctagatgtgtgtatttagccagaaaaagccaaggagtg
aaggttttagagaactggaggagataaagtggagtctgcatatgggaggcatttgaaatggacttaaatgtctttt
taatgctgactttttcagtttttctccttaccagacacattgttttcatgacattagccccaggcatagacacatcat
taaaatgaacatgtcaaaaaatgatttctgttttagaaataagcaaaaacattttcagttgtgaccaccagggtgtaga
ataaagaacagtgggaattgggagccctgagttctaacataaaacttttcttcatgacataaggcaagtcttctatggcc
tttggtttcttacctgtaaaacaggatggctcaatgaaattatcttttcttctttgctataatagagtatctctgtg
ggaagaggaaaaaaaagtcaatttaaaggctccttatagttccccaaactgctgttttattgtgctattcatgccta
gacatcacatagctagaaaggccatcagaccctcaggccactgctgttctctgtcacacattcctgcaaaggacca
tgttgctaacttgaaaaaattactattaattacacttgcaagttgttgccttagtaacatttatgattttgtgtttct
cgtgacagcatgagcagagatcattaaaaataaacttcaaaagctgctaaagtgggaagaaggagaacttgaagcc
acaatttttgcacttgcttagaagccatctaactctcaggttttatatgctagatcttgggggaaacactgcatgtctc
tggtttatattaaccacatacagcacaactactgacactgatttgtgtctgggtgcagctggagtttatcaccaagac
ataaaaaaaccttgaccctgcagaatggcctggaattacaatcagatgggcccacatggcatcccgggtgaaagaaagc
ctaaccagttttctgtcttctgtttctgttttctcctacagTTCACCAGGTGAGAAGAGTGATGACCATCCTTTTC
CTTACTATGGTTATTTTACACTTTGGTTGCATGAAGGCTGCCCCCATGAAAGAAGCAAACCTCCGAGGACAGGTTGG
CTTGGCTTACCAGGTGTGCGGACCCATGGGACTCTGGAGAGCGTGAATGGGCCAAGGCAGGTTCAAGAGGCTTGA
CATCATTTGGCTGACACTTTTCAACACGTGATAGAAGAGCTGTTGGATGAGGACCAGAAAAGTTTCGGCCCAATGAAGAA
AACAAATAAGGACGCAGACTTGTACACGTCCAGGGTGATGCTCAGTAGTCAAGTGCCTTTGGAGCCTCCTCTTCTCTT
TCTGCTGGAGGAATACAAAAATTACCTAGATGCTGCAACATGTCCATGAGGGTCCGGCGCCACTCTGACCCTGCCC
GCCGAGGGGAGCTGAGCGTGTGTGACAGTATTAGTGAGTGGGTAACGGCAGCAGACAAAAAGACTGCAGTGGACATG
TCGGGCGGGACGGTCACAGTCTTGAAGAGTCCCTGTATCAAAAGGCCAACTGAAGCAATACTTCTACGAGACCAA
GTGCAATCCCATGGGTTACACAAAAGAAGGCTGCAGGGGCATAGACAAAAGGCATTGGAACCTCCAGTGCCGAACATA
CCCAGTCTGACGTGCGGGCCCTTACCATGGATAGCAAAAAGAGAATTGGCTGGCGATTACATAAGGATAGACACTTCT
TGTGTATGTACATTGACCATTAAGGGGAAGATAGTGGATTTATGTTGTATAGATTAGATTATATTGAGACAAAAA
TTATCTATTTGTATATATACATAACAGGGTAAATTTATTCAGTTAAGAAAAAATAATTTTATGAACTGCATGTATAA
ATGAAGTTTATACAGTACAGTGGTTCTACAATCTATTTATTGGACATGTCCATGACCAGAAGGGAAACAGTCATTTG
CGCACAACTTAAAAAGTCTGCATTACATTCCTTGATAATGTTGTGGTTTTGTTGCCGTTGCCAAGAACTGAAAAATA
AAAAGTTAAAAAATAATAAATTGCATGCTGCTTTAATTGTGAATTGATAATAAACTGTCTCTTTTCAGAAAAACAG
AAAAAAACACACACACACACACAAAAAATTTGAACCAAAACATTCGGTTTACATTTTAGACAGTAAGTATCTTCGT
TCTTGTTAGTACTATATCTGTTTTACTGCTTTTAACTTCTGATAGCGTTGGAATTAACAATGTCAAGGTGCTGTT
GTCATTGCTTTACTGGCTTAGGGGATGGGGGATGGGGGTATATTTTTGTTTGTGTTTTTTTTTTCGTTTGT
TGTTTTGTTTTTTAGTTCCACAGGGAGTAGAGATGGGGAAGAATACTTCTACAATATATATTCTGGCTGATAAAGA
TACATTTGTATGTTGTGAAGATGTTTGAATATCGATCAGATGACTAGAAAGTGAATAAAAAATTAAGGCAACTGAAC
AAAAAATGCTCACACTCCACATCCCGTATGCACCTCCAGGCCCGCTCATTCTTTGGCGTGGTTCAGAGTAAG
CTGCTTTTGACGGAAGGACCTATGTTTGTCTCAGAACACATTCTTTCCCCCCTCCCCCTCTGGTCTCCTCTTTGTTT
TGTTTTAAGGAAGAAAAATCAGTTGCGGTTCTGAAATATTTTTACCCTGCTGTGAACAAGTGAACACATTGTGTCA
CATCATGACACTCGTATAAGCATGGAGAACAGTGATTTTTTTTTTAGAACAGAAAAACAACAAAAATAACCCAAAAAT
GAAGATTATTTTTTATGAGGAGTGAACATTTGGGTAAATCATGGCTAAGCTTAAAAAATCATGGTGAGGCTTAA
CAATGTCTTGTAAAGCAAAAGGTAGAGCCCTGTATCAACCCAGAAACACCTAGATCAGAACAGGAATCCACATTGCCA
GTGACATGAGACTGAACAGCCAAATGGAGGCTATGTGGAGTTGGCATTGCATTTACCGGCAGTGCGGGAGGAATTC
TGAGTGGCCATCCCAAGGCTTAGGTGGAGGTGGGGCATGGTATTTGAGACATTTCCAAAACGAAGGCCCTCTGAAGGAC
CCTTCAGAGGTGGCTCTGGAATGACATGTGTCAAGCTGCTTGGACCTCGTGCTTTAAGTGCCTACATTATCTAACTG
TGCTCAAGAGGTTCTCGACTGGAGGACCACACTCAAGCCGACTTATGCCACCATCCACCTCTGGATAATTTTGA
TAAAATTGGATTAGCCTGGAGCAGGTTGGGAGCCAAATGTGGCATTGTGTGATCATGAGATTGATGCAATGAGATAGA
AGATGTTTGTCTACCTGAACACTTATTGCTTTGAACTAGACTTGGAGAAACCAGGGTTTATCTTTTGGAGAACTTTTG
GTAAGGGAAAAGGGAACAGGAAAAGAAACCCCAACTCAGGCCGAATGATCAAGGGGACCCATAGGAAATCTTGTCC

AGAGACAAGACTTCGGGAAGGTGTCTGGACATTCAGAACACCAAGACTTGAAGGTGCCTTGCTCAATGGAAGAGGCC
 AGGACAGAGCTGACAAAATTTTGGCTCCCCAGTGAAGGCCACAGCAACCTTCTGCCCATCCTGTCTGTTTCATGGAGAG
 GGTCCTGCCTCACCTCTGCCATTTTGGGTTAGGAGAAGTCAAGTTGGGAGCCTGAAATAGTGGTTCTTGAAAAAT
 GGATCCCCAGTAAAACCTAGAGCTCTAAGCCCATTCAGCCCATTTACACCTGAAAATGTTAGTGATCACCCTTG
 ACCAGCATCCTTAAGTATCAGAAAGCCCCAAGCAATTGCTGCATCTTAGTAGGGTGAGGGATAAGCAAAAGAGGATG
 TTCACCATAACCCAGGAATGAAGATACCATCAGCAAAGAATTTCAATTTGTTTCAGTCTTTTCATTTAGAGCTAGTCTT
 TCACAGTACCATCTGAATACCTCTTTGAAAGAAGGAAGACTTTACGTAGTGTAGATTTGTTTTGTGTTGTTTTGAAAA
 TATTATCTTTGTAATTAATTTTAAATATGTAAGGAATGCTTGGAAATATCTGCTGTATGTCAACTTTATGCAGCTTCCT
 TTTGAGGGACAAATTTAAAACAAACAACCCCCCATCACAACTTAAAGGATTGCAAGGGCCAGATCTGTTAAGTGGT
 TTCATAGGAGACACATCCAGCAATTGTGTGGTCAGTGGCTCTTTTACCCAATAAGATACATCACAGTCACATGCTTG
 ATGGTTTATGTTGACCTAAGATTTATTTTGTAAATCTCTCTCTGTTGTGTTTCGTTCTTGTCTGTTTTGTTTTGT
 TTTTTAAAGCTTGGCTGTGGTCTCTTTGTGGCAGAAGTGTTCATGCATGGCAGCAGGCCTGTTGCTTTTTTATGGC
 GATTTCCCATGAAAATGTAAGTAAATGTCTGTGGCCTTGTCTCTCTATGGTAAAGATATTATTCACCATGTAAGAAC
 AAAAAACAATATTTATTGTATTTTAGTATATTTATATAATTATGTTATTGAAAAAAATTTGGCATTAAAACCTAACCG
 CATCAGAAGCCTATTGTAATACAAAGTTCTATTTAAGTGTACTAATTAACATATAATATATGTTTTAAATATAGAAT
 TTTTAATGTTTTTAAATATATTTTCAAAGTACATAA

FIGURE 3

Natural antisense sequence (NR_002832.1): SEQ ID NO: 2

>gi|84872122|ref|NR_002832.1| Homo sapiens BDNF opposite strand (non-protein coding) (BDNFOS), non-coding RNA

CNGCNNAAGATTTCTTCACAGGGTCCTTTAAACTGTCNNTTTNTAAGAGGTCCCTTCCACTACAGGTAAAGGGAAAT
 TCCCTCTACCCTAGGGCCCCCTCAGGANCCCTTCCTCTCTCACACGTTTCTTCGACTGCTNNGATTTAAGCATTTCAG
 CTGGCCACGCAACGCAAGAAGCAATAAGAACACAAAACCCCTACCCTGTTTCNTCCTCTATCCGTGGCCTTTGCCACC
 ACCTCCACAACCTAGTTTCAGATTCCTCTTCTTTTCTCAAGGGAACGTCTAAAGCTCTCAAGTCCGTTTTTGGCAGGGC
 GATTTTGTAAAGTCTGAANCATTTTCAGTGTGTCTCTCGATCTCAGGCAGCTCAAAAGAAAAGATCTGCTGGCTGCGTG
 AAGGTGCATTAGAAACCTGCTGCTACCTTGCAGCCTGGGCTGAGCATATGCTCCGGAACCTGCTTCTCTCCAACAT
 CCTGCACCTCAGGGTTGCACGCTCTGGTTCCCAAGCCCCCGCCGCTGGCTTATGCAAACTACTTAGGTACATGCAA
 AAGTATCCCTTCTCCCGGAGCGCCATTGGCCCCGGGAGGTCTCGAGCTCATTACTATGCAGAGAGGAGAGCCGCCAT
 TGGCCAAGAGGAGGACCAGAGGGGCGTGTTCCTCGGGCAAATTGGATCTCCTAAATTGGATGACCTGGGCTGAAAAG
 CAACTTAAAGACCCCCAGAAAACCTCTGGTTTTATAGATAAGAAATCTGAGGCTCGAGAGAGAGTGTGTTCTGCCCAA
 CATCATCACGGAACAGCTCCTGGGCTCCTGGCTCCTAATCTGTTCATCGCTGTCTGGAACAGCGATGACTCGATCGCG
 AGATCAGGAAGGTGGCCGAGTGTGTGCGCCGCGCCATCAGGCACCTTCTCCTTCCCTGCCCTTGTATGAAGAAGGATGT
 GTTTGCTTCCCCTTGTGCCATGATTGTAATTTCTTGAGGCCTCCTCAGCCCTGCAGAACTGGGGTTATAGCCATGT
 GACTGATCTTCGTCCAAGAATATGTAAGAAAAAGTGTGAGTTGGCTTTTAGGGCTAGAGCAATGTATCTTAGGCT
 CACTTAAGGAAGCTGTAGAGATGAGCCCAAGGAGGGAAACCAGAAGAGCCCCCAGGCTCACCAAGTTGTTTTGTTGGC
 TCCCTACAAACATGTCATTCAAGTGGCTAATCTTACAACAGCACAAATTCATCTAACCAGAAAAGAGAAGAGGAGGCT
 CCAAAGGCACCTTGACTACTGAGCATCACCTGGACGTGTACAAGTCTGCGTCTTATTGTTTTCTTCATTGGGCCGA
 ACTTCTGGTCTCATCCAACAGCTCTTCTATCACGTGTTTCAAAGTGTGAGCCAATGATGTCAAGCATCTTGAACC
 TGCCTTGGGCCCATTCACGCTCTCCAGAGTCCCATGGGTCCGCACACCTGGAGATACTCTATTATAGCAAAGAAGAA
 AGATAATTTCAATTGAGCCATCCTGTTTTACAGTATTGAATTATTACCACAAGGTACCAACCATATATGCATACTTAA
 TAGGGTATTTTGTCAAACCTATGCATGAAGGTCAATTTGTTTGGAGATGTCAGAACATTTTCCCGTGAGAAGATCTCAT
 TGGGCATTGAAACAGAACCACATGCTCTTCAGACCAGCAACCGCGACTACCAAATACTCCTCTGTCAACTCTACTTG
 AGTAAGAACGCTTTCAATTAAGGCCTAAGTGTCAACATGCCTTTAAAAAAAATCGTGGTGACACAAAATCTTCTTT
 TTAGCACCCAACAGAATCCCTTCAAAGCCTCGTGGTCTGACACCCTATGCTACGTGACTTGTGACCCATCCATTTGT
 CATGTTCTTCGGGAATGTGGCTAAGGGCTAAGATGTGACTTGAAGAAAGGTAGAACAAGATCATCTCAAAATTA
 TTATCAAGGAATAGTTTCAGAAAACGACTTCAGACCACAGAGACAGCAGAACAGATGGTCCGGCATGGATAGAGCATC
 AGACACTCACAGACTGTGCCAACAAGAGCCATCGAGTCAAACAGCCAAAGGAAGGAGGGTCATGGAATGGGTTCTC
 TCACACCAAACCTGATGCCAGAGGCCCTCAGCATGAATAACAAAGGCAACCAGACCCACAAGCCATACTGAGTGGAT
 ACAAACCTATACCTAGGCTGACATCCCAATGTGTGTGGCAAGTTAGATGATGATGGCACAAAAGACAGAACACCT

TGCTTCTGGCCATTGTCAGCTCTTGGAAGAGAGCACACTTTTAGAGGAGCAGCTGCAAGGAGCCTGAGAACAAAAC
GGAAATGTCTGTTATGAAAGCCTTACAGGAAATCTGCAAGTGGCAACGTGGGTCCATTCCGTGTGTGTCACTAGA
GCTGGCGCAAGCCCATGGCCATGGTGAGGCAGCGTTTTCCACTGGAACATACTGATACCTGCACCAACTCTTGCAAC
TGTGCAGTGTTCCTACTGCAAACACGGATGGGGTAAAAGACTGCTCACCTCCTATTTCTCATCTAATCTCACACAC
TCTGTTTTGATGAGGCTATGGAGAAACAGGTCTTCTCATACACTAAAGGTGGGAGTACAAACAATTCAAGCCCTGTGC
AGGACAATTAGGCAATACCTATCAAATTATACATGATTTTTCTGCTGACCCAGCAATCCACTTTTGGGAATAAT
TGACAGATATAGGTGCATATGTACAAAATGATGGAAAGCTCTCTGGTATATATTAGTAAGTGATAAAACAAGGTGTG
TGTATATATGGCTACTACCTTTTGTTTTAAAAATGGGGGAAAATGGTGGAGCTTGCGGTGAGCCGAGATCGTGCCAC
TGCACTCCAGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAACAGGGTGGGGTGGGGGGAAAATAATAGTA
CATACTCATATTTACCTGTATCTATATAAAACACACTATCAAGGATTCACAAGAAACTAATACAAATGATCCCCTTA
TAGATGGTATGTATTGGGGGATACTGAGGTGAGCAGGGTATAAGTGGGGCAAGACTTTTCAGTGTAACCTCTTTTA
AATTTTATTTTGATTTTGAATAATGTAAATTAAGTGTCAAATAATTAATTAATAAATAACCAATTTATTAACAAAA
AAAAAAAAAAAAAAAAATA

FIGURE 4

Sequence ID	Sequence
SEQ ID NO:3	C**T**T**G**A**A**T**T**G**T**T**T**+G**+T**+A
SEQ ID NO:4	A**+G**+T**T**G**C**A**A**G**A**G**T**+T**+G**+G
SEQ ID NO:5	A**+T**+C**T**G**T**T**C**T**G**C**T**+G**+T**+C
SEQ ID NO:6	C**+A**+T**A**T**T**C**T**T**G**G**A**+C**+G**+A
SEQ ID NO:7	T**+G**+T**G**C**T**G**T**T**G**T**A**+A**+G**+A
SEQ ID NO:8	T**+G**+A**C**A**G**A**G**G**A**G**T**+A**+T**+T

FIGURE 5

Sequence ID	Sequence
SEQ ID NO:9	GCACACCTGGAGATACTCTATTATA
SEQ ID NO:10	CCTGCAGAAATGGCCTGGAATTACAA